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Skin, more specifically the outermost skin layer, the stratum corneum (SC), forms an 
extremely effective barrier, preventing both the loss of heat and water, and the ingress of 
micro-organisms and chemicals. Assessing the rate and extent of drug permeation into or 
through the skin is important both to evaluate the usefulness of a drug for topical or 
transdermal delivery, and to compare different formulations to assess their 
bioequivalence.  
 
Prediction of drug permeation is logistically, ethically and economically preferable to in 
vivo measurements. The recent progress that has been made with empirical and 
mechanistic mathematical models, along with in vitro diffusion cell techniques has been 
reviewed. However, currently, in vivo measurements, in man, are still required. For new 
chemical entities, the need for clinical trials is clear. In the case of generic products, 
however, there is considerable effort currently being expended to replace expensive, 
subjective clinical trials with objective, validated measurements of drug permeation, in 
vivo, in particular to assess bioequivalence.  
 
The tape stripping technique has emerged as a promising technique to objectively 
measure drug permeation through skin, and is the focus of this thesis. After formulation 
application and removal, layers of SC are sequentially removed by adhesive tapes. As the 
SC performs the main barrier function of the skin, measuring the rate and extent of drug 
permeation through this layer is assumed to be related to overall topical bioavailability.  
 
The work in this thesis concentrates on performing tape stripping studies such that all 
tapes are analysed individually, and drug concentration as a function of SC depth is 
measured. The concentration depth profiles across the SC may be fitted to an appropriate 
solution of Fick’s second law of diffusion to obtain estimates of the vehicle-SC partition 
coefficient and the drug’s diffusivity in the membrane. These dermato-pharmacokinetic 
parameters may be compared for different formulations. 
 
Models to estimate SC thickness 
 
SC thickness varies between volunteers, and within volunteers according to season, skin 
condition and skin treatment. Therefore, it is important to measure each volunteer’s SC 
thickness at an untreated site to normalize drug permeation profiles in dermato-
pharmacokinetic studies at adjacent sites.  
 
Traditionally, a linear transformation of Fick’s first law has been used to correlate the 
progressively thinner barrier with the corresponding increase in transepidermal water loss 
and to estimate the thickness by linear regression. However, the data from an important 
subset of subjects are poorly fitted to this linear model. This is typically due to the 
removal of loose outer layers of SC, which do not contribute significantly to barrier 
function.  
 
This work proposes two alternative non-linear models. All three approaches were used to 
fit data from in vivo tape-striping experiments and their outcomes and goodness-of-fit 
compared. The results suggest that the linear model may overestimate the SC thickness 
and is open to subjectivity regarding the selection of data points to be fitted. The non-
linear models satisfactorily fitted all the data, including all data points. No significant 
differences were found between the thicknesses derived from the two non-linear models. 
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10 
preference for the baseline-corrected non-linear model described. 
 
Quantifying the amount of SC per tape strip 
 
Each tape strip removes a variable amount of SC. In order (i) to express the mass of drug 
extracted from each tape as a concentration; (ii) to measure the depth reached within the 
SC with each successive tape strip; and indeed (iii) to measure the total SC thickness as 
above, the amount of SC per tape must be known. The amount of SC per tape is thus 
crucial to produce robust, reproducible drug penetration profiles.  
 
In this work, four methods to quantify the amount of SC per tape are studied. First, the 
traditional method of weighing tapes before and after stripping. The weighing method was 
found to be laborious and slow; to have poor precision and reproducibility; and to be 
fundamentally flawed due to the mass of SC being 200-2000 times smaller than the 
mass of a tape strip. Alternative methods must therefore be urgently investigated.  
 
Second, keratin was extracted from the tape strips and analysed by protein analysis. It 
was shown that the concentrated NaOH solution, suggested in the literature as an 
extraction solution, degrades keratin and fails to extract keratin from SC. A urea/thiol 
mixture was tested and preserves and extracts keratins satisfactorily. However, the 
protein assay method used is insufficiently sensitive to accurately distinguish between 
the low amounts of keratin on tape strips.  
 
Third, the UV pseudoabsorption of corneocytes at 430nm, as reported in the literature, 
was examined. This method was shown to be rapid, precise and reproducible. However, 
the signal of the SC layer was only 1 to 10 times larger than the noise of a blank tape; 
light scattering may affect the results from inhomogeneous layers; and a maximum of 
44% of the SC strip may be analysed.  
 
A novel imaging method to measure the amount of SC per tape strip 
 
Fourth, a novel imaging method was developed during this work. For this method, a high 
resolution image is taken of each tape under controlled conditions. Each pixel of the 
resultant image has a greyscale value (on a 16 bit scale) which may be measured in the 
range 0 to 64608, where 0 and 64608 designate black and white respectively. The mean 
greyscale value across all pixels can be calculated, and corrected by subtracting from that 
of a blank tape. When an appropriate scale is applied to the image, the area of the strip 
may also be measured, which is multiplied by the mean corrected greyscale value to 
obtain the integrated pixel density for the tape. Both the mean greyscale value and the 
integrated pixel density are used as relative measures of SC amount. An example image, 
with relevant measurements is shown below: 
 
 
Number of pixels = 4875239 
Mean greyscale value of tape = 46451 
Mean greyscale of blank tape = 64355 
Mean corrected greyscale value of tape = 17904 
Scale (for analysis) = 159.07 pixels/mm 
Area of strip = 195.1 mm2 
Integrated pixel density = 3493270 mm2 
 
The imaging method was shown to be the most rapid and simple of the four methods; has 
high precision and reproducibility; has SC signals 20 to 100 times larger than the noise of 
a blank tape; and can fully analyse any strip size up to 2.3 cm x 3.5 cm. Furthermore, 
permanent records of the amount of SC per tape are obtained which may be further 





































Application of the novel imaging method in tape dermato-pharmacokinetic studies 
 
The imaging method thus provides a sensitive relative measure of the amount of SC per 
tape. To verify the usefulness of the mean greyscale value as a measure of SC thickness 
in our existing dermato-pharmacokinetic models, sites were stripped and the SC on tapes 
assayed by the traditional weighing and novel imaging methods.  
 
Firstly, sites were examined to assess total SC thickness. Cumulative integrated pixel 
densities (derived from imaging method) were substituted into the non-linear model 
previously developed (in place of cumulative thickness values derived from mass 
measurements) to derive a ‘greyscale’ estimate of the SC thickness, G. The traditional SC 
thickness, H, with SC mass measured per tape, was also estimated. H and G correlated 
well but intra-subject variability was favourably lower for the imaging measurements. The 
plots of TEWL as a function of depth within the SC were normalised using the H and G 
estimates, respectively, such that the normalised plots and parameter estimates from 
both the weighing and imaging methods could be directly compared. Improved sensitivity 
was found for the imaging method. 
 
Secondly, a full dermato-pharmacokinetic study was performed to compare two acyclovir 
creams. Again, the amount of SC per tape was assayed using the weighing and imaging 
methods to construct two types of drug permeation profiles. The normalised profiles from 
both SC quantification methods are comparable, as are the resultant dermato-
pharmacokinetic parameters, the SC-vehicle partition coefficient and the diffusivity. The 
partition coefficient of acyclovir was found to be numerically close to 1, similar to other 
drugs such as ibuprofen and betamethasone valerate, despite differences in their 
physicochemical properties. This could be due to residual formulation on the skin after 
cleaning, or the result of excipient ‘carrying’ the drug into deeper layers of the SC.  
 
In conclusion, a new method to estimate the total SC thickness is demonstrated. It has 
been shown that the mean greyscale value of a tape may be used as a sensitive, 
reproducible and precise relative measurement of the amount of SC per tape. This 
greyscale value may be used directly in the appropriate mathematical models (i) to 
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Chapter summaries 
Assessing the rate and extent of drug permeation into or through the skin is important 
both to evaluate the usefulness of a drug for topical or transdermal delivery, and to 
compare different formulations to assess their bioequivalence.  
 
Prediction of drug permeation is logistically, ethically and economically preferable to in 
vivo measurements. The recent progress that has been made with empirical and 
mechanistic mathematical models, along with in vitro diffusion cell techniques has been 
reviewed in Chapter 1. However, currently, in vivo measurements, in man, are still 
required. For new chemical entities, the need for clinical trials is clear. In the case of 
generic products, however, while testing of efficacy remains a requirement, there is 
considerable effort currently being expended to replace expensive, subjective clinical 
trials with objective, validated measurements of drug permeation, in particular to assess 
bioequivalence. In Chapter 1, three prominent methods are discussed: microdialysis, 
pharmacodynamic approaches, and tape stripping.  
 
The tape stripping technique is the focus of this thesis, where, after formulation 
application and removal, layers of SC are sequentially removed by adhesive tapes. As the 
SC performs the main barrier function of the skin, measuring the rate and extent of drug 
permeation through this layer is assumed to be related to overall topical bioavailability.  
 
The work in this thesis concentrates on performing tape stripping studies such that all 
tapes are analysed individually, and drug concentration as a function of SC depth is 
measured. The concentration depth profiles across the SC may be fitted to an appropriate 
solution of Fick’s second law of diffusion to obtain estimates of the vehicle-SC partition 
coefficient and the drug’s diffusivity in the membrane. These dermato-pharmacokinetic 
parameters may be compared for different formulations.  
 
SC thickness varies between volunteers, and within volunteers according to season, skin 
condition and skin treatment. Therefore, it is important to measure each volunteer’s SC 
thickness in order to express the depth reached with each successive tape strip relative 
to this total. SC relative depth therefore has a value of 0 at the skin surface and 1 at the 
SC-stratum granulosum interface. This eases comparison between the drug penetration 
profiles from different volunteers and on different occasions. SC thickness, H, is 
measured at an adjacent, untreated site, by fitting the increase in transepidermal water 
loss (TEWL) as progressive layers of SC are removed with each tape, to an appropriate 
model. A linear model was previously described [1, Section 5.2.4], but can overestimate 
SC thickness due to the influence of the stratum corneum disjunctum. In Chapter 2, a 
baseline-corrected non-linear model is described to objectively estimate SC thickness 
irrespective of the SC disjunctum, and full analysis of the non-linear goodness-of-fit is 
performed.   
 
Each tape strip removes a variable amount of SC. In order to (i) express the mass of drug 
extracted from each tape as a concentration; (ii) measure the depth reached within the 
SC with each successive tape strip; and indeed (iii) measure the total SC thickness as 
above, the amount of SC per tape must be measured. The amount of SC per tape is thus 
crucial to produce robust, reproducible drug penetration profiles.  
 
Traditionally, weighing tapes before and after stripping has been often used to derive a 
mass of SC per tape, but this is a time-consuming and laborious process. 
 
Protein forms ~80% of the total SC mass, and as such, extraction of protein from tapes as 
a SC quantification method has been explored. In Chapter 3, two extraction solutions are 
tested for their potential to degrade and extract SC keratins. Furthermore, the protein 




















































s     
    
concentrations extracted from more than 300 tape strips were correlated with two other 
measures of SC thickness: the gravimetric method and a novel imaging method. 
 
The novel imaging method, as a method to quantify the amount of SC per tape, features 
heavily in the remainder of the thesis. For this method, a high resolution image is taken of 
each tape under controlled conditions. Each pixel of the resultant image has a greyscale 
value (on a 16 bit scale) which may be measured in the range 0 to 64608, where 0 and 
64608 designate black and white respectively. The mean greyscale value across all pixels 
can be calculated, and corrected by subtracting from that of a blank tape. When an 
appropriate scale is applied to the image, the area of the strip may also be measured, 
which is multiplied by the mean corrected greyscale value to obtain the integrated pixel 
density for the tape. Both the mean greyscale value and the integrated pixel density are 
used as relative measures of SC amount. An example image, with relevant measurements 
is shown below: 
 
 
Number of pixels = 4875239 
Mean greyscale value of tape = 46451 
Mean greyscale of blank tape = 64355 
Mean corrected greyscale value of tape = 17904 
Scale (for analysis) = 159.07 pixels/mm 
Area of strip = 195.1 mm2 
Integrated pixel density = 3493270 mm2 
 
In Chapter 4, three methods to quantify the amount of SC per tape, namely weighing, UV 
pseudo-absorption and the imaging method, were assessed in terms of practical features: 
(i) reproducibility and precision, (ii) signal:noise ratio, (iii) proportion of the total strip 
sample, (iv) time cost. Next, more than 600 tape strips were analysed by each method, 
and correlations compared.  
 
In Chapter 5, cumulative integrated pixel densities were substituted into the non-linear 
model developed in Chapter 2 (in place of cumulative thickness values derived from mass 
measurements) to derive a ‘greyscale’ estimate of the SC thickness, G. The true SC 
thickness, H, with SC mass measured per tape, was also estimated, and H and G were 
correlated. The plots of TEWL as a function of depth within the SC were normalised using 
the H and G estimates, respectively, such that the normalised plots and parameter 
estimates from both the weighing and imaging methods may be directly compared.  
 
In Chapter 6, two different acyclovir creams were compared using 
dermatophamacokinetic profiles. Two types of drug penetration profiles are fitted where 
(i) the mass of SC per tape, and (ii) the integrated pixel density per tape, are used as 
measures of SC amount. The normalised profiles from both SC quantification methods 
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Abbreviations 
AIC Akaike Information Criterion 
ACV  Acyclovir 
ANGi Absolute normalised greyscale of SC on tape i 
ANN Artificial Neural Network 
ANOVA Analysis of Variance 
ANTi Absolute normalised thickness of SC on tape i 
ASCII American Standard Code for Information Interchange 
AUC Area Under the Curve 
B Baseline correction factor for non-linear model using cumulative thickness 
BC-NL Baseline-corrected Non-Linear Model 
Bg Baseline correction factor for non-linear model using cumulative greyscale 
bit Binary digit, taking a value of either 0 or 1. 
Cg Concentration of drug at position, g, within the SC, as measured by 
cumulative integrated pixel densities 
Cmax Maximum drug concentration achieved in SC 
Corr. Corrected 
Cum. Cumulative 
CV Coefficient of variation 
Cv Concentration of drug in the vehicle 
Cx Concentration of drug at position, x, within the SC, as measured by thickness 
measurements 
D water’s diffusivity in the SC 
D/H2 Drug’s diffusivity in the SC 
DPK Dermato-pharmacokinetics 
EDETOX Evaluations and Predictions of Dermal Absorption of Toxic Chemicals 
FDA U.S. Food and Drug Administration 
Fluo. Fluorescence 
G Total SC thickness, estimated by greyscale non-linear model 
g Cumulative integrated pixel density of SC removed by tape stripping  
g/G Relative depth reached within the SC, measured by integrated pixel density of 
SC per tape 
h Cumulative thickness of SC removed by tape stripping 
H Total SC thickness, estimated by thickness non-linear model 
h/H Relative depth reached within the SC, measured by weighing SC per tape 
HPLC High Performance Liquid Chromatography 
IAM Immobilised Artificial Membrane 
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KB Kilobyte. 1024 bytes where a byte is an ordered collection of 8 bits. 
Kg SC-vehicle partition coefficient of drug, as measured from drug concentration 
as a function of cumulative integrated pixel density profiles 
Km SC-vehicle partition coefficient of drug, as measured from drug concentration 
as a function of cumulative thickness profiles. 
Ko/w Oil-water partition coefficient  
kp Permeability coefficient of drug through SC 
LM Linear Model 
MW Molecular Weight 
NSAID Non-Steroidal Anti-Inflammatory Drug 
Pred. Predicted 
Q Total quantity of drug in SC after a given time 
QRPR Quantitative Retention Permeability Relationship 
QSPR Quantities Structure Permeability Relationship 
r Molecular radius 
Rg Average concentration of drug in SC, with SC amount quantified by mean 
greyscale value 
Rm Average concentration of drug in SC, with SC amount quantified by mass 
rs Spearman’s correlation coefficient (non-parametric correlation) 
SC  Stratum Corneum 
SER Standard Error of Regression 
SES Stable Extraction Solution; namely 8M urea, 50mM Tris, 0.1M β-
mercaptoethanol, pH 8.4 
TEWL Transepidermal Water Loss 
TEWL0 Initial transepidermal water loss measured before tape stripping 
Tmax  Application time after which maximum concentration measured 
UV Ultra-violet 
VE Viable epidermis 
WRSS Weighted Residual Sum of Squares 
Zov. Zovirax 
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1 Measurement and prediction of the rate and extent 
of drug delivery into and through the skin 
1.1 Abstract 
 
Empirical mathematical models retrospectively analyse data to predict skin permeation 
from drug physico-chemical properties. Quantitative Structure Permeability Relationships 
are discussed along with alternatives to linear modelling. Mechanistic mathematical 
models, derived from first principles are also considered. Further, in vitro experiments 
allow predictions to be made using suitable membranes (cultured cell lines or excised 
skins). In vivo methods to assess (trans)dermal drug delivery aim to minimise clinical 
studies, especially to determine bioequivalence. Microdialysis is discussed, together with 
the FDA-approved skin blanching (pharmacodynamic) assay for corticosteroids. Progress 
made with the tape-stripping methodology is reviewed. Two distinct strategies have 
emerged: (i) in which the total amount of drug in the stratum corneum (SC) at one uptake 
and one clearance time are compared; and (ii) another which generates drug permeation 
profiles across the SC, and allows dermato-pharmacokinetic parameters to be derived. 
1.2 Introduction 
 
The skin is the largest organ of the human body. Skin forms an extremely effective 
barrier, preventing both the loss of heat and water, and the ingress of microorganisms 
and chemicals. Drugs may be applied topically to skin for the local treatment of 
inflammation, infections (bacterial, viral or fungal) or to anaesthetise an area. The target 
site may be the outermost layer of the skin, the stratum corneum (SC), or deeper layers. 
Potent drugs may also be administered transdermally, travelling through the skin to the 
dermal blood vessels and into the systemic circulation. 
 
Assessing drug permeation into or penetration through the skin is important both to 
evaluate the usefulness of a drug for topical or transdermal delivery, and to compare 
different formulations to assess their bioequivalence.  
 
Prediction of drug movement through skin layers is logistically, ethically and economically 
preferable to in vivo measurements. With respect to permeation prediction, mathematical 
models, based on empirical measurements or mechanistic deductions, have been 
explored. The most important predictors of permeation are lipophilicity and molecular 
weight (MW). In vitro measurements of skin penetration using diffusion cells, separated 
by an appropriate membrane, either synthetic or ex vivo, provide important empirical 
measurements to use in the development of mathematical models. Bioengineered skin is 
being developed but currently, excised pig skin offers the most frequently chosen match 
to human skin.  
 
Predictions help to reduce the number of in vivo measurements required, by focusing 
experimental strategy, but the latter are currently still required. The in vivo strategies 
developed are intended to provide objective measurements of drug permeation, and 
minimise the need for expensive, subjective clinical trials. Three prominent methods are 
discussed: microdialysis, phamacodynamic approaches, and tape stripping. Within tape 
stripping, two improved metrics for evaluating the data are presented alongside the 
approach originally proposed by the (U.S.) Food and Drug Administration. 

























    
1.3 The prediction of topical and transdermal drug delivery 
 
The main benefits of predictions over measurement of drug delivery are clear: it is usually 
cheaper and quicker. Furthermore, there are no problems with ethical issues, recruiting 
volunteers, or housing animals.  
 
Ideally, predictions should provide a reliable indication of the extent to which drugs are 
going to permeate the skin, either to the target skin layers (for topical products) or to the 
systemic circulation (for transdermal products). Predictions are also useful to select and 
design the best drug molecules for these purposes.  
 
Mathematical models, developed using existing experimental results, provide self-
evidently the most convenient predictive tools. In vitro experiments can assess drug 
permeability through various membranes, which bear increasing relevance to human 
skin.  
1.3.1 Mathematical models 
 
Two main approaches have emerged for the prediction of drug permeation: empirical 
models and mechanistic models. The former are derived from a retrospective analysis of 
experimental results, and correlate skin permeation data with drug properties. 
Mechanistic models are derived from first principles. Permeation is predicted and 
modelled based on skin compartments and diffusion pathways. Within these broad 
categories, several other classes of models may be differentiated and are reviewed here.  
 
1.3.1.1 Empirical models 
 
The most intensively researched area involves quantitative structure permeability 
relationships (QSPRs) which correlate experimental permeation data with (i) physico-
chemical properties, or (ii) molecular structural properties of the permeant.  
 
1.3.1.1.1 Quantitative structure permeability relationships (QSPRs) 
 
Before any empirical modelling based on permeability can begin, the permeability of the 
chemical through the skin must be measured. The permeability coefficient, kp (units: 






=  Eq. 1-1 
Where Km is the drug’s SC-vehicle partition coefficient; D is the diffusivity of the drug in 
the SC; and H is the SC thickness. 
 
In vitro experiments are performed to generate data as shown in Figure 1-1. Using the 
appropriate solution of Fick’s second law (Figure 1-1, legend, [2]) for non-steady state 















































































1.3.1.1.1.1 Databases of kp values 
 
Databases of kp values have been created retrospectively. The most extensively used of 
these is the so-called Flynn database [5]. It comprises 97 kp values, for 94 compounds, 
covering a broad range of molecular weights (18-765), and octanol-water partition 
coefficients (-3 to +6). The values are mostly from human skin in vitro, with the drug 
usually delivered from an aqueous solution. Its principal shortcomings are: the 
proportionally small number of both hydrophilic compounds (9/94 with log Ko/w ≤0) and 
highly lipophilic compounds; and the lack of consideration of the chemical’s ionisation 
state and of the temperature at which measurements were made [6]. 
 
Several other compilations of log kp values have been assembled, often using some 
values from the original Flynn database. The value of these other databases have been 
described succinctly by Vecchia and Bunge [6].  
 
Recently, a European Union funded study, “Evaluations and Predictions of Dermal 
Absorption of Toxic Chemicals” (EDETOX), produced a database containing permeation 
data for 300 compounds (http://edetox.ncl.ac.uk). The work also generated new data for 
the in vitro transport of 60 chemicals across human skin [7]. The experiments were well-
designed and allowed comparison of: rat vs. human skin; static vs. flow-through diffusion 
cells; finite vs. infinite dose; skin thickness; vehicle composition; and physico-chemical 
properties (MW, log Ko/w solubility) [7]. The results have been modelled using QSPRs and 
a novel mechanistic model, the Kruse model [8], developed. 
 
1.3.1.1.1.2 QSPR models 
 
The most cited QSPR proposed is that reported by Potts and Guy [9]. Their equation was 
derived from linear regression of the kp, MW and log Ko/w values in the Flynn database (93 
compounds). The best fit equation was: 
 )(0061.0)(log71.072.2).(log /
1 MWKhcmk wop −+−=
−
 Eq. 1-2 
which had an overall correlation coefficient (r2) of 0.67. The model indicates that the 
permeability coefficient will be highest for smaller molecules, with higher log Ko/w. Given 
the typical level of variability in skin permeability measurements, the Potts and Guy 
equation performs remarkably well and certainly provides reasonable predictions. 
However, the approach focuses on the stratum corneum as the exclusive rate-limiting 
barrier and therefore significantly over-estimates kp for highly lipophilic compounds. This 
issue was successfully addressed by Bunge, Vecchia and Cleek [6, 10] whereby a 
corrected kp value of lipophilic compounds (kp (lip)) may be calculated using Eq. 1-3: 
 
Figure 1-1: The cumulative amount of drug permeating the skin, Q, under non-steady state 
conditions, after application of an infinite dose, as a function of time, t, may be modelled using the 
appropriate solution of Fick’s second law (equation as shown above); where Km is the drug’s SC-
vehicle partition coefficient; H is the SC thickness; Cv is the drug concentration in the vehicle; and D 









































































 Eq. 1-3 
 
 
where kp is that derived from the Potts and Guy equation (Eq. 1-2). The rationale behind 
this correction equation is discussed further below (section 1.3.1.2.1). 
 
Many other models have been proposed and compared [6]. Inconsistencies in the Flynn 
database relating to ionisation state (which affects Ko/w), inter-dependence of MW and 
Ko/w in some homologous series, and temperature (which affects diffusivity) have been 
identified. These factors have been explored, suitable adjustments to the permeability 
prediction equations have been proposed [6, 11-13] and slight improvements recorded. 
For example, using the logarithm of the chemical’s diffusion coefficient, log D, instead of 
log Ko/w allows the effects of pH on ionisation to be incorporated [14], although sufficient 
data do not yet exist for ionisable compounds. The comprehensive review of these factors 
is presented elsewhere [13]. If reliable data regarding log Ko/w are not readily available, 
estimates can be derived from the molecular structure, incorporating the contributions 
which various groups make to the overall lipophilicity [15]. Diffusion has also been shown 
to be related to partial charge interactions (such as H bonding), which may be predicted 
[16-19].  
 
1.3.1.1.2 Quantitative retention permeability relationships (QRPRs) 
 
Quantitative retention permeability relationships relate chromatographic parameters 
(rather than molecular parameters as in QSPRs) to permeability coefficients derived 
experimentally. Biopartitioning micellar chromatography uses modified high performance 
liquid chromatography (HPLC) columns as surrogates for biological barriers [20-24]. 
Solute capacity factors, directly calculated from retention times on the column, are used 
to derive QRPR models.  
 
The first modified HPLC column used cell membrane-mimicking phospholipids on a silica 
surface, the so-called Immobilised Artificial Membrane (IAM) columns. The resultant 
retention times correlated well with (human derived) log kp values for steroids, and slightly 
better in fact than the corresponding log Ko/w values [21]. Phenolic and ionic compounds 
showed a poorer correlation [21].  
 
A second column, with keratin immobilised on a silica support, was produced to mimic 
solute interaction with keratin in skin [20]. When a series of solutes were run on both this 
column and an IAM column, the resulting capacity factors were incorporated into one 
QRPR model which showed a good correlation (r2 = 0.87) with experimental log kp values 
for 17 compounds [20].  
 
Theoretically, by manipulating the HPLC method, the effects of pH, temperature, 
ionisation and presence of excipients on permeability may also be measured [23, 24]. 
This would be a potentially significant advantage when attempting to optimise 
formulations.  
 
1.3.1.1.3 Artificial Neural Networks (ANNs) 
 
In QSPRs, multiple linear regression is used to determine correlations between physico-
chemical properties (such as log Ko/w and MW) and permeability. Both linear and non-
linear correlations may be investigated using artificial neural networks (ANNs). ANN 



























    
22 
use of webs of interconnected neurons [25].  
 
ANNs have been successfully used [25] to predict skin permeation of 40 compounds (MW 
range ~30-390 and log Ko/w = -0.77 – 2.94). Further work, using different input 
parameters [26, 27], has again shown an improvement over multiple linear regression 
models.  
 
1.3.1.1.4 Fuzzy modelling 
 
Fuzzy models cluster data for different compounds into appropriate subsets based on 
their properties. For example, a subset may contain compounds with a log Ko/w around 
+2. Each compound will have a degree of membership of this set, between 0 and 1; that 
is, a compound with a log Ko/w exactly equal to 2 would be assigned a membership degree 
of 1.0; if log Ko/w = +1.8, then the membership degree may be ~0.9; for compounds with 
log Ko/w ≤ +1 or ≥ +3, the membership degree is zero. Of course, compounds may be 
members of several subsets as these may not be mutually exclusive. 
 
The Fuzzy model algorithms consider all the compounds in the data set and, after a 
learning period, cluster the data points into appropriate subsets and determine the 
degrees of membership of each compound to each subset. Fuzzy modelling can simplify 
complex models by revealing patterns in the data. The algorithms are numerous and 
complex but they essentially find links between inputs and outputs via Fuzzy clustering 
techniques [28]. 
 
Fuzzy modelling has been used [28] to analyse the molecular parameters (including MW, 
log Ko/w, H-bond donor activity, H-bond acceptor activity, and polarizability) from three 
sources [5, 29, 30]. The correlation between the (Fuzzy) predicted and experimental log 
kp was very good, with r2 of 0.83, 0.97 and 0.96 for three distinct data sets (with 94, 37 
and 54 compounds per dataset, respectively). In addition, fewer molecular parameters 
were required for the Fuzzy model compared with the original multiple linear regressions. 
 
1.3.1.2 Mechanistic models 
 
Mechanistic models predict permeation based on knowledge of skin compartments and 
diffusion pathways. 
 
1.3.1.2.1  Stratum corneum and viable epidermal contributions to barrier 
function 
 
To evaluate the normalised cumulative mass of drug absorbed into the SC, a series of 
three mechanistic models were derived [10], all related to exposure time, and such that 
unsteady state exposure may also be estimated.  
 
The three models (Figure 1-2) consider (1) the SC alone as a single finite membrane; (2) 
the SC alone where it is assumed that the membrane is sufficiently thick, and the 
exposure time short enough, such that it behaves as a semi-infinite membrane; and (3) 
both the SC and viable epidermis (VE) as a finite two-membrane composite, incorporating 
the partition, diffusivity and pathlength variables for both skin layers.  
 

























    
SC 
 
Figure 1-2: 3 mechanistic models proposed by Cleek and Bunge. Models based on: 1. Single finite 
membrane; 2. Semi-Infinite membrane; 3. Finite two-membrane composite. H: SC thickness. 
Redrawn from [10].  
 
For unsteady state (short) exposure times, the drug will not have reached the VE to any 
significant extent and models 1 and 2 are applicable. 
 
Model 3 is important for longer exposure times, when steady state may be reached, and 
the overall drug flux may be affected by the hydrophilic VE. This is indeed the case for 
highly lipophilic chemicals which will partition slowly from the SC and eventually become 
rate-limited by the VE. The extent to which the VE contributes to the total resistance to 
transport may be captured in a modified expression to calculate the normalised 
cumulative mass of drug absorbed into the SC, incorporating a SC-VE permeability ratio, B 
[10]. For lipophilic compounds, for which B ≥100, it is apparent that the VE affects the 
skin permeation process [31].  
 
Experimentally, however, B is difficult to measure and various approximations have been 
introduced to enable its use in Model 3 [31]. For example, the Ko/w is used to estimate the 
chemical’s SC/VE partition coefficient, and molecular weight is used to correct 
diffusivities. Both parameters are extracted from the Potts and Guy equation [29]. 
 
The correction introduced in this way places a limit on the calculated values of the 
cumulative mass of drug absorbed into the SC. The impact is greatest for lipophilic 
compounds to which the skin is exposed for long application times (and longer than the 
conventional lag time for diffusion across the skin) [32]. 
 
1.3.1.2.2 Scaled particle theory 
 
Scaled particle theory calculates the work required for solutes to be incorporated into 
lipid bilayers [33]. This theory has been applied to transdermal permeation, and used to 
calculate diffusion and partition coefficients of solutes [33]. These parameters will 
depend on lipid density and lipid disorder (assumed constant) [33].  
 
The model first assumed a tortuous pathway for diffusion across the SC [34]. Empirical 
data was used to derive the relationship Km = (Ko/w)0.7 which was then used to estimate 
Km in the model [33]. The solute’s diffusivity through the SC was estimated from the 
molecular radius (r, (Å)) which, in turn, was calculated empirically from the MW [33, 35], 
using data from Mitragotri et al [Table 1 of reference 35] to derive:  
 
 3 22.0 MWr ×=  Eq. 1-4 
 The final expression for the permeability coefficient was:  
 )46.0exp(02.0*)().( 27.0/
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24 
Or, in logarithmic form: 
 2
/
1 20.070.17.0).(log rKhrcmk wop +−=
−
 Eq. 1-6 
This model and the Potts and Guy equation give very similar results [12]. Although they 
are derived in very different ways, by re-substituting MW in place of the radius (using Eq. 
1-4), Eq. 1-6 can be rewritten as: 
 3/2
/
1 072.070.1log7.0).(log MWKhrcmK wop +−=
−
 Eq. 1-7 
which bears remarkable similarity to the Potts and Guy equation (Eq. 1-2) [12].  
 
The model was tested using a compilation of experimental values [34], and a slightly 
lower mean absolute error was found for the mechanistic model (5%) as compared with 
Potts and Guy (6.3%) [33]. Notable deviations from Eq. 1-6 are molecules with MW > 400 
Da.  
 
Subsequently, the model in its original form (which focussed on solute permeation 
through the intercellular lipid domains of the SC) was expanded to include alternative, 
parallel pathways, including transport via putative aqueous ‘pores’ and through various 
shunts, such as hair follicles and sweat glands [36]. This more complex approach was not 
only able to match the predictions of the Potts and Guy equation, but could also fit the 
results for larger hydrophilic compounds, the permeability of which is usually 
underestimated by earlier models. On the other hand, it should be pointed out that the 
‘price’ for this improvement is a more complex model containing an increased number of 
adjustable parameters.  
 
In summary, the most straightforward and widely used mathematical model is the 
empirical Potts and Guy equation (Eq. 1-2). It provides an adequate prediction based on 
two easily obtainable physicochemical properties, MW and logKo/w. Modifications and 
refinements have been proposed, and the adaptation for lipophilic compounds [10, 31, 
32] is a sensible and necessary development. Introduction of additional parameters or 
incorporation of other parallel pathways can improve the overall correlation between 
predicted and experimental results but there is a cost in terms of simplicity and 
practicality. 
1.3.2 In vitro experiments 
 
In vitro experiments use vertical or side-by-side diffusion cells, with the receptor fluid 
separated from the solution/formulation by an appropriate membrane. Measurements of 
drug flux through the membrane are obtained from the cumulative amount transported as 
a function of time (Figure 1-1). Solutions of Fick’s first and second laws can then be used 
to derive the permeability coefficient, or other representative transport metrics in steady 
or unsteady state situations, respectively [3]. In vitro experiments provide a quantitative 
measure of drug penetration, and are cheaper and are less complicated to perform than 
in vivo studies.  
 
1.3.2.1 Choice of membranes 
 
The best membrane for in vitro studies is human skin, which may be obtained from 
surgical procedures. However, a regular supply is not always available; the use of cadaver 
skin is not generally possible and frequently leads to highly variable data. As a result, 
alternatives have been investigated.  
 
1.3.2.1.1 Cultured cell lines 
 

























    
Cultured cell lines represent a development from the field of tissue engineering (i) to 
provide biomimetic, non-immunogenic skin layers to protect, and aid the healing of, acute 
and chronic wounds, burns and ulcers; and (ii) as a model for permeation and 
toxicological assessment of cosmetic and medicinal products. Research has accelerated 
because, from 2009, European Union directives will prohibit the use of animals in toxicity 
studies for cosmetic products [37]. In addition, the use of donated human tissue for 
purposes of financial gain is prohibited [38].  
 
There are two principal categories of cultured skin tissues: living skin equivalents 
comprising a dermis, epidermis and partially differentiated SC, but without skin 
appendages; and human reconstructed epidermis which consists simply of keratinocytes 
grown on a substrate. Examples of the latter are more common (EpiSkin® (L’Oréal, Clichy-
Cedex, France), SkinEthic® (SkinEthic Laboratories, Nice, France), EpiDerm® (MatTek 
Corporation, Ashland, MA, USA)) than the former (Apligraf®, Graftskin® (Organogenesis, 
Canton, MA, USA)).  
 
The morphology and biochemistry of human reconstructed epidermis has been compared 
with ex vivo human tissues [39-41]. Both have a differentiated epithelium, with stratum 
corneum, stratum granulosum, stratum spinosum and stratum basale but several 
histological and biochemical differences are apparent [39]. The SC is typically thicker and 
more variable that human skin, and is not always fully keratinised [39]. The morphology, 
lipid composition, and biochemistry of Epiderm®, SkinEthic® and EpiSkin® have been 
reviewed, together with their applications in phototoxicity, irritancy and absorption testing 
[41].  
 
Generally speaking, chemical penetration across human reconstructed epidermis is quite 
reproducible, but significantly higher than through human, pig or rat skin [40-44]. They 
have thus been proposed as useful tools with which to compare and optimise 
formulations [45], but care must be exercised if excipients are present which may alter 
barrier function (and result in artefactually amplified penetration results).  
 
Living skin equivalents, despite their greater similarity with human skin [41], have shown 
to similarly overestimate chemical penetration [43, 44, 46]. 
  
Overall, therefore, while valuable, for example, for skin irritation assessment, skin cell 
culture models are not yet able to provide quantitative predictions of percutaneous 
penetration.  
  
1.3.2.1.2 Excised skins 
 
Many animal models have been suggested for evaluating percutaneous penetration, 
including primates, ungulates (pigs, including miniature pigs), rodents (mice, rats and 
guinea pigs) and reptiles (snakes).  
 
Rodent skin is widely available and is often used. Hairless species are preferred since 
potentially damaging shaving or depilation is avoided, and the follicular density resembles 
human skin more closely. Results show that penetration rates are higher for rodent skin 
than human skin, with rat skin up to ten times more permeable [47, 48] 
 
Pig skin has been repeatedly shown to be a relevant and convenient animal model for in 
vitro penetration studies [43, 44]. When compared to human skin, pig skin is similar in 
terms of histology and dimensions but the diameter of porcine hair follicles is larger [49].  
 
Flux profiles of diverse compounds across pig skin are similar to those through the 
human barrier [44, 50] and it appears unlikely that the use of the porcine model will over-



























    
26 
discussed below, the concentration profiles of drugs (such as ibuprofen) across pig SC 
closely resemble those observed in vivo in humans [51]. 
1.4 Measurement of (trans)dermal drug delivery in vivo 
 
Clearly, for transdermal products, whose target site is the systemic circulation, well-
established in vivo pharmacokinetic studies, taking blood and/or urine samples at 
particular times post application and removal of the product, provides the most reliable 
measurement of transdermal drug penetration. These pharmacokinetic studies, similar to 
those of controlled release formulations, are accepted from a regulatory perspective for 
transdermal products [52, 53]. 
 
Despite the advances made in predictive models and in vitro testing, and their inherent 
advantages, the ultimate evaluation of topical drug delivery into and though the skin has 
to be performed in vivo, in man. For new chemical entities, the necessity of clinical trials 
is clear. In the case of generic products, while testing of efficacy remains a requirement, 
there is considerable effort currently directed at the assessment and validation of 
alternative approaches, with which to assess bioequivalence. 
1.4.1 Microdialysis 
 
Microdialysis is an in vivo technique for sampling free drug concentrations in the 
extracellular fluid within tissues or organs. A thin dialysis membrane tube is inserted into 
the site of interest and perfused with a site-compatible physiological solution (Figure 1-3). 
Molecules of interest (usually small and water soluble) diffuse across the membrane, are 
collected and measured.  
 
 
With respect to (trans)dermal drug delivery, the microdialysis probe is inserted 
subcutaneously or intradermally. The technique boasts many advantages: (i) continuous 
measurements of drug concentration with time are possible, allowing pharmacokinetics 
to be followed; (ii) large molecules are size-excluded by the dialysis membrane, limiting 
analytical interference and enzymatic degradation [54, 55]; (iii) no tissue or bodily fluids 
are removed permitting an unlimited number of samples to be taken; and (iv) 
endogenous compounds, such as lactate, glucose, neurotransmitters, etc may also be 
measured.  
 
Limited experiments have assessed drug concentrations in subcutaneous tissue and 






Figure 1-3: Schematic of microdialysis membrane used for dermato-pharmacokinetics. 

























    
underlying muscle after topical and oral administration of ibuprofen [56]. Dermal 
concentration profiles of lidocaine [57], salicylic acid [58] and 8-methoxypsoralen [59] 
have been measured, including comparisons with plasma levels for 8-methoxypsoralen.  
 
The drawbacks of the technique include tissue reactions as the probe is inserted [60]; the 
choice of flow rate and sampling times requires fine tuning [61]; analytical techniques 
require high sensitivity due to dilution with perfusate [62]; and selection of perfusate and 
dialysis membrane depends on the drug of interest, with lipophilic, large drugs posing 
particular problems [63]. The mathematical extrapolation of extracellular fluid 
concentrations from the dialysate concentration is also challenging, often requiring the 
co-administration of a reference molecule (reviewed, [64]). Inter- and intra- individual 
variability is relatively large, with coefficients of variation between 50-100% [60].  
1.4.2 Pharmacodynamic assessment of topical corticosteroids.  
 
Corticosteroids typically exert a quantifiable blanching effect on the skin caused by 
vasoconstriction of dermal microvasculature after the drug has permeated through the 
epidermis. The FDA has adopted this pharmacodynamic effect as an acceptable method 
for assessing the bioavailability and bioequivalence of topical corticosteroids [65]. 
Originally the colour change of the skin was assessed by a trained operator, but the 
development of the chromameter has allowed objective, sensitive and quantifiable 
measurements to be made. This apparatus assesses (skin) colour based on the L-scale 
(light-dark), the a-scale (red-green) and the b-scale (yellow-blue). The FDA guidance 
document specifies only the use of the a-scale [65]; however, the L-score [66, 67] and all 
three [68] have also been used successfully. 
 
The main advantage of the skin blanching assay is its non-invasive nature and that, as a 
result, many measurements may be made over an extended time period on the same 
site. Corrections for changes in skin colour unrelated to the formulation are made at an 
adjacent site. Further advantages, compared with clinical trials, are that formulations may 
be quickly and objectively assessed in a relatively small number of healthy participants, 
avoiding the problems associated with patient selection.  
 
The FDA protocol involves two stages [65]. First, a pilot study determines the effect of 
dose duration (0.25 – 6.0 hours) on the blanching response for all the formulations of 
interest. Second, the “pivotal in vivo bioequivalence study” evaluates the 
pharmacodyanmic changes that occur (over 24-28 hours) after the formulation has been 
removed and the skin cleaned. 
 
The degree of skin blanching has been correlated with drug potency [67] and with the 
permeation of the corticosteroid through the skin [66, 69-71]. Bioavailability has also 
been assessed using the technique [69] and formulations have been compared [66, 70, 
72, 73]. Attempts to correlate skin blanching results with clinical results [69, 74] have 
been reported too.  
 
However, the method has its limitations. The precision of chromameter readings has been 
unfavourably compared with the visual assessment of blanching [68, 75]. Skin colour 
may be affected by the pressure with which the chromameter is applied, by 
inhomogeneity in the initial skin colour and by circadian variation [75]. There is evidence 
that the blanching response can be saturated preventing differences between 
formulations from being observed [76, 77].  
 
Clearly, the vasoconstrictor assay is only applicable to drugs eliciting the appropriate 
pharmacological response, and it is approved by the FDA uniquely for topical 



























    
28 
been efforts to determine whether other types of compound may be amenable to a 
pharmacological assay.  
 
For example, while non-steroidal anti-inflammatory drugs (NSAIDs) do not produce a 
comparable visual response per se, their ability to diminish the action of a subsequently 
applied vasodilator (such as an ester of nicotinic acid) may be assessed objectively using 
a chromameter [67, 78] or a laser Doppler velocimeter [79].  
 
Equally, topical retinoids typically induce an increase in transepidermal water loss (TEWL) 
[80-83] a response which can again be quantified with existing biophysical tools. The 
same drugs also cause visible irritation [83], which can be assessed instrumentally as 
described above, and this action has been reported to be better quantifiable than the 
change in TEWL [83]. These two measurements should be correlated as well, although 
this has not been shown unequivocally.  
1.4.3 Tape stripping 
 
The removal of sequential layers of the stratum corneum using adhesive tapes can be 
performed with minimum discomfort and relative ease in vivo, usually on the volar 
forearm of healthy volunteers.  
 
When a formulation has been applied to the skin prior to tape stripping, drug may be 
extracted from the tapes to quantify the amount of drug which has permeated into the 
SC. Since the SC is the principal barrier to drug absorption, it may be assumed that the 
(dermatopharmaco)-kinetics (DPK) of drug passage through this layer are related to 
topical bioavailability [84]. Formulations may be applied for various application times, or 
stripping delayed after formulation removal to measure SC clearance, and DPK 
parameters derived. The latter can be used to compare topical formulations and to 
assess bioequivalence. In the original application of tape-stripping to assess chemical 
uptake across the skin, good correlations were observed between those amounts 
recovered on the strips and that which penetrated through to the systemic circulation 
[85]. 
 
Three approaches, summarised schematically in Figure 1-4, have been proposed for the 































    
Figure 1-4: Three approaches for the analysis of dermato-pharmacokinetic (DPK) data. A. Original 
FDA metric. The total amount of drug in the SC after 4 application times (▬) and 4 clearance times 
(­­­­­) are determined and plotted as a function of time. The maximum amount of drug in the SC 
(Amax), the time at which Amax was achieved (tmax), and the area under the curve (AUC) are found 
and used to evaluate and compare formulations. B. ‘Two-time’ method. Ratio of drug amounts (± 
95% confidence interval) for an innovator drug A, compared with two generic formulations, B and 
C. Two application times (one uptake, and one clearance (CL)) and uptake + CL data combined are 
considered. To be bioequivalent, the ratio should lie in the 0.8-1.25 bioequivalence window. C. 
‘Drug in SC profile’ method. For each tape, the concentration of drug in SC is plotted against the 
corresponding relative position within the SC (h/H). The curve is fitted to Eq. 1-9 to generate a best 
fit profile (­­­­­) and to extract partitioning and diffusivity parameters. 
 
1.4.3.1 Original FDA dermato-pharmacokinetic (DPK) metric 
 
In 1998, the FDA issued draft guidance for the DPK method to assess the bioequivalence 
of topical products for application to the skin, except those causing severe SC disruption 
[86]. The draft guidance required quantification of the total amount of drug in the SC as a 
function of time, akin to the typical concentration-time profiles of traditional 
pharmacokinetic studies using blood sampling. Four application times, and four 
elimination times were required per formulation. From these profiles, area under curve 
(AUC), Cmax and Tmax were evaluated per unit area of skin (Figure 1-4A). For the test 
products to be bioequivalent, the 90% confidence interval for the ratio of population 
geometric log means of test to reference should be 80-125% for AUC and 70-143% for 
Cmax. 
 
The draft guidance was withdrawn in 2002 [87] following the results of two studies which 
compared tretinoin gel formulations, specifically Retin-A, the innovator, and Avita, an 
approved generic product. Avita is qualitatively and quantitatively different, and has been 
found to be therapeutically inequivalent to Retin-A [88-90]. Both investigations concluded 
that the formulations were bioinequivalent but, worryingly, one measured higher retinoid 
levels from Retin-A than Avita [89, 90] while the other found the opposite [88]. Naturally, 
these opposing results prompted concern about reproducibility; furthermore, the 
adequacy of the method to assess drugs whose target site is beyond the SC was 
questioned.  
 
Parenthetically, it should be noted that the divergent tretinoin findings were probably due 
to differences in the areas of SC stripped by the two laboratories. One group stripped an 
area exactly equal to the application area, while the other stripped an area larger than the 
treated site. Because one of the formulations was subsequently shown to spread radially 
on the skin surface during the application period, the drug amounts removed were 
Tmax 
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30 
different, did not match and the two laboratories revealed opposite conclusions.  
 
With this observation in mind, a subsequent large-scale study was performed comparing 
the innovator tretinoin gel with therapeutically inequivalent and equivalent formulations 
[89]. Following the FDA guidance, eight time points were examined per formulation in 49 
volunteers, resulting in a total of 1176 sites. The results confirmed the clinical findings for 
the different gels. In contrast, another DPK study did not confirm the clinical findings for 
two miconazole nitrate vaginal creams [91], when compared using the FDA’s DPK 
protocol; however, it could be expected that a pharmacokinetic study conducted on volar 
forearms would be difficult to compare with a clinical study where formulations were 
applied to vaginal epithelium, due to the inherent differences between these membranes.  
 
In addition to ensuring that the area of SC stripped is less than, or equal to, the area of 
application, a further modification of the FDA guidance encourages analysing drug 
content from all tapes. The FDA proposal to discard the first two tape-strips was never 
validated and typically results in significant amount of compound being ignored. This is 
important because the first tape-strips invariably take off the largest amounts of SC [92]. 
Including all tapes, on the other hand, requires that the cleaning of the skin surface at the 
end of the application period is efficient to ensure that unabsorbed drug (i.e., that not 
taken up into the SC) is completely removed. This is particularly important for real 
formulations which may lodge in the ‘furrows’ of the skin [93]. It appears that an alcohol 
wipe, similar to that used to sterilise the skin before an injection, may offer a useful 
solution to this challenge [94]. 
 
A further stipulation of the 1998 FDA draft guidance was that, having discarded the first 
two strips, drug should be quantified in the subsequent ten tape-strips. Two obvious 
weaknesses of this approach are clear: (i) ten strips do not remove the same amount, nor 
the same fraction of the SC, in each volunteer, and (ii) ten strips will not remove (in most 
instances) the entire barrier layer and will not necessarily ‘capture’, therefore, all the drug 
taken up into the SC at the sampling time. A simple approach to overcome this problem is 
to continue stripping until most, if not all, of the SC is removed. Transepidermal water loss 
(TEWL) measurements provide a convenient means with which to ensure that this is the 
case [1, 93], as shown in Figure 1-5.  
 























Figure 1-5: Example of experimental data (□) of TEWL against cumulative SC thickness removed, h. 
A non-linear fit to Eq. 1-8 produces the best fit (▬) and an estimate of the total SC thickness, H.  
 
Other criticisms of the original FDA guidelines are apparent. For example, the requirement 
for eight time points (four for uptake, four for clearance) is very burdensome in terms of 

























    
study time and analytical work. Unlike the situation with oral drug administration, for 
which the pharmacokinetic parameters are determined by a complex function of 
absorption, distribution, metabolism and excretion, the uptake phase in a DPK 
experiment depends only upon drug partitioning and diffusion in the SC, while clearance 
is only dependent upon diffusion. Likewise, and specific to DPK, the clearance phase only 
begins after formulation removal at the longest application time [93]. It is a reasonable 
question, therefore, to ask whether the comparison between formulations requires such a 
large number of time points. The concomitant difficulty with a requirement for such a 
large number of test sites is that, for drugs which do not penetrate the SC well, it may be 
necessary to increase the surface area of application (and hence the area stripped) to 
have enough drug in the tape strips for reliable quantification. At some point, as a result, 
there may be insufficient skin surface to perform the experiment according to the FDA 
guidance. Furthermore, as no replicates are performed, the number of volunteers 
required to achieve statistical power is large.  
 
Research into alternatives has focused on two areas: (i) comparing the total amounts of 
drug in the SC at one uptake and one clearance time; and (ii) modelling drug in SC 
permeation profiles showing drug concentration at progressive depths within the SC. 
 
1.4.3.2 The ‘two-time’ metric 
 
This method examines only one uptake and one elimination time per formulation. This 
allows replicate sites to be studied, and higher statistical power to be achieved with fewer 
volunteers [95]. No tapes are discarded, but tapes are combined and extracted in groups 
to achieve high concentrations for analysis. The total amount of drug in the SC is 
measured for each site. The ratio of total drug amounts in the SC from formulation A to B 
or A to C is determined (Figure 1-4B). The two-time method correctly predicts 
bioequivalence or bioinequivalence of retinoids [93, 95, 96] and econazole [93, 95].  
 
The retinoid data produced to satisfy the full DPK metric [89, 97] have been reanalysed 
using four alternative metrics: (a) the sum of total drug amount from all four uptake time 
sites; (b) the sum of total drug amount from all four clearance time sites; (c) the sum of 
total drug amount from all uptake and clearance sites; and (d) the total drug amount from 
each uptake and clearance time separately [93, 96]. Ratios of each of these total 
amounts of drug in the SC were calculated and used to assess bioequivalence of 
formulations B (therapeutically inequivalent) and C (therapeutically equivalent) to the 
innovator (Retin-A). All four metrics confirmed the clinical results. Most interestingly, the 
fourth metric showed that the ratios were similar for each of the time periods examined 
individually, suggesting that information regarding bioequivalence may be gleaned from 
just one uptake and one clearance time. Considering the bioinequivalent gel, the 
reanalysis highlighted a greater difference from the innovator in the clearance phase than 
during the uptake phase.  
 
The simplified approach was further tested using econazole nitrate creams, for which the 
drug’s site of action is the SC. The innovator product (Spectazole®, Ortho-McNeil 
Pharmaceutical Inc., Rariton, NJ, USA) was studied alongside two therapeutically 
bioequivalent generics (made by Taro Pharmaceuticals USA Inc., Hawthorne, NY, USA and 
Clay-Park Laboratories Inc., Bronx, NY, USA). The general (controlled strip area; no tapes 
discarded; site cleaned with alcohol swab; number of tapes determined by TEWL) and 
specific (one uptake and one clearance time measured; duplicate measurements; tapes 
combined for analysis) modifications discussed above were all incorporated.  
 
In a preliminary study [93], all creams were studied on three occasions (separated by at 
least four weeks) in a single volunteer to check the proposed methodology for the 
subsequent ‘pivotal’ study, and to assess the intra-subject variability when 
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when to terminate stripping, reduced variability in the amounts of SC and drug collected. 
The variability between sites studied on different occasions was also low compared with 
the retinoid data discussed above. In the preliminary study only, the tapes were weighed 
before and after stripping, and the SC thickness was determined at a separate skin site. 
However, as the SC was almost completely removed (as determined by TEWL), it was not 
considered necessary to quantify the SC on the tapes in the pivotal study.  
 
The subsequent, larger, ‘pivotal’ study, involved just 14 volunteers, and confirmed the 
promising results obtained in the tretinoin reanalysis [93, 98]. When uptake and 
clearance were considered separately, the 90% confidence interval of the ratio of total 
drug amount in the SC (generic to innovator), conclusively lay within the 80-125% 
bioequivalence window, consistent with the clinical studies. The subject-to-subject 
variability was higher than the intra-subject variability, which may support the comparison 
of products within each subject [93]. 
 
1.4.3.3 Drug permeation profiles across SC 
 
In this approach, the drug concentration profile across the SC is determined by 
quantification, on each tape, of (a) the amount of drug, and (b) the amount of SC 
removed, and hence the depth within the barrier at which each drug amount is 
determined. Analysis of the concentration profile permits parameters describing the 
partitioning and diffusivity of the drug (reflecting the rate and extent of permeation, 
respectively) to be estimated and used to compare different formulations.  
 
Quantification of the SC removed on each tape is assessed by weighing the tape pre- and 
post-stripping. From the mass of SC, and its published density (1g/cm3) [99], the volume 
of tissue removed is found. Then, given that the area stripped is known and controlled, 
the average SC thickness (h) removed on each tape (and hence the cumulative depth 
sampled) can be calculated. If measurements of TEWL are made during the sequential 
tape-stripping process, the total thickness of the SC (H) can be found by fitting the results 
to a recently published non-linear model which describes how TEWL increases as the SC 







+=  Eq. 1-8 
where B is a constant, D is the diffusivity of water in the SC, K is the SC-viable tissue 
partition coefficient of water, and ∆C is the water concentration gradient across the SC. A 
typical fitted profile is shown in Figure 1-5.  
 
This analysis represent a refinement of the originally reported approach [101]. For an 
important subset of volunteers, the TEWL value remains constant as the SC is initially 
stripped. This could be due to the stratum corneum disjunctum providing a lower 
contribution to SC barrier function; or structural variability across the SC affecting inter-
cellular tortuosity, such that the diffusivity of water across the barrier is not constant. The 
refined model contains a constant, B, which allows a more precise estimate of H to be 
determined for sites where an initial plateau is apparent. Furthermore, by analysing the 
original values rather than reciprocal values, the errors associated with each point are not 
correspondingly distorted. Both the new approach and the method used earlier have the 
important benefit of allowing H to be found without having to completely remove the SC. 
Once TEWL has increased 4- or 5-fold (which corresponds to ~75% removal of the SC), 
sufficient information has been obtained to reliably find H. 
 
This procedure to evaluate H is typically performed at a site adjacent to the treatment 
site, to avoid any potential artefacts affecting TEWL, for example evaporation of residual 
excipients from the formulation. Knowledge of H for each volunteer permits all SC 

























    
concentration profiles to then be expressed as a function of h/H, or relative depth 
reached within the SC. This value varies, therefore, between 0 at the skin surface, to 1 at 
the SC-stratum granulosum interface.  
 
However, the drawbacks of the gravimetric (weighing) approach for the determination of 
the SC thickness are significant: the procedure is laborious and tedious; reproducibility 
and precision can be low as the mass of SC is small relative to the mass of the tape; and 
measurements can be influenced by environmental conditions (e.g., humidity) and static 
electricity.  
 
Other methods have been investigated. The UV pseudo-absorption of corneocytes has 
been extensively researched [102], but the correlation between this measurement and 
the mass of SC is unsatisfactory unless those tapes with an inhomogeneous layer of SC 
are ignored. Hence, this strategy is inappropriate to accurately measure the position 
reached within the SC, where the contribution from every tape is required.  
 
The extraction and quantification of proteins from tapes can also measure the amount of 
SC removed by tape-stripping [103-108]. However, this is a destructive test, often 
incompatible with drug extraction and quantification. While such an approach may be not 
useful for dermato-pharmacokinetic studies, a sensitive protein assay would be valuable 
to validate other techniques. Unfortunately such a sensitive technique does not currently 
exist.  
 
Attempts have also been made to correlate spectroscopic absorbance (using infra-red 
light at 850nm) with masses of protein determined from SC extraction and assay [103] 
Correlation coefficients were high (r2=0.85) with all 238 tapes included, but issues 
regarding sensitivity remain, as expressed above.  
  
Most recently, a novel imaging method to quantify SC on tapes has been investigated and 
the results presented in this thesis. High-resolution images are taken of each tape under 
carefully controlled optical conditions. Photographs fully illustrating this method are 
shown in General Appendix I. An image is composed of ~64000 pixels, each of which has 
a greyscale value associated with it when examined using image analysis software. 
Statistical analysis on the distribution of these pixels provides a mean greyscale value 
that offers a relative measure of SC content of the tapes. The approach has been shown 
to be more rapid, simple, sensitive and precise than either the weighing or UV 
pseudoabsorption methods (Chapter 4). Further, the greyscale values have been shown 
to be a useful relative measure of SC amount per tape for the determination of SC total 
thickness in drug permeation experiments (Chapter 5), and for full dermato-
pharmacokinetic studies of acyclovir creams (Chapter 6).  
 
The concentration profiles of a drug as a function of the relative position in the SC (h/H) 
(Figure 1-4C) have typically been fitted to a solution of Fick’s second law of diffusion 
assuming the following boundary conditions: (i) that an infinite dose is applied; (ii) that 
the SC is initially drug-free; (iii) that the SC is homogeneous in its barrier properties; and 
(iv) that the viable epidermis provides a perfect sink for permeating drug. Under these 
circumstances, the concentration (Cx) of drug, as a function of time (t) and of position (h) 



























 Eq. 1-9 
where Cv is the drug concentration in the vehicle. By fitting the concentration profile to 
this equation, estimates of the drug’s SC-vehicle partition coefficient (Km) and its 
characteristic diffusion parameter (D/H2, which has units of [time]-1 like a first order rate 



























    
34 
the drug’s permeability coefficient (kp) across the SC, when delivered from the vehicle 










p )( 2==  Eq. 1-10 
















































 Eq. 1-11 
This estimation can be compared with the total drug recovered experimentally to check 
that the SC was indeed mostly removed during the tape stripping process. It can also be 
appreciated that Km, D/H2 and Q provide useful pharmacokinetic parameters with which 
to characterise and compare formulations. The value of Km will impact significantly on the 
extent of uptake (Q), and D/H2 offers a metric with which to characterise the rate of drug 
absorption across the SC. It will also be appreciated, once Km and D/H2 have been found 
from the concentration profile at a specific time, t, that these values can be substituted 
into Eq. 1-11 to predict the evolution of Q as a function of time (offering thereby a means 
with which to simplify a DPK study considerably).  
 
Experiments, from which drug concentration profiles across the SC have been obtained, 
are robust and reproducible even with relatively small numbers (n = 4-6 per experiment) 
of subjects and sites [51, 109-112]. By judiciously using the data derived from individual 
tapes, information on the rate and extent of drug permeation has been derived both in 
vivo in man and ex vivo using porcine skin.  
 
These experiments have allowed both the practical comparison of formulations (such as 
ibuprofen gels [110]) and the deduction of mechanistic information. For example, the 
addition of oleic acid to a formulation containing terbinafine, enhanced drug uptake into 
the SC by increasing the value of D/H2 but had no effect on Km [92]. On the other hand, 
the role of a co-solvent (propylene glycol) on ibuprofen formulations clearly had a major 
impact on Km, while D/H2 was unaltered [51, 111]. In this instance, it was possible to 
deduce that the excipients had increased the solubility of the drug in the SC, thereby 
significantly modifying their uptake into the skin [111, 113]. The effect of formulating 
betamethasone-17-valerate in novel microemulsions (with significant concentrations of 
different surfactants) showed that Q was dependent on both concentration in the vehicle, 
and the degree of saturation of the drug in the formulation [112]. 
 
Furthermore, as mentioned above, it has also been possible to use values of Km and 
D/H2, derived from SC concentration profiles observed following relatively short periods of 
exposure, to predict the uptake kinetics over time up to the attainment of steady state 
conditions using Eq. 1-11 [84, 94, 109] The value of this approach, of course, is the 
potential to significantly simplify a DPK protocol for the comparison of formulations. As 
fewer sites are required than for the original FDA guidance, replicates can also increase 
statistical power.  
 
An important caveat to this strategy, however, is that it is sensitive to the application time 
chosen for the determination of Km and D/H2. This period must be long enough that a 
measurable profile of drug across the SC is achieved, but should not be too close to 
steady state because the information about D/H2 will be lost. The use of too short an 
application period not only brings with it a potential analytical chemistry problem, it also 
risks the introduction of an artefact if the exposure time is similar to the time required to 
effectively strip the skin [114]. Selection of the optimal time at which to conduct the 
experiment needs to be confirmed by the drug’s diffusion lag time across the SC, a 

























    
parameter largely determined by its molecular volume (or molecular weight) [93]. 
1.5 Conclusion 
 
The empirical mathematical model proposed by Potts and Guy provides an adequate 
prediction of drug permeation based on two easily obtainable physicochemical properties, 
MW and logKo/w. Drug flux is the product of the permeability coefficient and drug 
solubility. There are numerous software programs which provide estimates of logKo/w and 
solubility although experimental values are most certainly preferred. Mathematical 
models consider solely the drug molecule of interest, and cannot predict the significant 
effects of formulation on permeation.  
 
For in vitro penetration studies, the use of porcine skin is favoured and provides a useful 
indication of in vivo penetration. The influence of formulation is measurable, and can thus 
be used for development work.  
 
From a regulatory perspective, in vivo measurements are required, and there is certainly 
enthusiasm to replace subjective clinical trials with a sensitive objective method such as 
tape stripping. In vivo measurements offer scope for objectively comparing formulations. 
The pharmacodynamic assessment of corticosteroids is approved and improvements 
made to the tape stripping methodology have shown promise for comparing many drugs, 
and may offer explanations why formulations perform differently.  
1.6 Notes  
 
This chapter has been submitted for publication to the Expert Opinion on Drug Delivery 
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2 The determination of stratum corneum thickness – 
an alternative approach 
2.1 Abstract 
 
The individual thickness of the stratum corneum (SC) is required to normalize drug 
permeation profiles in dermato-pharmacokinetic studies. The thickness is often 
estimated using tape-striping combined with transepidermal water loss measurements. A 
linear transformation of Fick’s first law is used to relate the progressively thinner barrier 
with the corresponding increase in transepidermal water loss and to estimate the 
thickness by linear regression. However, the data from an important subset of subjects 
are poorly fitted to this linear model. This is typically due to the removal of loose outer 
layers of SC, which do not contribute significantly to barrier function. This work proposes 
two alternative non-linear models. All three models were used to fit data from 31 in vivo 
tape-striping experiments and their outcomes and goodness-of-fit compared. The results 
suggest that the linear model may overestimate the SC thickness and is open to 
subjectivity regarding the selection of data points to be fitted. The non-linear models 
satisfactorily fitted all the data, including all data points. No significant differences were 
found between the thicknesses derived from the two non-linear models. However, the 




The individual thickness of the stratum corneum (SC) is required in order to normalise 
drug penetration profiles from different volunteers during dermato-pharmacokinetic 
studies. Bioavailability describes the rate and extent to which a drug, in an active form, 
reaches its target site. In the case of topical formulations seeking a local effect, the target 
site is the skin. By measuring the ‘rate’ and ‘extent’ of drug penetration into the skin, so-
called dermato-pharmacokinetic parameters may be derived. These parameters and the 
drug penetration profiles provide information with which to assess bioavailability and 
demonstrate bioequivalence between different formulations. It has been suggested that 
since the SC is the principal barrier to drug absorption, that kinetic data of drug passage 
through this layer can be related to bioavailability in the target tissue [84, 86, 115].  
 
The tape stripping technique has attracted considerable interest from regulatory bodies, 
such as the U.S. Food and Drug Administration, as a means to determine dermato-
pharmacokinetic parameters, and ultimately test bioequivalence between formulations  
[86, 115]. Tape stripping involves the sequential removal of layers of the SC using 
adhesive tapes. It can be performed with minimum discomfort and relative ease in vivo. 
Typically, formulations are applied to the accessible volar forearm, which has a SC 
thickness shown to be consistently between 10-20 µm for most volunteers [116]. 
Restoration of the 80-90% of SC’s barrier function is complete within 3 days [117] and 
transepidermal water loss (TEWL) values return to normal after eight [118] to eleven 
[119] days.  
 
In 1998, the FDA issued guidance on the tape stripping technique for evaluating drug 
penetration through the SC [86]. It was later withdrawn when the comparison of three 
products by two laboratories resulted in contradictory outcomes. Since then, some 
problems with the original guidance have been identified: (i) discarding two tape strips 
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absorption eventually [84, 120] (ii) in an attempt to relate the drug concentration to a 
particular depth within the SC, and in order to normalise the data derived from different 
volunteers [51, 84, 92, 109, 120, 121], the total thickness of the SC is now measured 
[101, 122].  
 
An exact measurement of the SC thickness (H) is impossible in a completely non-invasive 
way. However, a solution of Fick’s first law allows the easily measurable TEWL value from 






=0  Eq. 2-1 
Where TEWL0 is the baseline TEWL, D is the diffusion coefficient of water in the SC; K is 
the SC-viable tissue partition coefficient of water; ∆C is the water concentration gradient, 
and H is the thickness of the SC. This equation assumes that the SC is the main barrier to 
water loss, and that it provides a homogeneous barrier to water diffusion, justified by 
Kalia et al. [1]. 
 
Therefore, once a certain cumulative thickness of the SC, h, is removed by tape stripping, 







=  Eq. 2-2 
h is calculated from the area of strip; mass of SC on tape; and the density of the SC 
(~1g/cm3  [99]). A reciprocal transformation of equation Eq. 2-2 provides a linear 

















 Eq. 2-3 
Experimental data expressed according to Eq. 2-3 should yield a single straight line that 
can be analyzed by simple linear regression. Extrapolation of this linear regression to 
1/TEWL = 0 yields h = H, allowing H to be found.  
 
However, data from a significant subset of subjects are not satisfactorily fitted by this 
Linear Model (LM). In these cases, representation of the data according to Eq. 2-3 yields 
an initial plateau followed by a declining straight line. This suggests that the barrier 
function to water loss across the SC is not homogeneous. It could be hypothesized that 
this initial plateau corresponds to the removal of the stratum corneum disjunctum; the 
looser outer SC layer [123-126] which does not provide a significant barrier to water loss. 
It follows that its removal would contribute a significant mass change without a 
corresponding increase in TEWL. Alternatively, variation in corneocyte size or arrangement 
at different SC depths may also account for variability in water diffusivity across the 
barrier. Thus, the Linear Model (Eq. 2-3) which assumes that the SC barrier properties are 
homogeneous, cannot reflect experimental findings accurately. 
 
Another disadvantage of the LM results from the mathematical procedure: upon inversion 
of the TEWL values into 1/TEWL, there is also an inversion of the errors associated with 
each data point, which can skew the goodness-of-fit of the linear regression [127, Section 
5.2.4]. 
 
The aim of this work was to develop an improved model which avoids the problems 
mentioned above. We propose first the Baseline-corrected Non-Linear (BC-NL) model (Eq. 
2-4) which (a) fits directly TEWL versus cumulative thickness data, thus avoiding the 
errors associated with the reciprocal transformation [127, Section 5.2.4], and (b) 
incorporates a baseline parameter, B, to reflect the initial plateau during which TEWL 





































+=  Eq. 2-4 
The second model proposed is the “Simple Non-Linear” (S-NL) model (Eq. 2-2) which also 
fits the data directly to Fick’s first law equation (Eq. 2-2) but does not incorporate a 
baseline factor. 
 
To decide on the best approach for estimating the SC thickness we examined data sets 
collected from different volunteers on different occasions. We evaluated the performance 
of the three models and compared their outcomes. Each set of data (TEWL versus 
cumulative thickness removed) has been analyzed separately using each of the three 
models: LM, S-NL and BC-NL. The SC thickness (H) estimated for each volunteer by each 
model is compared, along with a discussion of the goodness–of–fit, and the relative 
merits and weaknesses of each method.  
2.3 Materials and Methods 
2.3.1 Subjects  
 
18 healthy volunteers (3 male, 15 female, age range 22-43 years), with no history of 
dermatological disease, participated in the study. Ethical approval was granted by 
Salisbury Local Research Ethics Committee, the Declaration of Helsinki protocols were 
followed, and written informed consent was obtained from all volunteers. A total of 31 
sites were examined over a period of 2 years. Participants refrained from using any 
topical products on the test area on the day of the experiments.  
 
As TEWL measurements may be affected by sweating or the changes to the relative 
humidity or temperature of the laboratory, the volunteers rested in the room for at least 
15 minutes prior to taking first TEWL measurement; the experiment was completed in 
less than 1 hour; and repeated initial TEWL measurements were taken until they 
stabilised. Temperature and relative humidity in the study room was measured before 
each experiment, and the mean (±SD) were 21.9±1.5°C and 37.8±9.7% respectively.  
 
Subjects were given code numbers (1 to 18) and nine subjects participated only once in 
the study. Six subjects participated twice; Subjects 9 and 14 participated thrice, and 
subject 8 participated four times. Repeated participation was coded with a letter, for 
example subject 1a and 1b for the first and second participation of subject 1. Repeat 
participation using the same arm was delayed by at least 1 month, which is sufficient for 
barrier regeneration [117-119].  
2.3.2 Tape stripping procedure 
 
Two tapes, with pressure applied using a roller, were taken and discarded. These pre-
tapes are also taken before all dermato-pharmacokinetic experiments in our laboratories, 
to remove and exogenous substances and prepare the skin surface in a systematic way. A 
plastic template was applied, to delimit a constant area to be stripped. An initial TEWL 
measurement was taken with a closed-chamber evaporimeter (Biox Aquaflux AF102, Biox 
Systems Ltd, London, UK; measurement range 0-100 g.m2h-1; resolution ±0.05 g.m2h-1; 
the probe was applied for a minimum 60 s, the TEWL was obtained once the mean of 10 
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A pre-weighed (Sartorius Microbalance SE-2F, precision 0.1µg; Sartorius AG, Goettingen, 
Germany) piece of Scotch Book tape 845 (3M, St Paul, MN) was placed over the template 
and adhesion to the skin was assured systematically with a set number of rolls with a 
roller. The tape was removed swiftly and another TEWL measurement taken. The 
sequence was repeated until the TEWL value was 3-4 times its initial value (usually 60-
80g.m-2h-1). All tapes were reweighed following completion of the stripping procedure, 
with prior removal of any hairs as necessary. To correct for any variations in 
environmental conditions, and the change in mass that may occur with time, 3-5 blank 
correction tapes were weighed at the same times as the tapes used for stripping. The 
change in mass of these blank tapes was used to correct the calculated mass of SC on 
each tape. 
2.3.3 Models to estimate SC thickness, H 
 
2.3.3.1 Linear model (LM) 
 
Linear regressions were performed on each data set of 1/TEWL versus cumulative SC 
thickness removed, using GraphPad Prism® (version 4.00 for Windows, GraphPad 
Software, San Diego, CA). All the data points were fitted into the regression unless stated 
otherwise. All the slopes were significantly non zero (p<0.0001) which confirmed a 
statistically significant relationship between 1/TEWL and cumulative SC thickness 
removed. 
 
2.3.3.2 Non-linear (S-NL and BC-NL) models 
 
All data sets were evaluated separately using WinNonLin® software (Version 5.1, 
Pharsight Corporation, Mountain View, CA) using an ASCII user-defined model written for 
models S-NL and BC-NL. In all cases, no data points were excluded; uniform weighting 
was applied; no bounds were used; and the initial parameter estimates were: H = last h 
value + 1; (D.K.∆C) = 30; B = initial TEWL value before stripping (for BC-NL model only). 
Iterations were continued until the relative change in weighted sum of squares was 
<0.0001. The model derived parameter estimates were used as the new ‘initial’ values in 
the model, and the model rerun until there was no change in the parameter output. All 
parameter estimates are those from the final iteration of the model, with the smallest 
resultant residual sum-of-squares; however, usually, no change was seen after the first 
run, suggesting the modelling was stable. All statistical tests for comparisons between 
parameter outputs for different data sets were done using GraphPad Prism®. 
2.3.4 Evaluation of goodness-of- fit of each model 
 
The statistical evaluation of ‘goodness-of-fit’ of a model is not a trivial matter, especially in 
the case of non-linear models [127, 128]. Obviously, a first step involves a visual 
graphical assessment of how well the model fits the experimental values. Models are 
usually evaluated for their accuracy; but this was not possible as there are no 
independent methods to obtain SC thickness that can be considered the “gold standard”. 
Thus, in an effort to evaluate objectively all three models, a series of statistical tools were 
considered concurrently. 
 
First of all, the precision of the parameter estimates is evaluated using the coefficient of 
variation (CV, %), which relates the parameter’s standard error of the regression (SER) to 
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The SER is an absolute measure whereas CV is a relative error that can be used to 
compare the three models. Normally, the model resulting in the smaller CV should be 
preferred. 
 
Next, the two non linear models were compared; it would be expected that the BC-LN 
would fit the data better than the S-NL model, simply because it has one extra parameter. 
Thus, two statistical tools, the Akaike Information Criterion and an F-test, that take into 
account the difference in the number of parameters, were used to compare objectively 
the two non-linear models. 
 
The Akaike Information Criterion (AIC) for the S-NL and BC-NL models was calculated for 
each of the 31 data sets separately as follows [127]: 
 
parobs NWRSSNAIC ⋅+⋅= 2)ln(  Eq. 2-6 
where Nobs is the number of data points of each data set; WRSS is weighted residual sum 
of squares (provided by WinNonlin®); Npar is the number of parameters which were 2 
(“DK∆C” and “H”) and 3 (“DK∆C”, “B” and “H”) for the S-NL and the BC-NL models 
respectively. The absolute value of the AIC for a single model on its own is meaningless; 
hence the AIC is always used to compare several models. Briefly; the model with the 
lowest AIC is more likely to be correct. Furthermore, the probability that the BC-NL model 
is correct, rather than the S-NL model, for a given data set can calculated via the 













y Probabilit  Eq. 2-7 
The S-NL and BC-NL models can be considered as nested models; that is, the BC-NL 
model can be considered an extension of the other. Crucially, both models would be 
identical if a single parameter, B, is set to zero. Under these conditions, an F test [127, 
129] can examine the effect of the additional parameter on the WRSS. The F* value was 









=  Eq. 2-8 
where: df1 and df2 are the degrees of freedom for the S-NL and BC-NL models 
respectively, and WRSS1 and WRSS2 the corresponding weighted residual sum of squares 
(both provided by WinNonlin®). The F* was then compared to critical values (Ftable) taken 
from F tables [130] for a two-tailed test, with a p value of 0.05, column value = |df1-df2|; 
and row value = df2. If F* is greater than Ftable, it can be concluded that the full model is 
better than the reduced model. 
 
The AIC and the F test consider which model, S-NL or BC-NL, may be more appropriate for 
each data set individually. However, an overall preferred model may be suggested based 
on the preferred model selected for all 31 cases. 
2.4 Results and Discussion 
 
TEWL was measured before and after each tape strip in 31 experiments. The average 
baseline (before stripping) and final (after stripping) TEWL values, along with their 
standard deviations, were 10.12 ± 2.65 g.m-2h-1 and 61.48 ± 18.78 g.m-2h-1 respectively. 
This increase in TEWL is due to the barrier disruption and is in agreement with previous 
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2.4.1 Evaluation of the linear model (LM) 
 
The first method considered was the linear model, LM, which has been widely used [51, 
84, 92, 101, 109, 110, 121] since its introduction [1, 122]. The linear transformation of 
Fick’s first law (Eq. 2-3) predicts a straight line when the 1/TEWL values are plotted 
versus the cumulative thickness of the SC removed (h). Figure 2-1.a shows example plots 
for two volunteers: a single straight is observed for both subjects; the linear regression 
fits the experimental data well (R2=0.99) and the thickness of the SC is easily 
extrapolated from the regression line. 
 
Figure 2-1: Estimation of SC thickness (H) by the linear model (panel a) and by the simple (S-NL) 
and baseline corrected (BC-NL) non-linear models (panel b) for subjects 1a and 2b. [■] 
Experimental data points. Panel a: [−] prediction by LM. Panel b: [−] prediction by BC-NL; […] 
prediction by S-NL model. The vertical lines mark the value of H estimated by the LM (panel a, solid 
line), the S-NL (panel b, dotted line), and the BC-NL (panel b, solid line). 
 
 
However, there were several sets of data which were not satisfactorily described by the 
linear model. Figure 2-2.a illustrates five of these examples which show an initial plateau 
before a clear linear descent is observed. Clearly, the LM fails to fit all the experimental 
data to the regression line. Worryingly, there is a clear potential for overestimation of H as 
the slope of the regression line is shifted upwards to include the initial plateau as Figure 
2-2 illustrates. The dilemma is how to deal with this type of data which was apparent in 
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BC-NL; H = 13.20µm
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LM H = 10.76µm, R2=0.93
LM 9 points excluded.
H = 9.61µm, R2=0.98
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0.15 LM;  H = 9.92µm, R2=0.90
LM 12 points excluded.
H = 8.23µm, R2=0.99






















BC-NL; H = 8.35µm
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LM; H = 10.17µm, R2=0.91
LM 8 points excluded.
H = 8.45µm, R2=1.00
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LM; H = 10.05µm, R2=0.94
LM with 4 points excluded.
H = 8.90µm, R2=0.98
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0.08 LM; H = 10.59µm, R
2=0.96
LM with 12 points excluded;
H = 9.72µm, R2=0.99
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Obviously, the key question is the reason for this initial plateau. We could not find any 
trend (age, gender…) that would assign this plateau to any “skin type”. In any case, we 
hypothesised that the initial plateau is due to loose outer portions of SC, which are soon 
to be lost through natural shedding. These loose portions seem to constitute a minor 
barrier to water loss, but do represent a considerable mass when removed. This agrees 
with the heterogeneous nature of the SC structure [123, 124, 126, 132]; where the SC 
compactum evolves into the SC disjunctum as the corneocytes migrate towards the 
surface, and progressively loose their corneodesmosome links. The cells of the SC 
disjunctum do not contribute significantly to the water barrier function of the SC. 
Therefore, when the SC disjunctum layers are removed, a large mass change, and hence 
cumulative SC thickness removed, h, is registered, without a corresponding increase in 
TEWL, resulting in the plateau. Since these layers represent a poor barrier to water loss, it 
can be argued that they would also constitute a reduced barrier with regards drug ingress, 
and hence should be considered separately from the main SC barrier during the 
estimation of H. Alternatively, potential variation in corneocyte size or shape with SC 
depth could affect inter-cellular tortuosity, and lead to variability in water diffusivity across 
the barrier. 
 
A potential solution is to subjectively exclude these initial plateau values and fit the rest 
with LM. An example of such procedure is illustrated in Figure 2-2.a. The exclusion of the 
initial plateau values provides higher R2 values, and an 8.2 – 17% change (0.87-1.72 µm) 
in H. Because the regression line fits only the declining straight line, its gradient shifts 
downward, resulting in lower values of H as shown in Figure 2-2.a. It should be noted that 
these fits are produced through the exclusion of a considerable proportion of data points: 
 9 out of (27) total data points; 12 (24); 8 (18); 4 (17); and 4 (15) for the subjects 
sequentially shown in Figure 2-2.a. Unfortunately, is impossible to define an algorithm to 
exclude these points objectively, thus, a researcher would be forced to subjectively 
exclude points by eye in order to improve the linear fit if this approach was adopted. This 
potential subjectivity in deciding upon the portion to be fitted by the regression 
constitutes an important disadvantage of the LM. Clearly, any step of a future dermato-
pharmacokinetic “modus operandi” aiming to compare topical formulations in an 
objective way, should allow minimal room for inter-laboratories or inter-researcher 
variability. Therefore, the crucial step of H determination, in order to normalise data from 
different volunteers, should clearly be standardised. 
 
2.4.2 Evaluation of the non-linear models: S-NL and BC-NL 
 
To attempt to remedy the problems associated with the LM, namely the poor fit and the 
potential subjectivity of removing data points, two alternative non-linear models have 
been proposed: the Simple Non-Linear (S-NL) (Eq. 2-2) and the Baseline-Corrected Non-
Linear (BC-NL) models (Eq. 2-4) which were applied to all data sets with no data points 
excluded. The first step to evaluate their performance is a visual assessment of the 
model’s predicted fit as compared to the raw data points. Figure 2-1 and Figure 2-2, 
panel b, show 7 examples of data fitted with the S-NL and BC-NL models. The predicted 
line fit the experimental data closely in all cases, independent of the existence of an 
initial plateau (Figure 2-2). A comparison of the two non linear models, suggests that the 
Figure 2-2: Estimation of SC thickness (H) by the linear model (panel a) and by the simple (S-NL) 
and baseline corrected (BC-NL) non-linear models (panel b) for five subjects. [■] Experimental data 
points. Panel a: [−] prediction by LM including all experimental data; […] prediction by LM 
excluding a number of data points.  Panel b: [−] prediction by BC-NL; […] prediction by S-NL model. 
The vertical lines mark the value of H estimated by: LM – all data points (panel a, solid line), LM – 
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BC-LN model fits the earlier TEWL values slightly better, which was the rationale behind 
the introduction of the baseline parameter, B, into this model. The baseline parameter 
allows some vertical translocation of the resultant fit, and thus improves the fitting in 
some cases (subjects 3a, 5b and 6). 
 
Figure 2-1 shows two sets of data 1a and 2b which were well fitted by all three models. 
The estimated total SC thickness for subject 1a was 12.9±0.19µm (LM), 13.1±0.07µm 
(S-LN) and 13.2±0.16µm (BC-NL). The estimated H for subject 2b was 8.8±0.12µm, 
8.5±0.10µm and 8.0±0.17µm according to the LM, the S-NL and the BC-NL models 
respectively. Thus, when there is no initial plateau, namely for subjects having little SC 
disjunctum, the three models fit well the data and the values of H obtained are very 
similar. Other sets of data that showed this behaviour are highlighted on Table 2-1.  
 
Next, we should consider the data shown in Figure 2-2, or cases showing an apparent 
initial plateau. Contrary to the LM, both non-linear models fit the data very well. Both non-
linear models resulted in very close values of H which were approximately 1µm smaller 
than those estimated by the linear model. Interestingly enough, when values are excluded 
from the linear fitting the differences become smaller.  For example, the estimated values 
of H for subject 5a were 8.5±0.04µm (S-NL) and 8.4 ± 0.05µm (BC-NL); clearly lower that 
that estimated by linear regression 9.9 ± 0.45 µm. However, when 12 points were 
excluded from the linear regression, the value of H decreased to 8.26 ± 0.07µm, very 
similar to the non-linear estimates. A similar trend is observed for all the cases shown in 
Figure 2-2 and for a total of 16 of the 31 cases analyzed. This suggests that the three 
models would agree on a common value for H if the linear regression is applied only to 
the latter linear portion of the data. However, as discussed before, excluding the initial 
plateau values, and deciding on linearity is a process subjected to researchers’ 
subjectivity. On the contrary, the two non-linear models fit all the experimental data letting 
the model to correct for the baseline in an objective way. 
 
The values of H estimated by the S-NL and BC-NL models were very similar in cases 3a, 
5a, 5b and 7 (Figure 2-2). Some differences between the S-NL and the BC-NL models are 
illustrated by Subject 6: the S-NL prediction misses six experimental points, while the BC-
NL misses only two; the latter model is probably aided by the vertical translocation 
permitted by the baseline parameter. This results in a slightly larger (1.16µm) difference 
in the values of H estimated by the two non linear models in this case. 
2.4.3 Variation in H estimated by each model 
 
Before discussing the goodness of fit of the three models by statistical tools we should 
discuss whether H, the parameter of interest for dermato-pharmacokinetic studies, is 
significantly different when estimated by different models. A compilation of the H 
estimates together with the standard error of the regression (SER) and the coefficient of 
variation (CV(%)) for the 31 data sets are presented in Table 2-1. The H and 
corresponding SER may be compared graphically in Figure 2-3. A matched-observations 
Friedman test (equivalent to a non-parametric 1-way matched ANOVA) followed by the 
corresponding Dunn’s post-test was used to compare the values of H estimated by the LM 
(with no data excluded), the S-NL and the BC-NL models. The test concluded that the 
value of H estimated by the linear model was statistically significantly greater than that 
derived from the S-NL (p<0.01) and the BC-NL (p<0.001) models. In other words, the 
linear model tends to overestimate the thickness of the SC. On the other hand, although 
the S-NL model tends to estimate a higher value of H than the BC-NL model, the 
differences between the non-linear models did not reach the level of statistical 
significance (p <0.05). 
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and model. It is interesting to note that in 28 of the 31 cases considered, the highest 
relative error was associated with the linear method. The performance of the linear model 
can be improved but only via the exclusion of some data points. Overall, these results 
suggest that the two non-linear models proposed here offer a better-quality fit than the 






















F* / Ftable 
1 a 12.9 0.19 1.5  13.1 0.07 0.6  13.2 0.16 1.2  0.39 45 1.4 / 6.2 
1 b* 20.1 0.53 2.7  17.2 0.33 1.9  15.4 0.09 0.6  -37.74 100 101.5 / 56.0 
2 a 11.5 0.25 2.2  11.4 0.15 1.3  11.5 0.34 3.0  1.84 29 0.1 / 5.8 
2 b 8.8 0.12 1.4  8.5 0.10 1.2  8.0 0.17 2.2  -3.90 88 5.8 / 6.0 
3 a* 10.8 0.41 3.8  9.6 0.06 0.6  9.3 0.08 0.8  -10.93 100 14.7 / 5.7 
3 b 6.4 0.19 2.9  5.8 0.03 0.5  5.7 0.05 0.8  -2.43 77 4.2 / 6.0 
4 10.5 0.25 2.4  10.1 0.06 0.6  9.9 0.13 1.3  -0.88 61 2.6 / 6.0 
5 a* 9.9 0.45 4.5  8.5 0.04 0.5  8.4 0.05 0.6  -11.50 100 15.85/ 5.8 
5 b* 10.2 0.51 5.0  8.6 0.10 1.2  8.1 0.08 1.0  -18.97 100 33.1 / 6.2 
6* 10.0 0.44 4.4  8.6 0.20 2.3  7.4 0.07 1.0  -32.39 100 91.8 / 6.3 
7* 10.6 0.41 3.8  9.6 0.08 0.8  9.4 0.11 1.2  -4.31 90 6.3 / 6.6 
8 a* 7.4 0.29 3.8  6.8 0.07 1.0  6.5 0.05 0.7  -18.50 100 36.6 / 6.8 
8 b 13.0 0.37 2.8  11.8 0.14 1.2  11.3 0.16 1.4  -7.19 97 9.9 / 6.1 
8 c 10.0 0.20 2.0  9.5 0.04 0.5  9.5 0.08 0.8  1.36 34 0.5 / 9.9 
8 d* 7.5 0.28 3.8  6.5 0.17 2.7  5.7 0.05 1.0  -26.04 100 70.5 / 6.7 
9 a * 13.0 0.88 6.8  10.4 0.14 1.4  10.0 0.12 1.2  -9.29 99 13.2 / 6.3 
9 b 8.8 0.14 1.5  8.7 0.05 0.6  8.8 0.09 1.1  -0.02 50 1.8 / 6.3 
9 c 12.4 0.27 2.2  11.7 0.11 0.9  11.2 0.11 1.0  -10.86 100 15.0 / 5.9 
10 a 6.4 0.17 2.6  5.9 0.04 0.7  5.7 0.05 0.9  -7.40 98 10.4 / 6.4 
10 b* 8.6 0.33 3.9  7.2 0.06 0.9  7.0 0.05 0.7  -12.85 100 19.0 / 6.1 
11 6.2 0.16 2.6  6.0 0.04 0.8  6.0 0.09 1.5  0.21 47 1.5 / 6.4 
12 a* 13.1 0.38 2.9  11.3 0.10 0.9  10.8 0.07 0.7  -24.33 100 38.5 / 5.7 
12 b 14.5 0.24 1.7  15.2 0.06 0.4  15.4 0.10 0.7  -9.18 99 12.6 / 5.9 
13 8.1 0.25 3.1  7.6 0.05 0.6  7.6 0.09 1.2  1.76 29 0.2 / 6.2 
14 a* 16.2 0.52 3.2  13.9 0.32 2.3  12.0 0.07 0.6  -53.67 100 192.6 / 5.8 
14 b* 18.1 0.68 3.8  17.8 0.12 0.7  17.2 0.08 0.5  -25.40 100 56.2 / 6.3 
14 c* 9.4 0.27 2.9  9.6 0.16 1.7  10.6 0.66 6.2  -3.41 85 5.3 / 6.0 
15* 12.7 0.27 2.2  12.0 0.11 0.9  11.4 0.13 1.2  -10.28 99 14.2 / 5.9 
16 9.1 0.20 2.2  8.5 0.06 0.7  8.4 0.09 1.1  -2.77 80 4.5 / 6.5 
17* 8.8 0.34 3.9  7.5 0.09 1.2  7.1 0.05 0.7  -23.63 100 51.5 / 6.4 
18 5.6 0.22 4.0  5.0 0.12 2.4  4.4 0.13 2.8  -7.81 98 11.1 / 6.6 
Average 10.7 0.30 3.1  9.8 0.10 1.1  9.5 0.10 1.3   84   
H±SD3 10.7 ± 3.4  9.8 ± 3.2  9.5 ± 3.1     
Table 2-1: Estimation of SC thickness (H) by the linear model (LM) and by the simple (S-NL) and 
baseline corrected (BC-NL) non-linear models for 18 subjects (31 experiments). 
1 Cases were a plateau was apparent to the authors are indicated with *.    
2 ∆AIC=AICBC-NL – AICS-NL    
























































































































Figure 2-3: Stratum corneum thickness, H (µm) as determined by the LM, S-NL, and the BC-NL 
models, for 18 different volunteers at 31 different sites. The error bars show the standard error of 
the regression (SER) associated with each estimate. 
 
2.4.4 Comparison of goodness-of-fit of the non-linear models, S-NL and BC-NL 
 
Finally, we should discuss the relative performance of the two non-linear models. The S-
NL model fits directly experimental values (TEWL and cumulative thickness removed) to 
Fick’s first law. This basic difference already provides a certain advantage over linearly 
fitting the transformed values of water loss (1/TEWL) [Reference 127, Section 5.2.4]. The 
baseline parameter was built into the BC-NL model to describe the removal of the outer 
SC layers that do not significantly contribute to the barrier to water loss. However, the BC-
NL model would be expected to fit the data better, and have smaller residual sum-of 
squares than the S-NL model simply because it has one extra parameter. Therefore, to 
decide which model was superior, the use of some statistical tools that take into 
consideration the number of parameters used by each model was required, as outlined in 
Materials and Methods.  Two statistical tools: the AIC and an F Test (Table 2-1) (described 
in Materials and Methods) were used to compare the non linear models. The F test 
performed here is only applicable for nested models (i.e., where one model (S-NL) can be 
considered a simplified version of a more complex one (BC-NL). The value of F* 
calculated is compared to a critical F value obtained from published F tables [130]. If the 
value of F* is bigger than the critical value, the null hypothesis can be rejected and we 
can accept that the more complex model fits better the data. Table 2-1 shows that in 19 
of the 31 cases, the BC-NL model is preferred (p<0.05). 
 
The AIC offers complementary information as it tells us the probability of the preferred 
model being the correct one. The value ∆AIC = AICBC-NL – AICS-NL was calculated as 
described in materials and methods and the values are shown in Table 2-1. The model 
with the lowest AIC is considered superior, therefore negative values of ∆AIC indicate that 
the BC-NL is preferred. The magnitude of this difference can be used to determine the 
probability of this assumption being correct via Eq. 2-7. For simplicity, Table 2-1 always 
shows the probability of the BC-NL model being the correct one.  For example, for subject 
1b, the negative value of ∆AIC (-37.74) indicates that the BC-LN model fits better the data 
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correct one. On the contrary, in the case of subject 2a, the positive value of ∆AIC (1.84) 
indicates that the S-NL model is superior in this case, and that there is a 71% chance of 
the S-NL model being correct (29 % chance for the BC-NL model shown in the column). 
On the whole, the ∆AIC of 25 of the 31 data sets were negative, indicating a preference 
for the BC-NL model (probability of BC-NL being correct >61%). In fact, in 20 of the 31 
cases there was a probability ≥90% of the model BC-NL being correct. 
 
The use of these two parameters can be illustrated by considering subject 6. The SC 
thickness for subject 6 is 8.6±0.2µm (CV=2.3%) according to the S-NL model and 
7.4±0.07 (CV=1%) according to the BC-NL model. The difference in the ∆AIC for this 
subject was -32.39, resulting in a probability of 100% the BC-NL model being correct; the 
F test also shows that the BC-NL model fits better the than the S-NL. This is in good 
agreement with the graphic representation:  the S-NL prediction misses 6 experimental 
points, while the BC-NL misses only two. As discussed before, approximately 25 of the 31 
cases were better modelled by the BC-NL model, indicating the usefulness of the 
inclusion of the baseline parameter to fit the full breadth of the experimental data. In 
summary, the results in Table 2-1 suggest that the BC-NL has a better overall 
performance than the S-NL model. 
2.4.5 Intra-subject variation in H on different occasions 
 
In addition, Table 2-1 and Figure 2-3 show the data for some volunteers who participated 
on different occasions. It is worth noting that the H estimated on different occasions may 
differ markedly for the same volunteer, independent of the model used to fit the data. 
See for example, subjects 1-3, 5, 8, 9, 10, 12 and 14 (Figure 2-3). These differences 
imply that the SC thickness changes with time, potentially due to environmental 
conditions and the use of drugs, cosmetics or exfoliating agents. It follows that a 
determination of the SC thickness is necessary every time a dermato-pharmacokinetic 




In summary, we believe that non-linear models perform better than the standard linear 
model typically used to estimate the SC thickness via tape-stripping experiments 
combined with TEWL measurements. When the LM performs well, that is in the absence 
of an initial plateau, the three models estimate comparable values of H. However, when 
an initial plateau appears, probably corresponding to the removal of the SC disjunctum, 
the SL model tends to overestimate the thickness of the SC unless some subjective 
exclusion of data is made. On the contrary, the non-linear models offer a robust 
procedure, incorporating all data points, reflecting better experimental observations, and 
estimating the thickness with a smaller coefficient of variation. 
 
The incorporation, rather than the exclusion, of the initial plateau by the non-linear 
approach should be preferred as it follows more closely the SC physiology and its division 
into the SC compactum and disjunctum. The statistical comparison of the two non-linear 
models showed a higher probability for the baseline corrected model being the preferred 
one. However, there were no statistical differences between the values of H estimated 
from either of these models. 
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2.5 Notes 
This chapter has been published: Russell, L.M., S. Wiedersberg, and M.B. Delgado-Charro, 
The determination of stratum corneum thickness - An alternative approach. Eur J Pharm 
Biopharm, 2008. 69(3): p. 861-870. 
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Chapter 3 
Quantification of stratum corneum by protein assay: 
evaluation of extraction solutions, and comparison with 
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3 Quantification of stratum corneum by protein assay: 
evaluation of extraction solutions, and comparison 




Tape stripping removes layers of the stratum corneum (SC), into which applied drug has 
permeated, to assess the topical bioavailability and measure dermato-pharmacokinetic 
parameters. To compare formulations of the drug and to determine their bioequivalence 
(or not), it is important to quantify the amount of SC removed on the tape strips. One 
approach involves extraction and quantification of protein and this study aims to examine 
the usefulness of such a strategy.  
 
First, the stability of a commercially available solution of human epidermal keratins, 
when diluted with either a solution based on the commercial base (a urea/thiol mixture,  
referred to here as Stable Extraction Solution, SES) or concentrated sodium hydroxide, 
was measured. Second, protein was extracted directly from SC (obtained from heel 
scrapings), using either SES or concentrated sodium hydroxide, and was then quantified 
with a sensitive, fluorescence-based assay. Extraction with NaOH was inefficient and 
significantly lower than that achieved with SES, which resulted in an amount of protein 
equivalent to ~80% of that expected from the measured mass of SC used for extraction. 
Third, SC removed by a typical tape-stripping procedure was extracted from the individual 
tapes using SES, analysed for protein as before, and these values were then correlated 
with both the measured mass of SC removed and by a novel imaging technique (which 
also allows SC on tapes to be quantified). The correlation was significant but weak with 
both methods, which suggests that the protein assay is insufficiently sensitive to 
distinguish between tapes expressing small differences between tapes.  
3.2 Introduction 
 
There is currently a need for an objective method to assess the rate and extent of drug 
permeation through the skin from topical formulations. This method would be useful to 
assess whether different formulations of the same drug are bioequivalent, and would 
encourage the development of generic topical products. Such a method is desired by 
pharmaceutical companies and regulatory bodies such as the FDA [86].  
 
Topically applied drugs have their target site within the skin, and as such, systemic 
absorption is very low. Thus, to assess the bioavailability of these formulations, drug 
levels within the skin must be sampled.  
 
Since the stratum corneum (SC) is the principal barrier to drug absorption, it may be 
assumed that the (dermatopharmaco)-kinetics (DPK) of drug passage through this layer 
are related to topical bioavailability [84]. An intensely studied technique to sample the SC 
is ‘tape stripping’ where, after formulation application and removal, adhesive tapes are 
used to remove sequential layers of the SC.  
 
The tape strips provide a wealth of information, which allows drug penetration profiles 
across the SC to be constructed. Firstly, using a suitable extraction and analytical 
technique, the mass of drug per tape may be measured. Secondly, as tape strips remove 
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per tape is used for three purposes:  
 
• to express the mass of drug extracted as a concentration, in terms of the 
‘volume’ of SC per tape 
• to measure the depth reached within the SC by each successive tape strip 
• to estimate a volunteer’s total SC thickness, using tape stripping data from an 
untreated adjacent site coupled with transepidermal water loss measurements 
[1, 100]. As SC total thickness varies with volunteer, season and skin exposure, 
the total thickness may be used to express depth reached within the SC relative 
to total thickness. 
 
Robust, reproducible normalised profiles of drug concentration against relative depth 
reached within the SC are thus produced, allowing profiles from different sites and 
volunteers to be compared [51, 84, 92, 94, 109-112, 120]. Analysis of these profiles 
using an appropriate solution of Fick’s second diffusion law permits parameters 
describing the partitioning and diffusivity of the drug (reflecting the rate and extent of 
penetration, respectively) to be estimated and used to compare different formulations. 
 
Unfortunately, there is no absolute way to measure the amount of SC per tape. 
Traditionally, weighing tapes before and after stripping has been used as the ‘gold 
standard’ to derive a mass of SC per tape, but it is time-consuming and laborious, and, as 
we shall see in Chapter 4, somewhat insensitive, irreproducible and unstable. A novel 
imaging technique has been investigated to quantify SC on tape strips. This involves 
taking high resolution images under highly controlled conditions. Each image comprises 
many pixels and the greyscale value of each one can be found. The mean greyscale value 
across all pixels is being evaluated as a relative measure of SC per tape.  
 
Since the 75-80% of the SC mass is protein, notably keratin [133], a protein assay is 
logically a potentially useful approach to quantify SC on tape strips. Since protein 
extraction and quantification is unlikely to be compatible with drug extraction and 
analysis, the method would be most useful for validating other methods to quantify SC, 
rather than for use in tape stripping studies per se.  
 
This work aimed to evaluate and optimise (i) a solution suitable for extracting protein from 
SC; (ii) to measure the amount of protein extracted from tape strips using a suitable 
protein assay, and (iii) correlate the amount of protein extracted and measured with two 
other measures of SC amount on the tape, namely the mass of SC and the mean 
greyscale value.  
 
1M NaOH solution has been previously used to extract protein from SC-impregnated tape 
strips [103-108]. As 1M NaOH is incompatible with most protein assays, the solutions 
were neutralised with 1M HCl after extraction. Considering the work of other fields, 
keratin has been extracted from heel SC, nails and hair using a basic (pH 9) solution of 
Tris HCl, urea, phenylmethanesulfonyl fluoride and 2-mercaptoethanol [134, 135].  
 
The Bio-Rad DC [104], Bio-Rad [106-108] and Micro BCATM [103] protein assays have 
been used with NaOH extractions, which have increasing protein sensitivities of 
200µg/ml [136], 100 µg/ml [137, 138] and 2 µg/ml [139] respectively. Recently, an 
enzyme linked assay, SkinMAP, has been used to simultaneously measure multiple skin 
biomarkers using Luminex® bead-based detectors [140]. This method has very high 
sensitivity (30pg/ml for keratin-6, and 570 pg/ml for keratins 1 and 10 combined) but 
the mild extraction solutions used to simultaneously extract many skin proteins resulted 
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The standards used to calibrate the protein assays have included bovine gamma globulin 
[103, 108]; and bovine serum albumin [107], although neither of these produced 
sufficiently accurate results when compared to pure SC separated from the epidermis of 
cadaver skin [104]. A commercial keratin solution extracted from human epidermis has 
also been used [106].  
 
As a starting point, we noted that a dispersion of human epidermal keratins, from feet 
calluses, and with a protein molecular weight range of 45 – 60 kDa, is commercially 
available from Sigma-Aldrich (Sigma-Aldrich Company Ltd, Gillingham, UK). The protein 
concentration of this solution is assayed by Sigma, and provided upon purchase. This 
standard dispersion, in 8 M urea, 50 mM Tris, 0.1 M β-mercaptoethanol and 0.1% 
sodium azide (pH 8.4), is stable for 1 year at 2 – 8°C. This solution is remarkably similar 
to that used for SC extraction by Kitahara and Ogowa [134, 135]. We thus tested the 
solution of this commercial epidermal dispersion as an alternative for SC extraction 
(abbreviated Stable Extraction Solution, SES). Extraction with SES was compared with 1M 
NaOH.  
 
To quantify the small amount of SC extracted with each solution, we need a sensitive 
compatible assay. Both the 1M NaOH and SES are incompatible with the majority of 
protein assays. Several protein assays, with their sensitivities and incompatibilities are 
summarised in Appendix 3-B. In addition, the conditions used for the studies reported 
above, along with the corresponding protein assay used, are summarised in Appendix 3-C.  
 
We chose the EZQ method from Invitrogen, with a limit of quantification of 20 µg/ml, and 
universal compatibility due to its washing stages. Three studies were conducted. Firstly, 
the commercial epidermal solution from Sigma (of known concentration) was diluted in 
either 1M NaOH or the SES and the protein levels assayed to assess protein stability in 
each solution. Secondly, known masses of SC obtained from the heel of a volunteer were 
extracted in either 1M NaOH or the SES to establish extraction efficiency. Thirdly, a series 
of tape strips were taken from healthy volunteers and extracted using SES. The protein 
masses extracted were compared to the mass of SC measured on the tapes, and the 
mean greyscale values from a novel imaging method. 
3.3 Materials and Methods 
3.3.1 Materials 
 
A standard keratin solution (K0253, Sigma-Aldrich Company Ltd) was used to prepare all 
standards. It consists of keratin extracted from human foot epidermis, at a concentration 
of 8500 µg/ml in a solution of 8 M urea, 50 mM Tris, 0.1 M β-mercaptoethanol and 0.1% 
sodium azide, pH 8.4. Methanol (HPLC grade) and acetic acid (Fisher Scientific, 
Loughborough, UK) were also used in this work. 
3.3.2 Protein assay 
 
The EZQ® protein quantification kit (R33200, Molecular ProbesTM Inc., Invitrogen, OR, 
USA) was used for all protein quantification. The kit instructions were followed using the 
96-well cassette, with 2 corner cells reserved for labelling and correct alignment. When 
necessary, the sample paper was dried with a hairdryer. The fluorescence was read on a 
microplate reader (Fluostar Optima, BMG Labtech, Offenburg, Germany; software version 
1.32 R2) with excitation/emission settings of ~485/590 nm and a gain of 2213. All 
samples were spotted onto the plate three times and each spot was read in triplicate by 
the microplate reader. Mean values are reported. Three blank tapes were extracted and 
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values (denoted ‘mean corrected fluorescence’). 
3.3.3 Keratin stability in 1M NaOH and SES 
 
The standard keratin solution was diluted to produce standards in the approximate range 
of 20-1900 µg/ml range in either 1M NaOH (Fluka ion chromatography grade, Sigma-
Aldrich) or a freshly-prepared admixed solution of 8 M urea (Sigma-Aldrich), 50 mM Tris 
(Acros Organics, Geel, Belgium), 0.1 M β-mercaptoethanol (Sigma-Aldrich), hereafter 
denoted ‘Stable Extraction Solution’ (SES). Each dilution was assayed for protein 
concentration after 1, 2 or 3 days vigorous shaking.  
3.3.4 Extraction efficiency of 1M NaOH and SES 
 
Foot SC was harvested from the clean heel of one female volunteer, dried in an oven at 
25°C for 24 hours, and subsequently stored in a desiccator, until use. 
 
Known masses of dried foot SC were extracted in 1ml of either 1M NaOH or SES for 48 
hours before protein assay.  




A total of 21 sites were examined from 8 different healthy volunteers (3 male, 5 female, 
24-38 years) with no history of dermatological disease. The number of volunteers who 
provided (number of sites) is as follows: 1 (5 sites); 1 (4 sites); 6 (2 sites). Ethical 
approval was granted by Salisbury Local Research Ethics Committee, the Declaration of 
Helsinki protocols were followed, and written informed consent was obtained from all 
volunteers. Participants refrained from using any topical products on the test area on the 
day of the experiments. 
 
3.3.5.2 Tape stripping 
 
A series of 2cm x 3cm tapes were cut from Scotch Book tape 845 (3M, St. Paul, MN) and 
stored in covered trays. Tapes were manipulated using a small corner of each tape folded 
back on itself. 
  
Two tapes were applied, with pressure using a roller, to the study site, then removed and 
discarded. These pre-tapes remove exogenous substances, prepare the skin surface in a 
systematic way and are taken before all in vivo experiments. A plastic template was used 
to delimit a constant area (1.5cm x 1.5cm) within the study site. This template had an 
outline marked on its underside of 2cm x 3cm. An initial transepidermal water loss 
(TEWL) measurement was taken (Biox Aquaflux AF102, Biox Systems Ltd., London, UK; 
measurement range 0–100 g m2 h−1; resolution ±0.05 g m2 h−1; probe applied for a 
minimum 60 s, TEWL was obtained as mean of 10 successive measurements having a 
CV < 1%). 
  
Pre-weighed tapes (2cm x 3cm) were positioned over the template, using the marked 
outline to ensure that the tape was always placed in the same position. Firm adhesion 
was achieved by using a weighted roller. The tape was then removed swiftly. The 
sequence was repeated, with intermittent TEWL measurements, until the TEWL value was 
3–4 times its initial value (usually 60–80 g m−2 h−1).  
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stripping; with a novel imaging technique; and by protein extraction in SES, as described 
below. 
 
3.3.5.3 Quantification of SC amount per tape 
 
3.3.5.3.1 Mass measurement 
 
Tapes to be used for stripping were cut and stored covered in ambient conditions for 12 
hours before weighing. Static electricity was discharged from the tapes prior to weighing 
(R50 discharging bar and ES50 power supply from Eltex Elektrostatik GmbH, Weil am 
Rhein, Germany). The tapes were weighed, before and after stripping, using a 
microbalance with precision 0.1 µg (Sartorius SE-2F from Sartorius AG, Goettingen, 
Germany). Any hairs removed by the tape stripping procedure were carefully removed 
using fine tweezers before the second weighing. No tapes were discarded.  
 
Five blank tapes were weighed at the same time as the tapes used for the tape-stripping 
experiments, both before and after stripping, to correct the calculated mass of SC for any 




After their second weighing, the tapes were mounted on standard slide holders (5 cm x 5 
cm, with an internal window 2.3cm x 3.5cm) such that the 1.5cm x 1.5 cm square of SC 
was centrally aligned with its edges parallel to those of the slide.  
 
The slide holding the tape + SC was photographed (14 bit) using a Coolscan V ED slide 
scanner (Nikon UK Limited, Kingston upon Thames, UK) at a resolution of 4000 pixels per 
inch (157.5 pixels/mm). A crop of 2213 x 2203 pixels (approximately 1.4cm x 1.4cm) 
was centred over the image. Photographs fully illustrating this method are shown in 
General Appendix I. 
 
Cropped images (9822 KB each) were saved and analysed with ImageJ (Rasband, W.S., 
U. S. National Institutes of Health, Bethesda,  
Maryland, USA; freeware from http://rsb.info.nih.gov/ij/). A scale of 159.07 pixels/mm 
was applied. Full settings are described in General Appendix II. During image analysis, the 
greyscale value of each of the 4875239 pixels of the image is measured (16 bit) in the 
range 0 - 64608, where 0 and 64608 designate black and white respectively. The mean 
greyscale over all pixels was calculated and then subtracted from that obtained from 
blank tapes (see General Appendix III) to yield mean greyscale values which increase with 
image darkness (and hence with the amount of SC on the tape).    
 
This novel imaging technique to assess SC the quantity of SC from a series of tape strips 
is described and evaluated in detail in Chapter 4. 
 
3.3.5.3.3 Protein assay 
 
After images were taken, each tape was cut from the slide holder and extracted for 48hrs 




All statistical tests, as detailed in the results section, were performed with Prism® version 
4 (GraphPad Software, CA, USA). 
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protein concentration, slopes were compared using the methods outlined by Zar [141, 
following example 17.1], and using the appropriate tables for the t distribution. This 
method is reproduced in Appendix 3-A. 
3.4 Results and Discussion 
3.4.1 Keratin stability in the extraction solutions 
  
There was a linear relationship between the measured fluorescence and the 
concentration of keratin in the standards prepared in SES (Table 3-1). The absolute 
(corrected) fluorescence values changed slightly on different days, depending on the 
degree of fluorescent labelling, but the linear calibration curve was maintained, with 
r2 values ≥0.97 on three different occasions.  
 
Likewise, there was a correlation (r2 ≥ 0.96) between the measured fluorescence values 
and the protein concentration of the standards prepared in 1M NaOH (Table 3-1). This 
confirms that dilutions were performed correctly and that NaOH does not interfere with 
the protein assay.  
 
However, it is clear that the absolute values of fluorescence determined in SES were 
significantly greater (p<0.0001 paired 2-tail t-test for each day) than those in NaOH, 
suggesting that the latter caused degradation, and ultimately complete destruction of the 
protein within 1 to 3 days.  
 
The study was then repeated over a smaller concentration range, ~80 - 215 µg/ml, with 
similar results (Table 3-2). Linearity (r2 > 0.99) was again achieved but the overall keratin 
degradation in 1M NaOH was 51-91% over the 48 hour period, confirming that this is not 
a suitable solution in which to dilute keratin solutions before analysis.   
3.4.2 Evaluation of keratin extraction using protein extraction solutions  
 
In previous studies [103-108], 1M NaOH was used to extract protein from the SC on tape 
strips. In this work, we evaluated the potential of SES, in which keratin is stable, to extract 
a quantifiable amount of protein from SC scrapings obtained from the heel of a foot. 1M 
NaOH was also used to extract protein from the foot SC, and the results compared. As it 
was possible to weigh accurately the foot SC used for each extraction, and 1ml of each 
solution was used, the extraction efficiency may be compared.  
 
The experiments were performed on two separate occasions, and the results presented in 
Figure 3-1 A and B respectively.  
 
For the first experiment (Figure 3-1 A), the samples were assayed after 24, 48 and 72 
hours. It is clear that SES extracts a higher concentration of protein than the NaOH 
solution. The concentration of protein from SES is similar on the three successive days, 
although the concentration of protein in the NaOH samples decreases with increased 






  Day 1  Day 2  Day 3 



























Std 1 1888.9 35358  6479 283.25 85.00  46688  5251 169.13 91.05  47545  1954 26.27 98.61 
Std 2 1062.5 22067  3838 146.00 92.27  32297  3103 85.51 95.47  36330  2045 29.66 98.43 
Std 3 850.0 19976  2961 100.40 94.68  22151  2005 42.78 97.74  24254  976 ND 100.00 
Std 4 664.1 14332  2143 57.88 96.94  18988  2271 53.14 97.19  18876  1011 ND 100.00 
Std 5 483.0 12163  1494 24.15 98.72  15210  1077 6.64 99.65  15801      
Std 6 265.6 5915  1036 ND 100.00  7372  297 ND 100.00  7840  246 ND 100.00 
Std 7 106.3 1927  608 ND 100.00  3040  -72 ND 100.00  2994  39 ND 100.00 
Std 8 53.1 978  143 ND 100.00  772  -212 ND 100.00  1102  -131 ND 100.00 
Std 9 21.3 349  96 ND 100.00  223  -313 ND 100.00  512  11 ND 100.00 
Correlation coefficient 0.983  0.996    0.983  0.982    0.967  0.961   
Slope 19.2      25.7      26.7     
Average (Stds 1-7) 1029.2    95.4  906.1    97.3  1253.2    99.5 
Table 3-1: Standards were made in either SES or 1M NaOH, and shaken for a total of 72 hours, with samples taken every 24 hours. The mean corrected 
fluorescence (fluo.) of the standards in either solution is shown, along with the calculated concentration (conc.) of keratin in the NaOH solutions, and the 












  Day 1 Standards Set A  Day 2 Standards Set A  Day 3 Standards Set B 



























Std 1 212.5 7255  2407 118 45  7068  1010 97 54  10255  1010 82 62 
Std 2 159.4 4721  592 82 48  4254  918 95 40  6386  319 ND 100 
Std 3 106.3 1658  441 80 25  1013  ND ND 100  2523  ND ND 100 
Std 4 79.7 520  ND ND 100  470  ND ND 100  1083  ND ND 100 
Correlation coefficient 0.998      0.987      0.996     
Slope 51.7      51.8      69.9     
Average (Stds 1-4) -3669.3    54.5  -4026.8    73.6  -4692.7    90.4 
Table 3-2: Standards were made in either SES or 1M NaOH, and shaken for a total of 48 hours, with samples taken every 24 hours. The mean corrected 
fluorescence (fluo.) of the standards in either solution is shown, along with the calculated concentration (conc.) of keratin in the NaOH solutions, and the 
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In the second experiment (Figure 3-1 B), the NaOH samples again have a lower 
concentration of protein than SES samples. On the second day, the concentration of 
protein in SES had increased; whereas the concentration in the NaOH samples had 
decreased. 
 
The six samples, containing different initial masses of foot SC, are related with the results 
of the linear regression in the accompanying table (Figure 3-1). It can be noted that the 
correlation coefficient improves for SES after a longer extraction time. This suggests that 
the extraction is time-dependent and that up to 72 hours may be required to extract the 
keratin from SC. On the other hand, the correlation coefficient gets worse for the NaOH 
samples, consistent with our previous observation that the protein may be degraded with 
time by the NaOH solution. In addition, the concentration of protein in the NaOH samples 
decreases with extraction time.  
 
For each set of samples on each day, a linear regression was performed. The slopes of 
these regressions were compared in pairs (e.g. Experiment 1, SES Day 1 slope compared 
with Experiment 1, NaOH Day 1 slope) as described in Appendix 3-A. A total of six pairs of 
slopes were compared. The slopes of each of the six pairs were found to be statistically 
significantly different. Since the slopes are different, the linear regression outputs are 
statistically different for the two extraction solutions. 
 
The mass of SC used for each of the six extractions, for each solution, was known and is 
shown on the x axis of Figure 3-1 A and B. The concentration of protein quantified (y axis 
of Figure 3-1 A and B) relates to a mass of protein (as each extracted in 1ml) and may be 
compared to the mass of SC used. The proportion of SC mass extracted as protein, with 
each extraction solution may thus be calculated and the mean ± SD for each of the six 
samples are shown in Figure 3-2.  
 
Firstly we can note that the percentage of SC mass extracted as protein is higher for the 
SES than the NaOH samples. The percentage of protein extracted relative to the SC mass 
is relatively stable for SES. SES extracts a mean percentage of 83.5 ±1.1 % with the first 
experiment (over three days) and 48.4 ± 5.5 % for the second experiment (over two days). 
These values suggest that SES is very efficient at extracting protein from SC, as it is 
known that approximately 75-80% of SC is protein [133]. 
 
The percentage of SC mass quantified as protein for the NaOH samples decreases with 
time. This suggests that the protein is not stable in the NaOH solution. NaOH also extracts 
a lower percentage of the SC mass as protein: 6.08 ± 6.75% for the first experiment (over 
three days) and 10.51 ± 9.1% for the second experiment. This implies that the NaOH 
solution is not suitable for extracting protein from SC, as these values are well below the 
75-80% protein per mass of SC which would be predicted from the literature [133].  
 
In summary, SES should be preferred over 1M NaOH for the extraction of protein from SC. 
Firstly, keratin is stable in SES and the fluorescence values are high enough to be 
quantified. Secondly, it is possible to extract protein from SC using SES, to levels 
consistent with those presented in the literature [133]. On the other hand, a standard 
solution of keratin showed degradation in 1M NaOH, and considerably lower masses of 



























































































































Figure 3-1: Comparison of the mean (± SD) protein concentration (n = 3) measured using EZQ 
assay when foot SC samples were extracted in SES (■) or 1M NaOH (■). Two sets of 6 samples 
were assayed on separate occasions (A and B). Pair-wise comparisons of slopes reveal statistically 
significant differences between the SES and NaOH samples for all pairs (population regression 
coefficients compared using a version of Student’s t test (2 tailed t-test, α = 0.05, p<0.001), as 
detailed in Appendix 3A.  
 
   Day Symbol Slope Intercept R2 
1  0.71 61.18 0.93 
2 ● 0.66 80.80 0.98 SES 
3  0.67 82.45 1.00 
1  0.22 -30.73 0.98 
2 ● 0.11 -20.56 0.98 NaOH 
3  0.03 -10.99 0.70 
  Day  Symbol Slope Intercept R2 
1 A  0.12 299.40 0.81 
2 A ● 0.35 185.80 0.92 SES 
2 B  0.25 205.00 0.97 
1 A  0.08 96.41 0.94 
2 A ● 0.04 89.42 0.95 NaOH 
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Figure 3-2: Mean (± SD) (n = 6) percentage of the total mass of SC detected as protein after 1-3 
days extraction with either SES () 1M NaOH ( ). Two sets of 6 samples were assayed on separate 
occasions (Expt. A and Expt. B). 
3.4.3 Quantification of protein extracted from tape strips, and comparison to 
mass of SC on tape strips 
 
Quantification of the amount of protein extracted from tape strip samples was next 
examined, and correlations with the mass of SC determined gravimetrically, and with the 
greyscale values derived from the imaging method, were assessed.   
 
A total of 349 tapes were each extracted in 1ml of SES. The protein concentration of each 
sample was assayed in triplicate, and the mean and standard deviation values are plotted 
against the corresponding SC masses and greyscale readings in  Figure 3-3 and Figure 
3-4, respectively.  
 
The correlations however are not particularly impressive. Although there was a significant 
positive correlation between the protein measurement and the mass of SC (α = 0.05, 2-
tail p<0.0001), the Spearman correlation coefficient was only 0.37. Similarly, with the 
greyscale values, the positive correlation was significant (α = 0.05, 2-tail p<0.0001) but 
again the Spearman correlation coefficient was only 0.44.   
 
The relatively poor correlations are due, at least in part to (i) the high variability of the 
protein measurements (the average relative standard deviation (RSD) calculated from the 
data for 349 tapes was 18.9 (± 19.3%), and (ii) the low precision of the protein 
concentration measurements, most of which were in the range of 20-70 µg/ml and close 
to the limit of quantification. These factors contribute importantly, therefore, to the 
protein assay being unable to distinguish between tapes which have low and similar 
amounts of SC upon them. It seems unlikely, therefore, in the absence of a more 
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Figure 3-3: Correlation between the mass of SC on tape, with the protein concentration measured.  
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Full raw data and calculations for the tape set from one site, with SC measured by the 




It is important to be able to quantify the amount of SC per tape in order to express the 
mass of drug per tape relative to the ‘volume’ of SC and to plot relative depth reached 
within the SC with each successive tape strip for dermato-pharmacokinetic profiles. The 
weighing method is accepted but is tedious and somewhat unreliable. The greyscale 
technique used, while promising, requires further validation. A sensitive, accurate protein 
extraction and assay technique could provide this validation.  
 
Keratin extraction with concentrated NaOH has been used previously, but is clearly not to 
be further recommended as it degrades a standard keratin solution, and fails to extract 
sufficient protein from an SC sample. SES appears, from these results, to be better.  
 
Protein quantification, for assessment of the amount of SC per tape, even the more 
sensitive method described here, is still not sensitive enough to distinguish between the 
typically small amounts of SC removed on tape strips. With the present technique, better 
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Chapter 4 
Methods to quantify the amount of stratum corneum on tape 
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4 Methods to quantify the amount of stratum 
corneum on tape strips: experimental features 
4.1 Abstract 
 
An objective method to assess the rate and extent of drug permeation through the skin 
from topical formulations is required for bioequivalence purposes. Tape stripping the 
stratum corneum (SC) with adhesive tapes has emerged as a promising technique. When 
tapes are analysed individually, drug penetration profiles through the SC are constructed. 
For the profiles from different sites and different volunteers to be easily compared, they 
are normalised using the volunteer’s total SC thickness, such that drug concentrations as 
a function of relative depth reached within the SC are obtained. To create such 
normalised profiles, the amount of SC per tape must be measured. 
  
In this chapter, three methods to quantify SC amount per tape are compared in terms of 
practical usability: weighing, UV pseudo-absorption and a novel imaging technique. The 
imaging technique involved taking high resolution images under controlled conditions, 
and measuring the mean greyscale value across all pixels.  
 
6 tapes were measured 15 times with each method. The weighing method exhibits low 
precision, extremely low signal:noise ratio (up to 1 : 2000), and a long, variable time 
needed to obtain measurements. The UV pseudo-absorption method has high precision, 
is quick to perform and has an acceptable signal:noise ratio. However, a fixed 1cm2 of SC 
is analysed, and inhomogeneous tapes are affected by light scattering. The imaging 
method seems quite promising: not only is it very precise, but the signal for the SC layer 
is high relative to the blank tape. In addition, the method is quick, is able to measure any 
sample area up to 2.2 cm x 3.5 cm, and is unaffected by inhomogeneity. 
   
Subsequently, more than 600 tapes were measured by each technique. No simple 
correlation was found between the weighing and either the UV pseudo-absorption or the 
imaging method. A strong (correlation coefficient 0.98) positive correlation was found 
between the UV pseudo-absorption and the greyscale values. 
4.2 Introduction 
 
There is currently a need for an objective method to assess the rate and extent of drug 
permeation through the skin from topical formulations for bioequivalence purposes. 
Topical formulations deliver very low levels of drug to the systemic circulation; therefore, 
drug levels should be sampled within the skin.  
 
Since the stratum corneum (SC) is the principal barrier to drug absorption, it may be 
assumed that the (dermatopharmaco)-kinetics (DPK) of drug passage through this layer 
are related to topical bioavailability [84]. Tape stripping, where layers of SC are removed 
sequentially with adhesive tapes (after formulation application and removal), is being 
investigated as a potentially useful method.  
 
When tapes are analysed individually, drug penetration profiles across the SC may be 
derived. The mass of drug per tape is found after drug extraction and analysis. However, 
since each tape removes a variable amount of SC, it is logical to measure the amount of 



























    
67 
• express the mass of drug extracted as a concentration, in terms of the ‘volume’ 
of SC per tape. 
• measure the depth reached within the SC by each successive tape strip, rather 
than plotting tape strip number. 
• estimate a volunteer’s total SC thickness. SC thickness is estimated by tape 
stripping an untreated adjacent site with concomitant transepidermal water 
loss measurements [1, 100]. The depth reached within the SC is thus 
expressed relative to the volunteer’s total SC thickness. 
 
By measuring and using the amount of SC per tape, robust, reproducible normalised 
profiles of drug concentration against relative depth reached within the SC are thus 
produced, allowing profiles from different sites and volunteers to be compared [51, 76, 
84, 92, 94, 109-111, 120]. Analysis of these profiles, using an appropriate solution of 
Fick’s second law of diffusion, permits parameters describing the partitioning and 
diffusivity of the drug (reflecting the rate and extent of permeation, respectively) to be 
estimated and used to compare different formulations. 
 
Traditionally, weighing tapes before and after stripping has usually been used to estimate 
a mass of SC per tape, but it is time-consuming and laborious. The pseudo-absorption of 
corneocytes at 430nm has also been used as a relative measure of SC, but 
inhomogeneous regions of SC cause light scattering.  
 
Recently, a novel imaging method has been developed, whereby high resolution images 
are taken under highly controlled conditions. The pixels of the image each have an 
associated greyscale value which may be measured and analysed. The mean greyscale 
value across all pixels of the image offers a relative measure of SC per tape.  
 
In this work, we compare the practical properties of the weighing, UV pseudo-absorption 
and the imaging methods. Firstly, six tapes were assayed 15 times by each method to 
measure reproducibility and precision. Secondly, the signal:noise ratio of each method is 
calculated. Thirdly, the proportion of the total tape strip which may be measured is 
compared. The time required to typically perform each measurement is also discussed.  
 
A series of more than 600 tape strips were then assayed for SC amount by each of the 





2cm x 3cm tapes were cut from Scotch Book tape 845 (3M, St. Paul, MN) and stored 
overnight in covered trays. Tapes were manipulated using a small corner of each tape 
folded back on itself. 
4.3.2 Subjects 
 
Ethical approval was granted by the Salisbury Local Research Ethics Committee, the 
Declaration of Helsinki protocols were followed, and written informed consent was 
obtained from all volunteers. No volunteers had any history of dermatological disease, nor 
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For the reproducibility assessment, one volunteer (female, 30 years old) provided 6 tape 
strips from a single site on the volar forearm.  
 
For the correlation study, a total of 39 sites, from the volar forearm, were stripped from 
10 different volunteers (4 males, 6 females; age range 23-37 years), producing over 600 
tape strips.  
4.3.3 Tape stripping 
 
Two pre-tapes (larger than 2cm x 3cm) were applied, with pressure from a roller, to each 
study site, stripped and discarded. These pre-tapes remove exogenous substances and 
prepare the skin surface in a systematic way. A plastic template was applied to delimit a 
constant area (1.5cm x 1.5cm) within the study site. This template had an outline marked 
on its underside of 2cm x 3cm to ensure the tape was always placed in the same 
position.  
 
An initial TEWL measurement was taken with a closed-chamber evaporimeter (Biox 
Aquaflux AF102, Biox Systems Ltd., London, UK; measurement range 0–100 g m2 h−1; 
resolution ±0.05 g m2 h−1; probe applied for a minimum 60 s, TEWL was obtained as 
mean of 10 successive measurements having a CV < 1%). A pre-weighed (see 4.3.4.1) 
tape (2cm x 3cm) was positioned over the template. Adhesion was ensured with six rolls 
with a roller before swift removal. Tape stripping continued with fresh (pre-weighed) 
tapes, with intermittent TEWL measurements, until the TEWL increased to 4-5 times its 
original value. 
4.3.4 Techniques to quantify amount of stratum corneum on tapes 
 
For the reproducibility assessment, the amount of SC on each of six tape strips was 
measured 15 times by each of the three SC quantification methods in turn, as quickly as 
each method would allow.  
 
For the tape strip correlation study, the amount of SC per tape was measured by each 
method once.  
 
4.3.4.1 Weighing method 
 
Tapes were stored for at least 12 hours before their first weighing. Static electricity was 
discharged from the tapes prior to weighing (R50 discharging bar and ES50 power supply 
from Eltex Elektrostatik GmbH, Weil am Rhein, Germany). The tapes were weighed, before 
and after stripping, using a microbalance with precision 0.1µg (Sartorius SE-2F from 
Sartorius AG, Goettingen, Germany). The mass difference equals the mass of SC.  
 
Five blank tapes were weighed at the same time as the tapes used for the tape-stripping 
experiments, both before and after stripping, to correct the calculated mass of SC for any 
variations in weight due to environmental or other conditions. 
 
4.3.4.2 UV pseudo-absorption method 
 
After their second weighing, the tapes were mounted on slides (total size 5cm x 5cm, 
internal window 2.3cm x 3.5cm) such that the 1.5cm x 1.5cm square of SC was centrally 
aligned with its edges parallel to those of the slide. The mark showing the tape orientation 
after stripping was always positioned at the same edge of the slide. 
 
The slide was inserted into a specially adapted UV-vis spectrophotometer (Lambda 35, 
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and was delimited by a 1cm x 1cm square screen. The light passed through the tape from 
the sticky, SC-loaded side. Pseudo-absorption was measured first at 430nm then at 
278nm. A total of four measurements at each wavelength were taken, with the slide 
rotated through 90º between each one. A blank tape was used to calibrate the instrument 
before the first tape and after every five tapes. The mean pseudo-absorption was taken 
as a measure of SC amount. 
 
4.3.4.3 Imaging method 
 
The slide holding the tape + SC was photographed (14 bit) using a Coolscan V ED slide 
scanner (Nikon UK Limited, Kingston upon Thames, UK) at a resolution of 4000 pixels per 
inch (157.5 pixels/mm). Photographs fully illustrating this method are shown in General 
Appendix I. Lighting conditions and photographic settings were kept constant, using the 
settings detailed in General Appendix II. A crop of 2213 x 2203 pixels (approximately 
1.4cm x 1.4cm) was centred over the image, using the preview scan, before the full scan 
was taken.  
 
Cropped images (9822 KB each) were saved and analysed with ImageJ (Rasband, W.S., 
U. S. National Institutes of Health, Bethesda,  
Maryland, USA; freeware from http://rsb.info.nih.gov/ij/). A scale of 159.07 pixels/mm 
was applied to the full image width. During image analysis, the greyscale value of all 
4875239 pixels in the image is measured (16 bit) in the range 0- 64608, where 0 and 
64608 designate black and white, respectively. The mean greyscale across all pixels was 
calculated and then subtracted from that obtained from blank tapes to yield mean 
corrected greyscale values which increase with image darkness (and hence with the 
amount of SC on the tape). The results used for the blank tape correction are detailed in 
General Appendix III. 
 
The mean (corrected) greyscale value is used as a measure of SC amount, such that 
higher greyscale values correspond to darker images and more SC. 
4.3.5 Statistics 
 
All statistical tests, as detailed with the corresponding results, were performed using 
Prism® version 4 (GraphPad Software, CA, USA). 
4.4 Results and Discussion 
 
The 15 replicate measurements by each method were compared in terms of precision, 
signal-to-noise ratio, proportion of sample analysed and time costs. 




It is important to bear in mind, when comparing the weighing, pseudo-absorption and 
imaging methods, that the quantification of the SC by the weighing approach is not direct; 
it requires two weighings of the tape, before and after stripping, and the SC mass is then 
deduced from the difference. Thus, errors inherent with the weighing method can affect 
either weighing, and so the total inherent error is double. This is different to both the UV 
pseudo-absorption method and the imaging method, which offer direct quantification.  
 
The three methods for quantifying SC were assessed for their inherent precision. Six 
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each method fifteen times, as quickly as each method would allow. Table 4-1 presents 
the results obtained. 
 
Considering the weighing measurements, the standard deviation of the mass of the tape 
is very low, with relative standard deviations between 0.009% (tape 06) and 0.050% 
(tape 04). This represents the error of the balance and is indeed encouraging. However, 
we are not that interested in the mass of the tape!  
 
For each tape, from the 15 repeated measurements, there is always a maximum and 
minimum mass measured for blank tape and tape with SC (presented in Table 4-1). It is 
thus possible to consider, that when tapes are typically weighed just once for a tape 
stripping experiment, that extreme weights may be measured by chance. If the minimum 
mass of the tape with SC has the maximum mass of the blank tape subtracted from it, 
the resultant SC mass will be low; and vice versa. These extremes of calculated SC mass 
are presented in Table 4-1 for each tape. The differences between the maximum and 
minimum SC mass calculated from these extreme masses of the tapes vary from 0.0326 
mg (tape 02) and 0.1404mg (tape 04). When this is related to the average mass of SC on 
a tape, 0.1634mg, the large error calculating SC mass is now more apparent.  
 
The difference between the maximum and minimum calculated SC mass can be related 
to the average SC mass using the ‘extreme variability’ (Eq. 4-1, results labelled (2) in Table 
4-1). This value varies between 21.7% (tape 01) and 87.0% (tape 04). Looking at all 6 




mass SC  Ave.
mass SC  Min. -mass SC  Max.
  (%)y variabilit Extreme ×=  Eq. 4-1 
 
It is not possible to calculate a relative standard deviation (RSD) of SC mass. However, 










  (%)y variabilit averageWeighing 
−
=  Eq. 4-2 
 
This average variability (labelled (1) in Table 4-1) is between 3.1% (tape 01) and 10.7% 
(tape 04). The overall variability, for the six tapes, looking at average values is 5.6%.  
 
The pseudo-absorption results are presented similarly in Table 4-1. It is clear that the 
precision of the measurement is very good. Although the absolute values are different 
between the measurements at 430nm and 278nm, there are no significant differences 
between either the extreme variability (Eq. 4-1) or the average measure (RSD) using a 
paired non-parametric 2-tailed Wilcoxon signed rank test and, thus, only the results at 
430nm are discussed further.  
 
The extreme variability over the 15 measurements varies between 0.2 – 0.9%, with an 
average extreme variability of 0.34%. This equates to ~100 times lower than that of the 
weighing method (namely 32.5%). The average error, denoted by the RSD, is 0.34% over 
all 6 tapes, which is ~43 times smaller than that of weighing (5.6%).  
 
The imaging method similarly produces very precise values, with little overall variation in 
either the VA (0.8%) or the RSD (0.3%) over all replicates of the six tapes (Table 4-1). 
These are approximately 39 (=32.54/0.84) and 21 (=5.56/0.27) times lower than the 
corresponding VA and RSD values for the weighing method; and approximately double the 
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Comparing the precision of the three methods, it is clear that the weighing method is less 
precise than either the UV pseudo-absorption or the imaging methods. If we consider the 
most extreme ‘amounts’ of SC that could be derived, the VA for the weighing method is 
two orders of magnitude higher than that derived from the pseudo-absorption or the 
imaging method. Taking instead the error derived from the average ‘amount’ of SC, the 
average RSD is fairly similar for the pseudo-absorption and imaging methods, but one 
order of magnitude higher for the weighing method. 
 
Although it may seem pedantic to consider these ‘worst case’ scenarios for the 
quantification of SC by the weighing approach, the mass can only be measured once 
during tape stripping experiments due to time constraints. Hence, we do not have the 
luxury of averaging an outlier value away and these values may occasionally arise.  
 
Obviously, when trying to determine very slight differences in mass between different 
tapes, which is our aim for measuring the quantity of SC during tape stripping, an average 




























    
72 
 
























Average value 51.8474 52.0286 0.1812  0.4961 0.5481  21389 
SD  0.0056 0.0055    0.0005 0.0005  48 
RSD (%) 0.011 0.011 3.07 (1)  0.107 0.092  0.226 
Min value 51.8391 52.0195 0.1616 (2)  0.4955 0.5475  2[139]0 
Max value 51.8579 52.0401 0.2010 (2)  0.4969 0.5489  21455 
Max value - Min value 0.0188 0.0206 0.0394  0.0014 0.0014  155 
Tape 01 
Extreme variability (%) (3)     21.7   0.3 0.3   0.7 
Average value 51.0087 51.1456 0.1369  0.4491 0.4939  20711 
SD  0.0053 0.0042    0.0003 0.0003  41 
RSD (%) 0.010 0.008 3.44 (1)  0.058 0.054  0.196 
Min value 50.9996 51.1384 0.1208 (2)  0.4487 0.4935  20638 
Max value 51.0176 51.1528 0.1532 (2)  0.4495 0.4944  20780 
Max value - Min value 0.0180 0.0144 0.0324  0.0008 0.0009  143 
Tape 02 
Extreme variability (%) (3)     23.7   0.2 0.2   0.7 
Average value 48.8321 48.9746 0.1425  0.4584 0.5104  21466 
SD  0.0066 0.0065    0.0009 0.0010  59 
RSD (%) 0.013 0.013 4.58 (1)  0.191 0.204  0.277 
Min value 48.8178 48.9664 0.1199 (2)  0.4571 0.5090  21316 
Max value 48.8465 48.9892 0.1714 (2)  0.4597 0.5119  21576 
Max value - Min value 0.0287 0.0228 0.0515  0.0026 0.0029  260 
Tape 03 
Extreme variability (%) (3)     36.1   0.6 0.6   1.2 
Average value 48.7230 48.8843 0.1613  0.4619 0.5142  21049 
SD  0.0245 0.0101   0.0003 0.0003  61 
RSD (%) 0.050 0.021 10.74 (1)  0.064 0.064  0.290 
Min value 48.7010 48.8740 0.0715 (2)  0.4614 0.5137  20987 
Max value 48.8025 48.9129 0.2119 (2)  0.4623 0.5146  21191 
Max value - Min value 0.1015 0.0389 0.1404  0.0009 0.0009  205 
Tape 04 
Extreme variability (%) (3)     87.0   0.2 0.2   1.0 
Average value 50.8578 51.0270 0.1691  0.4483 0.5150  20889 
SD  0.0091 0.0134    0.0014 0.0020  40 
RSD (%) 0.018 0.026 6.66 (1)  0.321 0.379  0.189 
Min value 50.8459 51.0030 0.1295 (2)  0.4468 0.5130  20809 
Max value 50.8735 51.0564 0.2105 (2)  0.4509 0.5188  20934 
Max value - Min value 0.0276 0.0534 0.0810  0.0041 0.0058  124 
Tape 05 
Extreme variability (%) (3)     47.9   0.9 1.1   0.6 
Average value 50.0620 50.2510 0.1891  0.4809 0.5558  21831 
SD  0.0047 0.0137    0.0003 0.0002  90 
RSD (%) 0.009 0.027 4.86 (1)  0.053 0.043  0.412 
Min value 50.0517 50.2316 0.1630 (2)  0.4805 0.5553  21636 
Max value 50.0686 50.2817 0.2300 (2)  0.4814 0.5562  22002 
Max value - Min value 0.0169 0.0501 0.0670  0.0009 0.0009  366 
Tape 06 
Extreme variability (%) (3)     35.4   0.2 0.2   1.7 
Ave RSD     5.56  0.13 0.14  0.27 
Average ‘extreme variability’ (%)    35.99  0.34 0.35  0.84 
Average value    0.1634  0.4658 0.5229  21222 
SD value    0.021  0.019 0.024  415 
Over all 
tapes 



































4.4.1.2 Signal to noise ratio 
 
Later in this chapter, more than 600 tapes with a 1.5 cm x 1.5 cm square layer of SC 
were analysed by each of the three methods. The range of values obtained for each 
method is used to calculate a range of signal:noise ratios.  
 
The 3cm x 2cm tapes weigh approximately 50mg. The range of SC masses was between 
0.025 – 0.25mg, but more typically in the range 0.05-0.15mg (Section 4.4.2). Therefore 
the signal:noise ratio lies somewhere in the 1: 200 to 1:2000 range (Table 4-2). The fact 
that the ‘noise’ of the blank tape is up to 2000 times higher than the signal of the SC 
undoubtedly contributes to the low precision of this method.  
 
 





Signal:noise Size of signal 
relative to noise 
0.025 1 : 2048.0  Mass (mg) 51.2 
0.25 1 : 204.8  
0.053 1 : 0.887 ~1 pseudo-abs. 430nm 0.047 
0.453 1 : 0.104 ~10 
24600 1 : 0.010 ~100 Mean greyscale value (2) 253 
4600 1 : 0.055 ~20 
 
Table 4-2: Calculation of the signal:noise ratio of each method using values for the blank tape and 
the range of tape with SC measurements.  
(1)  Ranges of values taken from section 4.4.2, where > 600 tapes with SC were measured 
with each method. 
(2)  The greyscale value of a pure white pixel is 64608, not 0. All measured values, including 
mean greyscale of blank tape, were thus subtracted from this value before calculating the 
signal to noise ratio. 
 
 
The pseudo-absorption method provides a signal of 0.1 – 0.5 absorbance units for most 
samples (Section 4.4.2) at 430nm. 5 blank tapes assayed in the same way had a pseudo-
absorption of 0.0474 ± 0.0012. This results in a signal to noise ratio of between 1 : 0.9 
to 1 : 0.1 (Table 4-2). The signal is thus 1 to 10 times bigger than the noise value, which 
may mean that for some tapes, the signal may be difficult to distinguish from the noise.  
 
6 blank tapes cropped to an area of 2213 x 2203 pixels, had a mean greyscale value of 
64355 ± 29 over a total of 6×4875239 pixels (see General Appendix III). Approximately 
98.5% of all pixels had a greyscale value of 64424 ± 7, which is very close to the absolute 
minimum of 64608. In order to calculate a signal:noise ratio comparable to the weighing 
and UV pseudo-absorption methods, all greyscale values, for both the blank tape and the 
tapes with SC, were subtracted from the greyscale value of a pure white pixel (64608). 
 
 
Table 4-1: Three quantification methods were compared for their variability over 15 repeated 
measurements, for 6 tapes. RSD: Relative standard deviation. 
(1) It is not possible to calculate a true RSD for the calculated SC mass as this value is calculated 
from the measured masses of tape and tape with stripped SC. The value presented is a measure 
of the variability of the two masses measured, relative to the average SC mass calculated from Eq. 
4-2. 
(2) Minimum SC mass per tape is calculated from the maximum mass of blank tape, subtracted 
from the minimum mass of tape-with-SC; and vice versa for the maximum mass SC.  
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Thus, tapes with small amounts of SC are closer in value to the blank tape than tapes 
with a large amount of SC.  
 
The signal:noise ratio of the greyscale method is between 1 : 0.01 and 1 : 0.05 (Table 
4-2). This is better than UV pseudo-absorption method. In addition, the signal is 20-100 
times larger than the noise value, which means the signal will not be confused with the 
background noise. 
 
4.4.1.3 Proportion of sample analysed 
 
The weighing method measures all SC on the tape.  
 
The pseudo-absorption is restricted to a 1cm2 area. The slide holder positions the slides 
vertically. As such, it is awkward to see if the tape is correctly aligned with the incident 
beam. To avoid this problem, the SC strip should be at least 1.5cm x 1.5cm. The total 
area measured is 100mm2, which is at most 44% of the total SC area sampled 
(225mm2). Previous publications [102, 142] used very large tape strips (19mm x 57mm 
= 1083 mm2) and presumably measured a lower proportion of the total SC. If there is any 
inhomogeneity, the results from this method will be affected by light scattering [143]; and 
if inhomogeneous tapes must be discarded (as in [102, 142]), the method cannot be 
generally suitable for assessing the amount of SC.  
 
The imaging method is the most flexible in this respect as the crop can be adjusted to fit 
any size of strip, up to 2.3 cm x 3.5 cm (internal measurements of the slide). In these 
experiments, a crop of 1.4 cm x 1.4cm was applied over the 1.5 cm x 1.5cm strip. This 
equates to 196mm2 measured out of the total of 225mm2, i.e., 87.1%. 
 
4.4.1.4 Time cost 
 
The weighing method is the most variable in terms of time to complete the procedure, 
compounded by the fact that each tape needs to be weighed twice. In addition, as the 
mass of a tape changes with environmental conditions, 3-5 blank correction tapes must 
be weighed during both weighing sessions. For the 6 tapes, the average time taken to 
complete the 15 replicate blank tape and tape with SC weighings was 72±22 min. Both 
the UV pseudo-absorption and imaging methods are faster, with the 15 replicates 
performed in approximately 30 minutes for the pseudo-absorption assessment; and 15 
minutes for the imaging method (data not shown).  
 
Tape stripping typically required 20-25 strips per site and experiments usually consist of 
2-4 test sites, along with 1 site to assess SC thickness. Obviously, the weighing method 
thus required a long and unpredictable length of time for weighing. The other two 
methods are quicker, and less likely to vary with environmental conditions. Additionally, 
the imaging method has the potential for automation using a slide feeder. 
4.4.2 Correlation between SC amounts measured by each method 
 
A series of tape strips were collected from intact untreated SC. All mass and greyscale 
values were collected within a short space of time, and so are analysed together in Figure 
4-1 B. For tape set 1 (), the UV pseudo-absorption scans were also performed at the 
same time. For tape sets 2 and 3 (● and ), the UV pseudo-absorption measurements 
were taken some months after the mass/imaging measurements, and are thus presented 
separately in Figure 4-1 A and C.  
 
Firstly, comparing the weighing method to the UV pseudo-absorption (Figure 4-1 A). A 
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associated with higher pseudo-absorption at 430nm. The strength of the non-parametric 
correlation is similar for all sets with Spearman correlation coefficients, rs, of 0.53 – 0.57. 
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A. Weighing vs. mean (±SD) UV pseudo-
absorption (n=4 rotations) measured at 
430nm. 
  
rs values are 0.53, 0.53 and 0.57 for data 
sets 1 (, n=202), 2 (●, n=152) and 3 (, 
n=249) respectively. 
B. Weighing vs. imaging (n=601).  
rs value is 0.55. 
C. Imaging vs. mean (±SD) UV pseudo-
absorption (n=4 rotations) measured at 
430nm. 
  
rs values are 0.98, 0.85 and 0.75 for data 
sets 1 (, n=202), 2 (●, n=149) and 3 (, 
n=249) respectively. 
Figure 4-1: Correlation of SC measurements by weighing, UV-pseudo-absorption and imaging methods. 
All correlations significant (p<0.0001) with a 2-tail Gaussian approximation and non-parametric 
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It is interesting to note that our correlation coefficient is not as ‘good’ as that purported in 
the literature (linear regression (sic), r2 of 0.93 ± 0.05 [142] or 0.92 ± 0.02 [102])  
however, this can be explained as we did not eliminate any tapes from the correlation. We 
argue that the elimination of tapes on the grounds of “SC inhomogeneity” [102, 142] is 
not useful for the overall aim of using a technique to normalise drug penetration profiles 
for dermato-pharmacokinetic studies, since all tapes must be included for these profiles 
to provide meaningful pharmacokinetic measurements.  
 
Figure 4-1 B similarly shows a significant positive correlation between the mass of SC on 
the tapes and the resultant mean greyscale value (Spearman correlation coefficient, rs = 
0.55). There are a large number of data points with a mass of SC between 0.08 – 0.13 
mg. This suggests that the gravimetric approach is unable to distinguish between these 
masses, consistent with our findings in 4.4.1. We believe that the resultant poor 
correlation is mainly due to a lack of sensitivity and large inherent error of the weighing 
approach rather than the greyscale values. Nonetheless, this lack of correlation is 
problematic for converting the greyscale values into a workable quantity of SC for 
normalisation purposes. 
 
Finally, comparing the mean greyscale with the pseudo-absorption, a better correlation is 
seen, with a Spearman coefficient of 0.75 – 0.98 depending on when the pseudo-
absorption measurements were made relative to the imaging measurement. It is not 
appropriate to perform a linear regression, as neither variable is ‘controlled’. However, it 
can be seen from Figure 4-1 C that the slope of the three groups is similar. This is 
perhaps not surprising considering the similarities seen when both measurements were 
correlated with the mass (Figure 4-1 A and B). The broad range of both the pseudo-
absorption and mean greyscale measurements imply these methods offer a greater level 
of sensitivity compared to the gravimetric approach. It is thus easier to distinguish 
between the quantity of SC on the tapes using these methods. Of course, it is not known 
whether the quantities of SC are indeed as different as these methods suggest, however, 
considering the variability inherent with the gravimetric method, and the strength of the 
correlations (p<0.0001), these two methods would certainly be hard to dismiss outright.  
 
Considering the range of values obtained by each method, the mass values also show a 
lack of sensitivity, with most values in the range of 0.08 – 0.13mg (factor = 0.62). Both 
the pseudo-absorption and imaging methods show a wider spread of values, between 0.1 
– 0.6 (factor = 6) and 5000 – 25000 (factor = 5) respectively, which will increase their 
sensitivity for the very slight differences in SC amount on the tapes.  
 
There are differences seen between the correlations depending on when the UV pseudo-
absorption measurements were made relative to the other two measurements (Figure 4-1 
A and B). In Figure 4-1 A, tapes which had their UV pseudo-absorption measured after a 
delay (sets 2 (●) and 3 () have lower UV pseudo-absorption values for given masses of 
SC than those measured immediately (tape set 1 (). In Figure 4-1 C, tape sets 2 and 3 
have a similar slope but different position to tape set 1. For given greyscale values, tape 
set 2 has lower UV pseudo-absorption values, but set 3 has higher ones. Possible reasons 
for this are unclear; possibly the tapes have changed with time or the lamp of the 
spectrophotometer has aged. It is merely important to note that pseudo-absorption 
measurements should be taken from fresh tapes. 
 
Full raw data and calculations for the tape set from one site, with SC measured by the 
three methods (weighing, imaging, and UV pseudo-absorption) is shown in Appendix 3-D, 


































The weighing method of assessing SC amount per tape is clearly associated with 
numerous problems: namely low precision, extremely low signal:noise ratio (up to 
1:2000), and a long, variable time needed to obtain measurements. These results call 
into question the usefulness of this method.  
 
Two alternative methods have been considered concurrently, namely the UV-
pseudoabsorption method already discussed in the literature, and a promising novel 
imaging method developed in the course of this work.  
 
The pseudo-absorption method has high precision, is quick to perform and has an 
acceptable signal:noise ratio. However, the absorbance of the some tape strips is very 
similar to that of the blank tapes which brings into question the specificity of the method. 
Furthermore, the area of SC available to be measured is limited to only 1 cm2. Finally, if 
the tapes are inhomogeneous, the method can be affected by light scattering artefacts 
[143].  
 
The imaging method seems very promising: not only is it very precise, but the signal for 
the SC layer is high relative to the blank tape. In addition, the method is quick and simple 
to perform, and is able to measure any sample area up to 2.2 cm x 3.5 cm (1mm less 
than the internal measurements of the slide holder). Furthermore, permanent records of 
the SC measurements are obtained, which may be examined further using image analysis 
software.  
 
The low precision, reproducibility and signal:noise ratio of the weighing measurements, 
coupled with poor correlations with the pseudoabsorption and imaging, demonstrates 
conclusively that the weighing method is not sufficiently sensitive nor robust to evaluate 
the amount of SC per tape strip.   
 
From these results, the imaging method seems the most promising method to quantify 
the amount of SC per tape strip. It offers numerous practical benefits and high sensitivity. 
For further work, we consider whether the greyscale values can be used as a sensitive 
relative measure of the amount of SC per tape, as a direct substitute for SC thickness per 
tape in relevant dermato-pharmacokinetic equations. 
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Chapter 5 
Quantification of stratum corneum by imaging: application to 
dermato-pharmacokinetic studies. 


























    
5 Quantification of stratum corneum by imaging: 
application to dermato-pharmacokinetic studies 
5.1 Abstract 
 
An objective method to assess the rate and extent of drug permeation through the skin 
from topical formulations is required for bioequivalence purposes. Tape stripping the 
stratum corneum (SC) with adhesive tapes has emerged as a promising technique. When 
tapes are analysed individually, drug penetration profiles through the SC are plotted. To 
make comparisons between sites from different volunteers, the volunteer’s total SC 
thickness is measured and used to normalise the drug penetration profiles. Crucial to 
creating such normalised profiles is that the amount of SC per tape is measured. 
  
In this study, we compare two methods to quantify SC amount per tape, in terms of their 
potential to quantify total SC thickness, and to normalise drug penetration depths 
reached within the SC. First, the established method of weighing tapes before and after 
stripping to calculate the mass of SC per tape is examined, easily converted into a SC 
thickness. Second, a novel imaging method, whereby a high resolution image of each 
tape is taken under controlled conditions, is considered. Each pixel, of each image, has 
an associated greyscale value which may be measured and analysed. The mean 
greyscale value is multiplied by the scaled tape strip area to calculate the integrated pixel 
density, which is taken as a relative measure of SC per tape 
 
Initially, two non-linear profiles were fitted to an appropriate non-linear model: (i) 
transepidermal water loss (TEWL) against cumulative thickness removed or (ii) TEWL 
against cumulative integrated pixel density. This allowed estimates of total SC thickness, 
H and G respectively, to be derived and they were well correlated. Furthermore, by 
repeatedly measuring adjacent sites, the intra-subject variability was found to be lower 
for the greyscale profiles than the thickness profiles. 
  
Both non-linear plots were subsequently normalised using the relevant total SC thickness 
derived. This allowed the plots from the thickness and greyscale plots to be 
superimposed and directly compared. The normalised cumulative depth values from the 
thickness and greyscale profiles (for each successive tape) were found to be well 
correlated. Improved sensitivity and fewer outliers were highlighted for the absolute 
normalised greyscale values over the thickness values. Theoretically, there should be a 
correlation between the initial TEWL measured before stripping, with the estimates of two 
parameters from the normalised non-linear models. This was found to exist, and indeed, 
a slightly better correlation was found for parameters derived from the greyscale rather 
than the thickness profiles.  
 
To conclude, the cumulative greyscale values may be used directly in place of the 
traditional cumulative thickness values to measure normalised depth reached within the 
SC, without any conversion factor. 
5.2 Introduction 
 
There is currently a need for an objective method to assess the rate and extent of drug 
permeation through the skin from topical formulations for bioequivalence purposes. 
Topical formulations deliver very low levels of drug to the systemic circulation, so drug 
levels should be sampled within the skin.  

























    
 
Since the stratum corneum (SC) is the principal barrier to drug absorption, it may be 
assumed that the (dermatopharmaco)-kinetics (DPK) of drug passage through this layer 
are related to topical bioavailability [84]. Tape stripping, where layers of SC are removed 
sequentially with adhesive tapes (after formulation application and removal), has shown 
potential for deriving comparative DPK parameters. 
 
When each tape is individually analysed, penetration profiles across the SC may be 
plotted. The mass of drug per tape is found after drug extraction and analysis. However, 
since each tape removes a variable amount of SC, it is important to measure the amount 
of SC per tape in order to: 
  
• Relate the mass of drug extracted to a ‘volume’ of SC per tape 
• measure the depth reached within the SC by each successive tape strip rather 
than plotting tape strip number 
• estimate a volunteer’s total SC thickness. The depth reached within the SC is 
thus expressed relative to the volunteer’s total SC thickness.  
 
Thus, by measuring and using the amount of SC per tape, robust, reproducible 
normalised profiles of drug concentration against relative depth reached within the SC 
are produced, allowing profiles from different sites and volunteers to be easily compared 
[51, 84, 92, 94, 109-112, 120]. Analysis of these profiles, using an appropriate solution 
of Fick’s second law of diffusion, permits parameters describing the partitioning and 
diffusivity of the drug (reflecting the rate and extent of penetration, respectively) to be 
estimated and used to compare different formulations. 
 
Traditionally, weighing tapes before and after stripping has been used to estimate a mass 
of SC per tape, which can be converted to SC thickness per tape, since the area and 
population SC density (1g/cm3, [99]) are known. The cumulative SC thickness removed by 
sequential tapes is thus plotted. At an adjacent, untreated site, stripping is performed 
with concomitant TEWL measurements, to derive an estimate for the total SC thickness 
[1, 100].  
 
In Chapter 4, a novel imaging method to quantify SC amount per tape was shown to 
produce more precise and sensitive values than the weighing method, with a higher 
signal:noise ratio. For the imaging method, a high resolution image of each tape is taken 
under highly controlled lighting conditions. The pixels of the image each have an 
associated greyscale value which may be measured and analysed. The mean greyscale 
value across all pixels of the image is being taken as a relative measure of SC per tape.  
 
Also, in Chapter 4, it was shown that there is no simple conversion factor between the 
mass of SC per tape and the mean greyscale value per tape. This is probably due to the 
lower precision and sensitivity of the weighing method.  
 
In this study, the cumulative integrated pixel densities (=mean greyscale value × scaled 
strip area) were substituted directly in place of the cumulative thickness values in a non-
linear model to estimate SC thickness [100]. From these non-linear plots, the SC 
thickness estimates were correlated and the intra-subject variability compared. 
 
Furthermore, the cumulative thickness and cumulative greyscale values were normalised 
by dividing by the total SC thicknesses estimated from each model. This allowed the data 
and parameter estimates derived from each model to be directly compared. 
 


























    
5.3 Materials and Methods 
5.3.1 Subjects 
 
Healthy volunteers, with no history of dermatological disease, participated in the study. 
Ethical approval was granted by the Salisbury Local Research Ethics Committee, the 
Declaration of Helsinki protocols were followed, and written informed consent was 
obtained from all volunteers. Participants refrained from using any topical products on the 
test area on the day of the experiments.  
 
A total of 25 sites from eight volunteers (2 male, 6 female, age range 23-37 years) were 
examined over a period of 14 months. Subjects were given code numbers (1–8). 
Repeated participation on different occasions was coded with a letter. Multiple sites 
examined on the same day were denoted with a roman numeral. For example “Subject 1 
d (i)” denotes the results from the 1st stripping site on the 4th occasion that Subject 1 
participated. Repeat participation using the same arm was delayed by at least 1 month, 
which is sufficient for barrier regeneration [117-119].  
5.3.2 Tape stripping 
 
2cm x 3cm tapes were cut from Scotch Book tape 845 (3M, St. Paul, MN) and stored 
overnight in covered trays. Tapes were manipulated using a small corner of each tape 
folded back on itself. 
 
Two pre-tapes (larger than 2cm x 3cm) were applied, with pressure from a roller, to each 
study site, stripped and discarded. These pre-tapes remove exogenous substances and 
prepare the skin surface in a systematic way. A plastic template was applied to delimit a 
constant area (1.5cm x 1.5cm) within the study site. This template had an outline marked 
on its underside of 2cm x 3cm to ensure the tape was always placed in the same 
position.  
 
Initial transepidermal water loss (TEWL) measurements were taken, until stable, with a 
closed-chamber evaporimeter (Biox Aquaflux AF102, Biox Systems Ltd., London, UK; 
probe applied for at least 60 s, TEWL was obtained once the mean of 10 successive 
measurements had a CV < 1%). A pre-weighed (see section 5.3.3.1) tape (2cm x 3cm) 
was positioned over the template. Adhesion was ensured with six rolls with a roller before 
swift removal. TEWL was re-measured. This sequence of tape strip then TEWL 
measurement continued until the TEWL was 4-5 times its original value.  
5.3.3 Techniques to quantify amount of SC on tapes 
 
The amount of SC per tape was examined by the weighing and imaging methods. All 
statistical tests, as detailed with the corresponding results, were performed using Prism® 
version 4 (GraphPad Software, CA, USA). 
 
5.3.3.1 Weighing method 
 
Tapes were stored for at least 12 hours before their first weighing. Static electricity was 
discharged from the tapes prior to weighing (R50 discharging bar and ES50 power supply 
from Eltex Elektrostatik GmbH, Weil am Rhein, Germany). The tapes were weighed, before 
and after stripping, using a microbalance with precision 0.1 µg (Sartorius SE-2F from 
Sartorius AG, Goettingen, Germany). The mass difference equals the mass of SC.  
 
Five blank tapes were weighed at the same time as the tapes used for the tape-stripping 

























    
experiments, both before and after stripping, to correct the calculated mass of SC for any 
variations in weight due to environmental or other conditions. 
 
5.3.3.2 Imaging method 
 
The slide holding the tape + SC was photographed (14 bit) using a Coolscan V ED slide 
scanner (Nikon UK Limited, Kingston upon Thames, UK) at a resolution of 4000 pixels per 
inch (157.5 pixels/mm). Photographs fully illustrating this method are shown in General 
Appendix I. Lighting conditions and photographic settings were kept constant, using the 
settings detailed in General Appendix II. A crop of 2213 x 2203 pixels (approximately 
1.4cm x 1.4cm) was centred over the image, using the preview scan, before the full scan 
was taken.  
 
Cropped images (9822 KB each) were saved and analysed with ImageJ (Rasband, W.S., 
U. S. National Institutes of Health, Bethesda,  
Maryland, USA; freeware from http://rsb.info.nih.gov/ij/). A scale of 159.07 pixels/mm 
was applied to the full image width, to calculate a scaled area (195.1mm2). During image 
analysis, each of the 4875239 pixels in the image is assigned a greyscale value (16 bit) 
in the range 0- 64608, where 0 and 64608 designate black and white respectively. The 
mean greyscale over all pixels was calculated and then subtracted from that obtained 
from blank tapes to yield mean greyscale values which increase with image darkness 
(and hence with the amount of SC on the tape). The results used for the blank scan 
correction are detailed in General Appendix III. The mean greyscale value was multiplied 
by the scaled area of each strip (measured as 195.1mm2 for all tapes) to produce an 
integrated pixel density. Although all tapes had the same area in this case, the integrated 
pixel density will ease comparisons when strips of different areas are used.  
 
The mean greyscale value or the integrated pixel density of a tape is used as relative 
measures of SC amount per tape. 
5.3.4 Estimating SC total thickness with non-linear modelling 
 
The mass of SC per tape is obtained from the weighing method. Knowing this mass, the 
strip area and the SC density (1g/cm3, [99]), the thickness of SC removed per tape is 
calculated. 
 
As shown in a previous publication (Chapter 2, and [100]), a plot of the increasing TEWL 
measurements as tape strips progressively remove an increasing thickness of SC, can be 







+=  Eq. 5-1 
 
where: B is a baseline correction factor; D is the diffusion coefficient of water in the SC; K 
is the SC-viable tissue partition coefficient of water; and ∆C is the water concentration 
gradient across the SC. For a given volunteer on a given day, D, K and ∆C are assumed 
constant, and thus only the composite D·K·∆C term is estimated by the model.  
 
In this work, for each site, estimates of H were found using Eq. 5-1.  
 
In addition, for all sites, the integrated pixel density of each tape, derived from the 
imaging method, was also used to quantify SC amount. The cumulative integrated pixel 
densities, g, were substituted in place of cumulative thickness values, h, in Eq. 5-1, to 
find a ‘greyscale-based’ estimate of SC thickness, G, using Eq. 5-2.  




































 Eq. 5-2 
 
For each site, the TEWL values measured are identical, but the cumulative integrated 
pixel densities (g) are several orders of magnitude larger than the corresponding 
thickness values (h). Thus, the estimates of the other parameters (D·K·∆C and B) will also 
be numerically different when either Eq. 5-1 or Eq. 5-2 is used. Those estimated from the 
greyscale model (Eq. 5-2) have hence been attributed subscripts ‘g’.  
 
Plots from each experimental site were evaluated separately using WinNonLin® software 
(Version 5.1, Pharsight Corporation, Mountain View, CA) using ASCII user-defined non-
linear models written according to Eq. 5-1 and Eq. 5-2. In all cases, no data points were 
excluded; uniform weighting was applied; and no bounds were used. 
  
Non-linear models rely upon good initial parameter estimates in order to converge. For 
data fitted to Eq. 5-1, the initial parameter estimates for modelling were: H = final h value 
+ 1; D·K·∆C = 30; B = initial TEWL value before stripping. For data fitted to Eq. 5-2, the 
initial parameter estimates for modelling were calculated from ratios of those used for the 
cumulative thickness measurements, namely: G = ((final h + 1) × final g)/final h; (D·K·∆C)g 
= final g  3; and B = initial TEWL value before stripping.  
 
Iterations continued until the relative change in weighted sum of squares was <0.0001. 
The model derived parameter estimates were used as the new ‘initial’ values in the 
model, and the model rerun until there was no change in the parameter output. All 
parameter estimates presented are those from the final iteration of the model, with the 
smallest resultant residual sum-of-squares; however, usually no change was seen after 
the first run, suggesting that the modelling was stable.  
 
The precision of the parameter estimates derived from both non-linear models (Eq. 5-1 
and Eq. 5-2) is described by both the standard error of the regression (SER) and the 
coefficient of variation (CV (%)) as described in Chapter 2. 
5.3.5 Comparison of normalised plots  
 
To compare easily whether the plots of TEWL against either cumulative thickness or 
cumulative integrated pixel density, and the resultant fits to Eq. 5-1 or Eq. 5-2 
respectively, are equivalent, the profiles were normalised.  
 
To normalise the TEWL vs. cumulative thickness plots, all cumulative thickness values, h, 
were divided by the total thickness, H, generating h/H values. To normalise the TEWL vs. 
cumulative integrated pixel density plots, all integrated pixel densities, g, were divided by 
the total thickness, G, resulting in g/G values. 
 
Two new directly comparable normalised plots of TEWL against relative depth reached 
within the SC, either h/H or g/G, are thus produced and can be superimposed for 
comparison.  
 
In order to non-linearly model these normalised plots, if h is replaced with h/H in Eq. 5-1, 










+=  Eq. 5-3 
 




































+=  Eq. 5-4 
 
Of course, Eq. 5-3 and Eq. 5-4 are mathematically equivalent to Eq. 5-1 and Eq. 5-2, 
respectively.  
 
5.3.5.1 Absolute normalised SC measured per tape 
 
Correlating h/H with g/G values to compare the mass and imaging methods is possible. 
However, as these are cumulative values, the values of a single site are not independent, 
with higher values calculated using the values of lower tape numbers. To assess whether 
the mass and imaging methods produce comparable values for each tape individually, 
the absolute normalised thickness of tape i (ANTi) and the absolute normalised integrated 





















ANT  Eq. 5-5 




















ANG  Eq. 5-6 
 
5.3.5.2 Comparison of D·K·∆C/H, (D·K·∆C)g/G, and TEWL0 
 
From the fits of the normalised plots to Eq. 5-3 and Eq. 5-4, the estimates of D·K·∆C/H 
and (D·K·∆C)g/G may be compared directly.  
 
Furthermore, before any tape strips have been made, Eq. 5-1 and Eq. 5-2 will simplify to 



























0  Eq. 5-8 
 
Where TEWL0 is the measured initial TEWL. 
 
Estimates of B and Bg, as well as D·K·∆C/H and (D·K·∆C)g/G were derived from the fits to 
Eq. 5-3 and Eq. 5-4 respectively.  
 
To verify the validity of the non-linear model, the correlation between the measured 
TEWL0 and the estimated normalised B and D·K· ∆C factors was established. 


























    
5.4 Results and Discussion 
5.4.1 Comparison of the total thickness estimates: H and G 
 
For each tape stripping site, two estimates of total SC thickness, H and G, have been 
determined non-linearly from TEWL plotted against either the cumulative thickness of SC 
(measured by weighing method and fitted to Eq. 5-1) or the cumulative greyscale value 
(measured by the imaging method and fitted to Eq. 5-2) respectively. Plots of the raw 
data, and fits to the non-linear models, for Subject 2 is presented are Figure 5-1 A and B 
as an example. 





























G = 2.19 x 107




































Figure 5-1: TEWL vs. cumulative thickness and cumulative integrated pixel density values for 
Subject 2 
A. TEWL vs. cumulative thickness of 
SC removed (experimental data 
points (●) and resultant fit to Eq. 
5-1 (▬)).  
H estimate = 11.98µm. 
B. TEWL vs. cumulative integrated 
pixel density of SC removed 
(experimental data points (□) and 
resultant fit to Eq. 5-2).  
G estimate = 2.19 x 107 
C. Normalised profiles superimposed 
for comparison: (i) TEWL vs. 
normalised cumulative thickness, h/H 
(●) and the resultant fit to Eq. 5-3 (▬); 
(ii) TEWL vs. normalised cumulative 
integrated pixel density, g/G (□) and 
the resultant fit to Eq. 5-4 (▬). 





























Table 5-1 details the non-linear modelling estimates from the two non-linear models for 
25 independent experiments. The thicknesses measured with the gravimetric method 
vary from 8.9 – 22.6 µm, with a mean (±standard deviation) of 13.6 ± 4.0 µm. The mean 
thickness is in agreement with previous findings (Chapter 2 / [100]). The SC thicknesses 
obtained from the imaging method, G, are also shown in Table 5-1 but are not directly 
comparable with H values. 
 
 
Subject1 Parameter estimates derived from cumulative 
thickness calculations (Eq. 5-1) 
 Parameter estimates derived from cumulative mean 





 D·K·∆C SER CV 
(%) 
 10-7 










1 a  11.7 0.17 1.5  45.1 5.9 13.1  2.51 0.03 1.1  7.3 0.8 11.5 
1 b 8.9 0.13 1.5  88.7 12.7 14.4  2.33 0.03 1.1  24.4 2.6 10.5 
1 c 14.1 0.08 0.6  91.0 4.9 5.4  3.14 0.01 0.4  17.5 0.7 4.1 
1 d (i) 11.8 0.14 1.2  109.1 10.9 10.0  4.44 0.04 1.0  45.6 3.4 7.4 
1 d (ii) 10.2 0.04 0.4  114.2 4.9 4.3  4.19 0.02 0.4  50.5 2.2 4.3 
1 d (iii) 9.4 0.05 0.6  66.7 3.9 5.9  3.87 0.02 0.5  29.5 1.5 5.0 
1 d (iv) 12.0 0.18 1.5  126.7 13.9 11.0  4.13 0.06 1.5  44.3 4.7 10.6 
2 12.0 0.16 1.4  68.3 8.0 11.8  2.2 0.03 1.2  10.0 1.3 12.6 
3 9.1 0.15 1.6  104.4 11.7 11.2  2.31 0.04 1.6  24.5 2.9 12.0 
4 a 10.7 0.08 0.7  82.8 5.2 6.3  4.69 0.03 0.7  33.0 2.2 6.6 
4 b 15.9 0.11 0.7  44.6 6.9 6.5  6.58 0.04 0.6  26.5 1.7 6.5 
5 18.0 0.10 0.6  106.6 4.7 10.6  4.72 0.02 0.5  27.3 1.7 6.3 
6 a 18.7 0.23 1.2  107.3 8.7 8.1  7.34 0.08 1.1  41.2 3.1 7.4 
6 b (i) 22.6 0.68 3.0  160.3 26.1 16.3  7.36 0.21 2.9  49.4 7.8 15.9 
6 b (ii) 18.2 0.49 2.7  122.0 16.4 13.5  6.36 0.14 2.2  34.0 4.3 12.7 
6 b (iii) 16.9 0.28 1.6  86.4 10.5 12.2  6.21 0.10 1.6  30.0 3.7 12.2 
7 (i) 9.9 0.02 0.3  47.6 1.7 3.5  3.22 0.01 0.3  16.3 0.7 4.5 
7 (ii) 10.2 0.18 1.7  98.5 10.5 10.7  3.9 0.08 2.1  40.3 5.0 12.4 
7 (iii) 10.5 0.22 2.1  96.9 15.1 15.6  3.94 0.09 2.3  38.2 6.2 16.1 
7 (iv) 9.4 0.13 1.4  70.9 7.3 10.3  3.63 0.05 1.4  26.6 2.9 10.9 
8 (i) 13.7 0.34 2.5  79.5 16.8 21.2  5.31 0.19 3.5  42.9 9.9 23.1 
8 (ii) 14.1 0.18 1.3  132.3 13.8 10.4  5.13 0.05 0.9  47.6 3.5 7.2 
8 (iii) 14.2 0.24 1.7  103.0 15.4 14.9  5.36 0.09 1.7  44.6 5.8 13.1 
8 (iv) 18.9 0.21 1.1  111.4 14.4 12.9  5.36 0.06 1.1  31.2 4.0 13.0 
8 (v) 19.7 0.24 1.2  150.3 17.6 11.7  6.35 0.07 1.2  50.1 5.4 10.8 
Average 13.6 0.19 1.4  96.6 10.7 10.9  4.58 0.06 1.3  33.3 3.5 10.3 
SD 4.0    30.0     1.54     12.5    
RSD (%) 29.0    31.1      33.7      37.5     
Table 5-1: Estimation of non-linear parameter estimates for the cumulative thickness and 
cumulative greyscale models for 25 experiments. Goodness-of-fit of data to non-linear model is 
shown as standard error of the regression (SER) and coefficient of variation (CV (%)) 
1 Each volunteer given a code number (1-8); repeated participation given a letter (a-d); repeated 
participation on the same day (different sites, same arm) given a roman numeral (i-v).  
2 No significant difference in coefficient of variation (CV, %) of H and G estimates (non-parametric 
paired 2-tail T test with Wilcoxon signed rank test (p>0.05); pairing was significantly effective 
(p<0.0001)). 
 


























    
Figure 5-2 shows the significant correlation plot between the H and G estimates (with 
their SER) over the 25 sites (p<0.0001, 2-tailed Gaussian approximation, Spearman 
correlation coefficient, rs = 0.80). This is much better than the correlation seen between 
individual SC mass and SC greyscale values on individual tapes (rs = 0.55, Section 4.4.2), 
even with fewer replicates. A possible reason for this is the large error associated with the 
weighing method of assessing SC amount, as discussed in Chapter 4. Considering a 
single measurement of an individual tape, weighing errors can distort the correlation with 
the tape mean greyscale value considerably. On the other hand, the G and H 
measurements are global, incorporating the individual SC measurements of many tapes, 
so errors on a few tapes will not have such a great effect on the correlation. 




















Figure 5-2: Correlation between the SC thickness estimates, H and G, with their respective 
standard error of the regression (SER), for 25 experimental sites. Correlation is significant 
(p<0.0001) with a 2-tailed Gaussian approximation, Spearman correlation coefficient, rs = 0.80 
 
5.4.1.1 Intra-subject variability of H and G 
 
The SC thickness is measured at one site, in order to normalise the results from DPK 
experiments at adjacent sites. Therefore, it is assumed the thickness is constant, and the 
estimate of SC thickness should be similar across adjacent sites. For four volunteers, we 
estimated the SC thickness on 3-5 adjacent skin sites on the same arm on the same day, 
using the thickness (Eq. 5-1) and greyscale (Eq. 5-2) models, and the variability is 
presented in Table 5-2.  
 
  Subject 1 (n = 4)  Subject 6 (n = 3)  Subject 7 (n = 4)  Subject 8 (n = 5) 
  H (µm) 10-7 x G   H (µm) 10-7 x G  H (µm) 10-7 x G  H (µm) 10-7 x G 
Average 10.8 4.2   19.2 6.6   10.8 4.2   19.2 6.6 
SD 1.3 0.2  3.0 0.6  1.3 0.2  3.0 0.6 
RSD (%) 11.6 5.6   15.6 9.4   11.6 5.6   15.6 9.4 
Table 5-2: Variability in H and G for 4 volunteers where multiple sites were examined on the same 
arm on the same day. 
 
Comparing the relative standard deviation (RSD) values for the two models, in Subjects 1, 
6 and 8, the estimate for G has a lower RSD than the corresponding H estimate. It is also 
interesting to note that the G estimates from the numerous sites always had a RSD 
<10%, whereas the H estimates for Subjects 1, 6 and 8 have RSD >10%. These data 
suggest that the G estimate of SC thickness (from Eq. 5-2) is less variable than the H 
estimate (from Eq. 5-1).  
 

























    
For tape stripping experiments, the SC thickness is assumed constant across adjacent 
sites examined. As the SC thickness is measured at one dedicated ‘thickness’ site, which 
should be representative of the surrounding sites, these data suggest that the greyscale 
measure of SC thickness, G, with lower inter-site variability on the same volunteer, is 
preferable for assessing SC thickness. 
 
5.4.2 Comparison of normalised plots 
 
In order to compare easily the plots produced by the thickness (Eq. 5-1) and greyscale 
(Eq. 5-2) models, the cumulative thickness values were all divided by H (to produce h/H 
values); and the cumulative integrated pixel densities, g, were all divided by G (to produce 
g/G values) as explained in section 5.3.5. TEWL vs. h/H and g/G are modelled with Eq. 
5-3 and Eq. 5-4 respectively. The data and fits from both models may then be 
superimposed, as shown in Figure 5-1 C. 
 
5.4.2.1 Comparison of h/H and g/G values 
 
The absolute SC thickness, H or G, is not interesting for dermato-pharmacokinetic studies 
per se, but rather is useful as a tool to present the relative depth reached within the SC, 
namely h/H and g/G, for different volunteers on different days.  
 
In Figure 5-3, the h/H and corresponding g/G values for 388 tapes shown. There is a 
significant (p<0.0001) positive correlation, with a Spearman correlation coefficient, rs of 
0.99. This implies that the h/H and g/G values are interchangeable and that the results 
of the imaging method could be used to describe the relative position reached within the 
SC for dermato-pharmacokinetic studies. 
 










Figure 5-3: Correlation between the h/H and g/G values from 25 separate experiments (n = 388). 
The correlation (2 tail) is significant (p<0.0001), with a Spearman correlation coefficient, rs = 0.99. 
 
5.4.2.2 Comparison of absolute normalised SC measured per tape 
 
The h/H and g/G values shown in Figure 5-3 are cumulative values, with each successive 
value between 0 and 1 including the values of earlier tape strips from that tape stripping 
site. Hence, the values are not independent. Thus; the absolute normalised thickness 
(ANTi,) and absolute normalised integrated pixel density (ANGi,) values of each tape, i, 
were calculated using Eq. 5-5 and Eq. 5-6 respectively. These, along with means and 


























    











































































































Figure 5-4: The absolute normalised thickness (ANTi, ■, Eq. 5-5) and absolute normalised 
integrated pixel density (ANGi, ▼, Eq. 5-6) values for each tape, i (n=388); no significant difference 
between the ANT and ANG values (paired 2-tail T test (p = 0.98; pairing was effective (p<0.0001)). 
Mean (●) and SD ( I ) values also presented for each method. 
 
There is no statistical difference between the ANTi and ANGi values (paired 2-tail T-test, p 
= 0.98). However, the values derived from the weighing method (ANTi) have more extreme 
values than those derived from the imaging method (ANGi). Furthermore, the standard 
deviation of the ANG values (0.0154) is smaller than that of the ANT values (0.0186). 
This is consistent with the lower precision of the weighing method, as discussed in 
Chapter 4.  
 
It is also noted that the majority of values derived from the weighing method (ANTi) are 
clustered in the range 0.04 – 0.07, whereas the values derived from the imaging method 
are more widely and uniformly distributed (0.03 – 0.08). This suggests that the imaging 
method may have a higher sensitivity to distinguish between the subtly different amounts 
of SC on tape strips. 
 
5.4.2.3 Links between D·K·∆C/H, (D·K·∆C)g/G, and TEWL0 
 
The initial TEWL measured before stripping (TEWL0), and the normalised D·K·∆C 
estimates, with measures of their precision (SER and CV), are presented in Table 5-3. The 
normalised values derived from the weighing method (D·K·∆C/H) and the imaging method 
((D·K·∆C)g/G) are not significantly different (paired 2-tail T-test (p>0.05); pairing 
significantly effective (p<0.0001)). This, along with the lack of significant difference 

























    
between the h/H and g/G values (section 5.4.2.1 above) implies that the normalised 
curves produced by both methods overlap.  
The average values over all 25 data sets are remarkably similar: 7.38±2.27 and 
7.47±2.49 for D·K·∆C/H and (D·K·∆C)g/G respectively. The goodness-of-fit of the 
parameters to the relevant normalised models is also similar (Table 5-3).  
 
 
Subject1 Experimental TEWL0  Normalised with H  Normalised with G 
 Average SD  D·K·∆C/H 
estimate 
SER CV (%)  D·K·∆C/H 
estimate 
SER CV (%) 
1 a  6.6 0.34   3.9 0.51 13.2   2.9 0.34 11.8 
1 b 10.9 0.24  10.0 1.44 14.4  10.5 1.15 11.0 
1 c 10.8 0.27  6.5 0.35 5.4  5.6 0.24 4.3 
1 d (i) 10.5 0.35  9.3 0.92 10.0  10.3 0.8 7.8 
1 d (ii) 13.1 0.46  11.2 0.48 4.3  12.1 0.55 4.6 
1 d (iii) 11.7 0.59  7.1 0.42 5.9  7.6 0.4 5.2 
1 d (iv) 10.3 0.2  10.5 1.17 11.1  10.7 1.18 11.0 
2 6.7 0.15  5.7 0.68 11.8  4.5 0.59 12.9 
3 15.4 0.19  11.6 1.31 11.3  10.7 1.34 12.5 
4 a 8.7 0.07  7.7 0.49 6.3  7.0 0.48 6.8 
4 b 8.9 0.57  5.9 0.38 6.4  5.8 0.38 6.5 
5 10.4 0.41  2.8 0.3 10.6  4.1 0.27 6.7 
6 a 7.0 0.48  5.7 0.46 8.1  5.6 0.44 7.8 
6 b (i) 8.3 0.36  7.0 1.14 16.2  6.8 1.13 16.7 
6 b (ii) 7.5 0.18  6.7 0.91 13.5  5.4 0.72 13.4 
6 b (iii) 9.5 0.42  5.2 0.63 12.2  4.9 0.63 12.9 
7 (i) 17.6 0.79  4.8 0.17 3.5  5.1 0.24 4.7 
7 (ii) 18.2 0.54  9.8 1.04 10.7  10.4 1.36 13.1 
7 (iii) 20.3 0.54  9.2 1.44 15.6  9.8 1.64 16.8 
7 (iv) 15.3 0.73  7.6 0.78 10.3  7.4 0.85 11.4 
8 (i) 9.3 0.4  5.9 1.26 21.2  8.2 1.98 24.2 
8 (ii) 10.0 0.39  9.4 0.98 10.4  9.3 0.7 7.6 
8 (iii) 9.8 0.03  7.2 1.08 14.9  8.3 1.14 13.7 
8 (iv) 11.6 0.6  6.0 0.77 12.9  5.8 0.79 13.4 
8 (v) 14.5 0.63   7.7 0.9 11.7   7.9 0.88 11.2 
Average 11.32 0.40  7.38 0.80 10.87  7.47 0.81 10.72 
SD 3.70    2.27      2.49     
Table 5-3: Estimate of normalised D·K·∆C parameters from the two models, along with their 
respective SER and CV (%); and the experimental initial TEWL before stripping (TEWL0). 
 
The significant positive correlation seen between D·K·∆C/H and (D·K·∆C)g/G is also 
highlighted in Figure 5-5 (α = 0.05, Spearman correlation coefficient = 0.93). Eq. 5-7 and 
Eq. 5-8 predict that before any stripping has occurred, the original non-linear equations 
(Eq. 5-1 and Eq. 5-2 respectively) can be simplified. As such, for the cumulative thickness 
curves (with SC measured by weighing), there should be a correlation between B and 
TEWL0 − D·K·∆C/H; and for the cumulative integrated pixel density curves, a correlation 
between Bg and TEWL0 – (D·K·∆C)g/G. These two correlations are shown in Figure 5-6 A 
and B, and are indeed very good, with Spearman correlation coefficients of 0.91 and 0.94 
for the weighing and imaging methods respectively. This confirms that the original non-
linear models fit the data well and indeed that the imaging method performs slightly 
better than the weighing method. 
 
 
Full raw data and calculations for the tape set from Subject 1c, is shown in Appendix 5-A, 
as an example. 


























    
 






















Figure 5-5: Comparison of the (normalised) D·K·∆C/H and D·K·∆C/G estimates (with their respective 
SER) for 25 different sites; significant correlation (α = 0.05) found with a 2-tail non-parametric 
correlation (p<0.0001, Spearman coefficient = 0.93). 
 







































Figure 5-6: Testing the correlation between TEWL0 and normalised non-linear parameter 
estimates. 
A. Positive significant 
correlation between (TEWL0 
- D·K·∆C/H) and B for 25 
sites (p<0.0001, Spearman 
correlation coefficient, rs = 
0.91). 
B. Positive significant 
correlation between (TEWL0 
– (D·K·∆C)g/G) and Bg for 25 
sites (p<0.0001, Spearman 
correlation coefficient, rs = 
0.94). 

























    
5.5 Conclusions 
 
In this study, the SC on tapes from 25 untreated sites has been quantified by weighing 
and a novel imaging method. The use of the mass of SC per tape in dermato-
pharmacokinetic studies is established [51, 84, 92, 94, 109-112, 120]. When stripping is 
performed on an adjacent site, coupled with TEWL measurements, the total SC thickness 
may be estimated from a non-linear model (Chapter 2 / [100]).  
 
In this study, it was shown that the total SC thickness can be derived using cumulative 
greyscale values of successive tapes instead of cumulative thickness values in the non-
linear model previously described (Chapter 2 / [100]) The SC total thicknesses derived 
from either model correlate well, but the intra-subject variability is lower for the greyscale 
model. 
 
When the original plots are normalised using the SC thickness estimated from either 
model, such that the relative depth within the SC is plotted, the model outputs may be 
directly compared. Fortunately, the normalised profiles overlap and provide comparable 
non-linear parameter outputs: h/H correlated with g/G; and D·K·∆C/H correlated with 
(D·K·∆C)g/G. Dermato-pharmacokinetic studies plot drug concentration as a function of 
the relative depth across the SC. Since both relative measures, h/H and g/G investigated 
here are significantly correlated, they may be used interchangeably. There is therefore no 
need to perform any conversion of the imaging results to mass measurements.  
 
The absolute normalised SC amount per tape was also calculated for both models. The 
values from the greyscale model had fewer outliers (indicating better precision), and 
showed a greater spread of values (indicating better sensitivity) than the weighing 
method. This is consistent with findings in Chapter 4.  
 
Finally, before any stripping commences, the non-linear model simplifies to predict a 
relationship between the initial TEWL before stripping, the estimates of the baseline-
correction factor, B, and the estimates of the normalised D·K·∆C parameter. This is indeed 
the case, with a slightly better correlation seen between these parameters for the imaging 
rather than the weighing method. 
 
The mean cumulative greyscale values, derived from the imaging method, may therefore 
be used instead of the cumulative thickness values derived from the weighing method to 
directly measure the relative depth reached within the SC with each tape. Indeed, the 
cumulative greyscale values are more precise and sensitive; the normalised cumulative 
greyscale plots have less intra-subject variability; and a better correlation is seen when 
verifying normalised D·K·∆C and B  estimates with the initial TEWL measured before 
stripping. Considering the other benefits that the imaging method provides in terms of 
speed and ease of analysis; precision; signal:noise ratio; reproducibility; large proportion 
of tape assayed; and a permanent record of the tape’s image  (see Chapter 4), this is 
extremely promising. These results indicate that the imaging method can, and perhaps 
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Chapter 6 
Dermato-pharmacokinetics: methodological refinement of 
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6 Dermato-pharmacokinetics: methodological 




Tape stripping is a minimally invasive method to measure drug permeation through the 
stratum corneum (SC). Analysing the concentration of drug on each tape, as a function of 
the relative position within the SC, allows parameters characterising the penetration 
process to be derived after fitting the data to an appropriate solution of Fick’s second law 
of diffusion.   
 
Traditionally, drug penetration profiles measured the amount of SC per tape by weighing 
each tape before and after stripping. We have developed a novel imaging method which 
offers advantages in terms of sensitivity, reproducibility, precision, stability and speed 
over weighing. High resolution images, taken under controlled conditions, are analysed in 
terms of pixel greyscale values and distributions. The integrated pixel density (=mean 
greyscale value x strip area) of each tape is used as a measure of SC amount. In this 
article, we compare the drug penetration profiles from two acyclovir creams obtained 
using the mass of SC per tape, to those obtained by substituting the cumulative 
thickness measurements with cumulative integrated pixel densities. The drug penetration 
profiles are comparable.  
 
Furthermore, the images taken of each tape may be used to assess SC inhomogeneity. 
The original FDA guidance on dermato-pharmacokinetics stipulated that the tape 
stripping method is not suitable for formulations which disrupt SC structure and 
cohesivity, as drug partitioning into, and diffusivity through, the barrier may be affected. 
Here, we examine a formulation which caused significant SC disruption, where resultant 
tape strips were inhomogeneous and sometimes contained large clumps of tissue. Three 
methods were used to further analyse the stored images, to assess SC inhomogeneity. 
This could be a useful, objective method with which to reject SC-disrupting formulations 
from further clinical applications. 
6.2 Introduction 
 
Dermato-pharmacokinetics is the study of the rate and extent of drug permeation through 
the SC. Tape stripping is a minimally invasive method to measure drug concentrations at 
different depths within the SC. In studies where data are gleaned from each tape 
individually, drug penetration profiles are produced, relating a concentration of drug 
measured per tape (in terms of mass of drug per volume of SC) to a particular depth 
reached within the SC (this depth is expressed relative to the total SC thickness, 
measured separately). These drug concentration penetration profiles can be fitted to an 
appropriate solution of Fick’s second law, to derive the SC-vehicle partition coefficient 
and a measure of the drug’s diffusivity in the SC. These parameters may be compared for 
different formulations. The amount of SC on each tape is required (i) to express the drug 
mass measured per tape as a concentration (in terms of a ‘volume’ of SC); (ii) to measure 
the depth reached within the SC; and (iii) to measure the total SC thickness at a separate 
site, in order to express the depth reached relative to the total SC thickness per volunteer.  
 
Traditionally, the amount of SC per tape has been determined gravimetrically, whereby 
the tape is weighed before and after stripping and the mass of SC deduced. Knowing this 

























    
mass, the area of SC stripped and the density of SC (1g/cm3, [99]), the thickness 
removed per tape, and hence the cumulative thickness removed by each successive tape, 
is calculated.  
 
As an alternative method to assess the amount of SC per tape, a novel imaging technique 
has been investigated, whereby a high resolution image of each tape is taken under 
controlled lighting conditions. Each pixel of this image has an associated greyscale value, 
and the mean greyscale value across all pixels is used as a relative measure of SC 
amount per tape. We have already shown that the mean greyscale value of a tape is a 
more sensitive, precise, reproducible, rapid and stable method to assess the quantity of 
stratum corneum (SC) on tapes, as compared with weighing (Chapter 4). The integrated 
pixel densities are calculated simply by multiplying mean greyscale values by the strip 
area (in this study, 195.1mm2 for all strips) We have also shown that the cumulative 
integrated pixel densities (g) derived from tapes on an untreated site, with concomitant 
transepidermal water loss (TEWL) measurements, can be used to derive a measure of 
total SC thickness (G) for a volunteer (Chapter 5) Furthermore, the total (greyscale) 
thickness, G, can be used to measure the relative depth reached within the SC, denoted 
g/G (Chapter 5).  
 
Now we examine the usefulness of the greyscale measure of SC amount per tape to 
produce dermato-pharmacokinetic profiles for assessing and comparing topical 
formulations. Two types of drug penetration profiles are constructed for two acyclovir 
(ACV) creams: (i) ‘mass’ DPK profiles where the mass of SC is used to measure SC 
amount per tape; and (ii) ‘imaging’ DPK profiles where integrated pixel densities are used 
as a measure of SC amount per tape.  
 
Furthermore, the images of tapes which stripped an inhomogeneous layer of SC were 
studied further. Three image analysis techniques have been investigated to quantify the 
extent of inhomogeneous SC removal by these tapes. 
6.3 Materials and Methods 
6.3.1 Subjects and formulations 
 
Two female healthy volunteers (both 30 years old), with no history of dermatological 
disease, participated in this study. Ethical approval was granted by the Salisbury Local 
Research Ethics Committee, the Declaration of Helsinki protocols were followed, and 
written informed consent was obtained. Two 5% acyclovir cream formulations were 
compared: (i) Zovirax cream (GlaxoSmithKline plc, Brentford, UK), and (ii) a generic cream 
(Pliva Pharma, Ltd, Petersfield, UK).  Each volunteer provided five study sites: 2 sites for 
each of the two formulations, and one site to calculate SC thickness.  
6.3.2 Tape stripping 
 
Prior to any tape stripping experiment, loose outer layers of the stratum disjunctum at the 
skin sites was removed with two light “pre-tapes” and discarded. This was done to 
prepare all skin sites in a systematic way. 400µl (HandyStep® volume dispenser, Brand 
GMBH & Co. KG,  Wertheim Germany) of each formulation was spread over a demarcated 
area (2cm x 2cm, foam template, No.1772, 3M United Kingdom PLC, Bracknell, UK), 
covered with plastic and left in place for 30 minutes. This corresponds to an infinite dose, 
chosen such that (i) the reservoir of drug cannot be depleted during the course of the 
experiment, and (ii) and the dermato-pharmacokinetic models developed, based on Fick’s 
second law, may be used. At the end of the application, the site was carefully cleaned 
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Farnham, UK) and allowed to dry for 5 minutes. A plastic template delimiting an area of 
1.5 cm x 1.5 cm was centred over the application area.  
 
Initial transepidermal water loss (TEWL) measurements were taken at the site using a 
closed-chamber evaporimeter (Aquaflux AF102, Biox Systems Ltd, London, UK; 
measurement range 0-100 g.m2h-1; resolution ±0.05 g.m2h-1; the TEWL was taken when 
the mean of 10 successive measurements had a CV<1%) until stable. A pre-cut, pre-
weighed (see below) piece (2cm x 3cm) of Scotch Book tape 845 (3M, St Paul, MN) was 
placed over the template and adhesion to the skin was ensured using a weighted roller. 
Further pre-weighed tape strips were taken at the site, with periodic TEWL 
measurements, until the TEWL reached ~4 times its original value.  
 
For all sites, the amount of SC per tape was assessed by two methods, to construct the 
‘mass’ and ‘greyscale’ DPK profiles respectively. 
 
A. Mass of SC per tape 
 
Tapes were cut and stored (covered) for 12 hours in ambient conditions. Each blank tape 
was discharged of static electricity (R50 discharging bar with ES50 power supply from 
Eltex Electrostatik GmbH, Weil am Rhein, Germany), weighed using a microbalance (SE-
2F, precision 0.1µg; Sartorius AG, Goettingen, Germany) and then stored (maximum 24 
hours) before being used for tape stripping. Following tape stripping, all tapes were again 
discharged of static electricity and reweighed. The mass difference between the two 
allowed the mass of SC on each tape to be calculated. To correct for any variations in 
environmental conditions, and the change in mass that may occur with time, 3-5 blank 
correction tapes were weighed at the same time as the tapes used for stripping. The 
change in mass of these blank tapes was used to correct the calculated mass of SC on 
each tape. Knowing the mass of SC on the tape, the area, and the density of SC (1g/cm3) 
[99], the thickness of SC on each tape could be calculated, and hence the cumulative SC 
thickness removed derived. 
 
B. Integrated pixel density of tape 
 
The procedure followed the steps outlined above but, after the second weighing, the 
tapes were mounted onto slides before being photographed under controlled lighting 
conditions using a Coolscan V ED (Nikon UK Limited, Kingston upon Thames, UK) slide 
scanner. Photographs fully illustrating this method are shown in General Appendix I. 
Image resolution was 4000 pixels per inch. The scanner was set to positive scan in the 
greyscale colour space of 14 bit depth, with no transformations or camera adjustments. 
Full scanner settings are detailed in General Appendix II. Cropped images, 2213 x 2203 
pixels (approximately 1.4cm x 1.4cm; 9822 KB each) were taken, then analysed with 
ImageJ (Rasband, W.S., U. S. National Institutes of Health, Bethesda, Maryland, USA; 
freeware from http://rsb.info.nih.gov/ij/). A scale of 159.07 pixels /mm was applied by 
measuring the full length of one side of the image. During image analysis, the 16 bit 
greyscale value of each of the 4875239 pixels in the image is found. This greyscale value 
is between 0 and 64608, designating black and white respectively. The mean corrected 
greyscale value across all pixels was ‘corrected’ by subtracting from the mean greyscale 
value for a blank tape (64355) (Full calculations shown in General Appendix III); such that 
large corrected mean greyscale values correspond to dark images, and more stratum 
corneum. The mean greyscale value of each tape was multiplied by the tape strip area 
(195.1mm2 for all tapes in this study) to derive the integrated pixel density, which has 
been shown to be a useful measure of the amount of SC per tape (Chapter 5).  
6.3.3 SC thickness determination 
 
To determine the SC thickness of each volunteer, tape stripping was performed on an 

























    
adjacent, untreated site with TEWL measurements taken before and after each tape strip. 
The sequence was repeated until the TEWL value was 3-4 times its initial value (usually 
60-80g.m-2h-1).  
 
This allowed the SC thickness, H or G, to be estimated from the baseline-corrected non-
linear model using either the SC thickness or integrated pixel densities respectively, as 



















 Eq. 6-2 
 
In Eq. 6-1, the thickness of the SC removed (h), is determined gravimetrically. The change 
in TEWL as a function of thickness of SC stripped is fitted to Eq. 6-1 to obtain values of 
the SC thickness (H), the product of the SC-viable epidermal partition coefficient of water 
(K), its diffusivity in the barrier (D), and the concentration gradient (∆C) of water across 
the membrane, and the baseline correction factor (B). 
  
In Eq. 6-2, the SC removed by each strip is assessed by the cumulative integrated pixel 
density (g), and the fitting yields the total SC thickness (G), and once again, values for 
D·K·∆C and B. Values derived from this model are denoted with subscript ‘g’.  
 
Non-linear fitting of Eq. 6-1 and Eq. 6-2 was performed in WinNonLin® (software version 
5.1, Pharsight Corporation, Mountain View, CA) using an ASCII user-defined model.  
 
The derived values of H or G are used to normalise the measurements of h or g, 
respectively so that all concentration profiles, from either volunteer, at any treatment site, 
to which either formulation has been applied, could be expressed on a relative scale of 0 
to 1, where 0 corresponds to the SC surface, and 1 to the SC-stratum granulosum 
interface. 
6.3.4 Acyclovir extraction and analysis 
 
After imaging, tapes were cut from the slide holders, and extracted overnight in 1ml of 
distilled water, shaken at 210 shakes /minute. Samples were filtered (Chronus® 0.45µm 
nylon filters, SMI-LabHut Ltd, Maisemore, UK) before HPLC analysis (PG80 pump, ASI-100 
autosampler, TCC-100 column oven, PDA-100 UV lamp from Dionex Corporation 
Sunnyvale, California, USA) using a 15cm Acclaim 120 column (C18, 5µm, 120Å) at 25°C 
and a mobile phase of 0.5% acetic acid, 5% methanol, and 94.5% water (pH 2.97) 
running at 1ml/min.  
 
Standard solutions of acyclovir (Sequoia Research Products Ltd., Pangbourne, 
United Kingdom) were prepared in distilled water, over the concentration range 0.024 – 
1.96 µg/ml. 
6.3.5 Dermato-pharmacokinetic profiles 
 
Two concentration profiles were constructed, one based on SC depth determined by 
mass, the other according to the integrated pixel density.  
 
For the ‘mass-derived’ concentration profiles, the concentration of drug at a particular 
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when the SC is quantified by imaging, the ACV mass is divided by the corresponding mean 
greyscale value, expressed as Cg. To allow the two approaches to be directly compared, 
therefore, a normalisation procedure is used. The two sets of concentration data are 
divided, respectively, by the average concentration of drug in the SC as determined by 
mass (Rm) and the average concentration of drug is the SC as determined by imaging (Rg) 
from Eq. 6-3 and Eq. 6-4, respectively. Estimates for the average concentration of drug in 
the SC may also be estimated from the area under the concentration profile curves, as 
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The normalised concentration of drug (Cx/Rm  or Cg/Rg), as a function of time (t) and of 
position (h or g) in the SC of total thickness (H or G) may be expressed by the following 



































































 Eq. 6-6 
 
where Cv is the drug concentration in the vehicle. Dermato-pharmacokinetic parameters 
may be estimated from this model; namely a normalised estimate of the drug’s SC-vehicle 
partition coefficient (Km/Rm or Kg/Rg for the mass and greyscale measurements 
respectively) and its characteristic diffusion parameter (D/H2). Using Eq. 6-5 and Eq. 6-6 
assumes the following boundary conditions: (i) that an infinite dose is applied; (ii) that the 
SC is initially drug-free; (iii) that the barrier is homogeneous in its barrier properties; and 
(iv) that the viable epidermis provides a perfect sink for permeating drug. 
       
All statistical tests were performed, and graphs produced, with GraphPad Prism® (version 
4.00 for Windows, GraphPad Software, San Diego, CA). 
6.3.6 Assessing SC inhomogeneity 
 
In an attempt to quantify potential inhomogeneity of tapes, three further image analysis 
techniques were proposed and tested on homogeneous and inhomogeneous tapes from 
Volunteer 1, Pliva Site 2. 
6.3.6.1 Relative standard deviation of greyscale values 
 
Each tape strip has ~4.9 x 106 pixels, each of a particular greyscale value. The original 
standard deviation determined from Image J refers to the original greyscale values where 
low greyscale values correspond to dark pixels. The corrected greyscale variance of each 
tape strip (sB-X) was calculated using Eq. 6-7: 
 

























    














s  Eq. 6-7 
 
where n is the number of pixels per image (4875239); Bi is the greyscale value of pixel, i, 
on the blank tape; Si is the greyscale value of pixel, i, of the tape strip; and b and s are the 
mean greyscale values of the blank tape and the tape strip respectively. The standard 
deviation is the square root of the variance. As 98.8% of all pixels on the blank tape had a 
greyscale value of 64419 (where the palest possible greyscale value is 64608), this value 
was used as the greyscale value of all blank pixels (namely all Bi). 
6.3.6.2 Use of ‘particle analysis’ software application 
 
Inhomogeneous ‘clumps’ on tape strips from volunteer 1 site 2 were highlighted and 
measured by converting to 8-bit images (such that pixels have greyscale values between 
0 (dark) and 256 (light)), and applying an ‘auto’ threshold using Image J. The threshold 
highlights dark areas. The lower threshold was 0, and the upper threshold varied from 
145-161, depending on the mean greyscale of the particular image. From amongst those 
pixels highlighted by the threshold function, ‘particle analysis’ was performed by ImageJ 
(with no size or circularity restrictions, no shaped outlines drawn, and holes within clumps 
included) to find and measure inhomogeneous SC areas on the tape. Results from this 
analysis provide information about the clumps on the tape strip: total, and fraction of, 
image area affected; the average size; and a count of the pixels not contributing to 
clumps. 
6.3.6.3 Sectional profile plots 
 
Selected images from volunteer 1 site 2 were divided into five vertical sections. A plot of 
the greyscale values with distance across the tape was obtained for each of the five 
sections using the “plot profile” function in Image J. Inhomogeneous regions on the image 
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6.4 Results and Discussion 
6.4.1 Use of imaging to produce drug-permeation profiles 
 
Drug penetration profiles resulting from tape stripping experiments can be modelled 
using an appropriate solution of Fick’s second law to derive dermato-pharmacokinetic 
parameters. These can be used to characterise the rate and extent of drug permeation 
through the SC for different formulations, and hence compare different formulations of 
the same drug. 
 
Traditionally, the drug permeation profiles are constructed using mass measurements per 
tape to calculate the cumulative depth reached within the SC. Measuring the mass of SC 
per tape is neither precise nor reproducible, and a novel imaging method has been 
examined extensively in this work. Firstly, the imaging method is easy to use, quick to 
perform, precise and reproducible. The greyscale values calculated for each tape using 
the imaging method may be used to calculate a relative measure of total SC thickess, G. 
This thickness, G, may be used to normalise drug-permeation profiles to ease 
comparisons between different volunteers.  
 
In this work, two acyclovir creams were compared. All tapes from each application site 
were assessed for SC quantity by both the weighing and imaging methods. This generated 
two sets of drug-permeation profiles, allowing differences (i) between the weighing and 
imaging profiles, and (ii) between the two different acyclovir formulations, to be 
considered.  
 
Unfortunately, one Pliva site (volunteer 1, site 2) produced such significant SC disruption 
that its DPK results could not be considered. However, images from this set of tapes were 
used for inhomogeneity assessment as described in section 6.4.2.  
 
Figure 6-1 shows the non-normalised data for all Zovirax and Pliva sites. The data from 
the Zovirax sites are more reproducible than the Pliva sites. Overall, the profiles 
constructed using the mass of SC are of comparable shape to those constructed with the 
mean greyscale values (imaging method) of the tapes. 
 
Clearly, the mass (A and B) and imaging (C and D) drug-permeation profiles in Figure 6-1 
are not directly comparable due to scale. Therefore, the y-axes were normalised using the 
average concentration of ACV in the total SC removed (calculated using Eq. 6-3 and Eq. 6-4 
for the weighing and imaging methods respectively).  
 
The fully normalised DPK data, for both the mass and imaging SC quantification methods, 
are presented in Figure 6-3 (Zovirax sites) and Figure 6-4 (Pliva sites). It is apparent that 
the normalised profiles overlap well in all cases. This suggests that the measurements 
derived from the imaging method may be used directly in drug-permeation profiles, and 
do not require conversion to actual depths reached within the SC. Rather, the imaging 
method provides a perfectly usable relative measure of the amount of SC per tape.  
 
By fitting these normalised concentration profiles to Eq. 6-5 and Eq. 6-6, the DPK 
parameters of ACV diffusivity in the SC (D/H2), and the normalised partition coefficients, 
Km/Rm and Kg/Rg, are found for the mass and imaging methods respectively (Table 6-1). 
Neither the normalised K values, nor the D/H2 values, derived from the mass or imaging 
DPK plots, are significantly different from each other (2-tail paired non-parametric t-test, 
p>0.05). This reflects the similarity seen when the two different normalised drug-
permeation profiles were superimposed (Figure 6-3 and Figure 6-4).  

























    
 
Km and Kg estimates were derived from fitting the original, non-normalised concentration 
profiles to Eq. 6-5 and Eq. 6-6. The estimates found for the mass versus the imaging 
method are linearly related, with a regression coefficient, r2 = 0.73 (Table 6-1). The 
average concentrations of drug in the SC, Rm (Eq. 6-3) and Rg (Eq. 6-4) are also presented 
in Table 6-1. There is a linear relationship between the two ratios, with a regression 
coefficient, r2 of 0.92 (Figure 6-2).  This relationship between Rm and Rg may be used to 
convert Kg/Rg values into a true vehicle-SC partition coefficient, Km. This will allow  future 
dermato-pharmacokinetic studies of formulations performed using the imaging method to 
be directly compared with previously studied formulations, in which SC per tape was 
evaluated by the weighing method.  
 
The Km values obtained from the Zovirax sites are largely reproducible, with Km varying 
between 3.7 to 6.4, and Kg varying between 3.1 x 10-5 to 9.5 x10-5 over the four sites. The 
D/H2 values are consistently between 0.02 and 0.04 h-1 for both SC quantification 
methods. The higher D/H2 value for Volunteer 1 Zovirax site 1 (Table 6-1) is due to the 
peaks in ACV concentration approximately half way into the SC (h/H or g/G values ~0.6) 
(Figure 6-3A), which could be due to contamination.  
 
The partition coefficients, Km, obtained here for acyclovir (log P = -1.6, MW = 225 g.mol-1), 
are within the same order of magnitude as those obtained previously for ibuprofen (log P 
= 3.97, MW = 206 g.mol-1), betamethasone valerate (log P = 3.6, MW = 477 g.mol-1) and 
terbinafine (log P = 5.9, MW = 328 g.mol-1); they are all numerically close to 1. This is 
surprising considering the different physicochemical properties of these molecules. In 
other words, the drug concentration in the SC at the surface of the barrier approximately 
equals its concentration in the vehicle. One interpretation for this (apparent) coincidence 
is that residual formulation remains on the skin surface, or in the skin furrows, after 
formulation removal. An alternative hypothesis is that the drug, and key excipients in 
which the drug is soluble, enter the SC as a “unit”, only separating from one another 
deeper within the SC layers.  
 
 
From the above observations, it is clear that quantifying the amount of SC per tape using 
mass or greyscale measurements, provides comparable pharmacokinetic parameters for 
comparison. The greyscale method is thus useful for assessing and comparing 
formulations for bioequivalence studies, and given its advantages in terms of time, 
reproducibility, sensitivity and stability (see Chapter 4), it can offer a viable alternative to 


































































Figure 6-1: Data and resultant fits to Fick’s second law (Eq. 6-7).  For all graphs, ▲ data from Volunteer 1 Site 1;  data from Volunteer 1 Site 2; □ data from 
Volunteer 2 site 1; and ○ data from Volunteer 2 Site 2. A: plots generated for Zovirax sites using mass of SC on tapes. B: plots generated for Pliva sites using mass of 
SC on tapes. C: plots generated for Zovirax sites using mean greyscale values of tapes. D: plots generated for Pliva sites using mean greyscale values of tapes. 
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Figure 6-2: Comparison of the total mass of ACV relative to the total mass of SC (x-axis) or the total mean greyscale value (y-axis) from Zovirax (■) and Pliva (▲) sites. 


































































Figure 6-3: Direct comparison of the mass and imaging Zovirax DPK profiles, through normalisation of the y-axis concentrations. For tape data derived from SC mass 
(□), normalised concentration of ACV in SC is calculated as Eq. 6-3. For tape data derived from SC mean greyscale (), normalised concentration of ACV in SC is 
calculated as using the ratios calculated from Eq. 6-4. Fits to Eq. 6-5 (▬) and Eq. 6-6 (▬) also shown.  







































































































































































































































Figure 6-4: Direct comparison of the mass and imaging Pliva DPK profiles, through normalisation of the y-axis concentrations. For tape data derived from SC mass (□), 
normalised concentration of ACV in SC is calculated using the normalisation ratio, Rm (Eq. 6-3); For tape data derived from SC mean greyscale (), normalised 
concentration of ACV in SC is calculated from the normalisation ratio, Rg (Eq. 6-4). Fits to Eq. 6-5 (▬) and Eq. 6-6 (▬) also shown.  
Graphs A: Volunteer 1, site 1. Graphs C and D: Volunteer 2, sites 1 and 2 respectively.  
(1)  Graph B is Volunteer 1 Site 2, shown for information only, as this site had SC disruption (see section 6.4.2 and Figure 6-5) and is not considered for DPK analysis. 
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Rm (1) 105 x Rg(1) Normalised data  (D/H2)mass  (D/H2)greyscale  
    Km/Rm (3) (4) Kg/Rg (3) (4)  (h-1) (4) (h-1) (4) 
Km (2) 105 x Kg (2) 
1 Zov. 1 1.6 1.0 2.4 ± 0.3 4.9 ± 0.7  0.24 ± 0.09 0.03 ± 0.01 3.7 ± 0.5 4.7 ± 0.6 
 Zov. 2  0.9 0.5 4.8 ± 0.4 6.0 ± 0.3  0.03 ± 0.01 0.02 ± 0.00 4.1 ± 0.3 3.1 ± 0.2 
2 Zov. 1 1.6 1.3 4.0 ± 0.4 7.1 ± 0.5  0.04 ± 0.01 0.02 ± 0.00 6.4 ± 0.7 9.5 ± 0.8 
 Zov. 2  0.9 0.8 4.9 ± 0.5 5.6 ± 0.5  0.03 ± 0.01 0.04 ± 0.01 4.6 ± 0.5 4.4 ± 0.4 
1 Pliva 1 1.2 0.7 5.4 ± 0.7 4.3 ± 0.7  0.01 ± 0.01 0.03 ± 0.01 6.3 ± 0.9 2.9 ± 0.5 
2 Pliva 1 2.4 2.4 5.0 ± 0.4 5.8 ± 0.4  0.05 ± 0.01 0.04 ± 0.01 11.8 ± 0.9 13.8 ± 1.1 
 Pliva 2 1.8 1.5 1.7 ± 0.3 2.8 ± 0.5  0.17 ± 0.07 0.12 ± 0.04 2.9 ± 0.5 4.2 ± 0.7 
Table 6-1: Estimates (± standard error) of K and D/H2 from Fick’s second law (Eq. 6-5), with SC measured using mass and mean greyscale techniques. 
(1) Normalisation ratios: 
Rm = [Total mass ACV from all tapes] / [Total mass SC from all tapes] 
 Rg = [Total mass ACV from all tapes] / [Total mean greyscale value from all tapes] 
(2) Linear regression of K estimate from mass (Km) or greyscale (Kg) DPK plots results in a regression coefficient, r2 = 0.73 
(3) Normalised DPK plots fitted to Eq. 6-5 and Eq. 6-6 provide normalised partition coefficient estimates, Km/Rm and Kg/Rg for the mass and greyscale measures of SC 
respectively. These have been verified to equal the original partition coefficient normalised by the respective ratio.  



























    6.4.2 Using imaging to assess inhomogeneity 
 
We have previous experience that a 1-hour application of the Pliva formulation results in 
tapes on which SC clumping is observed (Appendix 5-A). Similarly, some degree of 
inhomogeneous SC removal was seen for three out of the four generic application sites 
(Figure 6-5, Appendix 6-H and Appendix 6-I) in this study, with an application of only 30 
minutes. For Volunteer 1, site 2, this is dramatically seen for tape 7 (Figure 6-5). 
Inhomogeneous layers were not seen for the Zovirax formulation (Appendices 6-F, 6-G, 6-J 
and 6-K). Formulations which affect SC cohesivity, such as the Pliva cream studied here, 
are clearly undesirable for most clinical applications. Drug-permeation profiles of these 
formulations are unsuitable for DPK analysis as the SC homogeneity is affected in an 
unpredictable way. Hence comparisons between the two formulations in terms of 
dermatopharmackinetics and bioequivalence, in section 6.4.1 above, are limited.  
 
However, the imaging method enables us to identify formulations affecting SC cohesivity 
in this way. Furthermore, the images of each tape record these effects shortly after tape 
stripping, before extraction of the drug, a significant further advantage over weighing the 
tapes to assess SC content. In order to exclude formulations that exhibit this effect, 
quantification of the degree of the problem would be useful. Three methods, using the 
tape strip images, have been investigated. Since the generic site 2 of volunteer 1 exhibits 
this effect most dramatically, this set of images (Figure 6-5) is used to test the 
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1 21731 20013 20173 
2 12080 12048 13079 
3 55.6 60.2 64.8 
4 0.079 0.051 0.098 






1 21679 25248 20154 
2 13735 12830 14149 
3 63.4 50.8 70.2 
4 0.067 0.089 0.049 






1 26627 19253 14876 
2 13734 14366 13491 
3 51.6 74.6 90.7 
4 0.283 0.077 0.040 




1 19540 17824  
2 13455 13091  
3 68.9 73.4  
4 0.056 0.035  
Figure 6-5: Images and SC measurements for Volunteer 1, Pliva, Site 2.  
1. Mean corrected greyscale value;  2. Corrected standard deviation;  



























    
6.4.2.1 Relative standard deviation of pixel greyscale values 
 
It was hypothesised that inhomogeneous tapes may have a larger standard deviation (SD) 
of greyscale values than homogeneous tapes. Considering the tapes from Volunteer 1 
Pliva Site 2 (Figure 6-5), pair-wise comparisons of: Tape 07 (clumps, SD = 13733.8) with 
Tape 04 (homogeneous, SD = 13734.8); and Tape 11 (pale hole corresponding to 
missing SC layers, SD = 13091) with Tape 03 (homogeneous, SD = 13078.6) show that 
the SD measurement is not able to distinguish inhomogeneous tapes specifically. The SD 
is a global measure of the pixel greyscale distribution, and as all tapes will have some 
white pixels, darker images tend to have the higher standard deviations, although there is 
no simple relationship.  
6.4.2.2  Use of ‘particle analysis’ software application 
 
By applying a threshold to highlight the darkest pixels of an image, it is possible to 
analyse and highlight these areas, using ImageJ’s ‘particle analysis’ function. Images with 
highlighted clumps of SC are shown for selected tapes in panels A of Figure 6-6, Figure 
6-7, Figure 6-8 and Figure 6-9. 
 
This function works particularly well for tapes which have removed inhomogeneous layers 
of SC, such as tape 07 (Figure 6-7 A and B). The darker inhomogeneous layer highlighted 
corresponds to 84.9% of the total area. It is clear that the ‘particle analysis’ function does 
not distinguish between the darkest fractions (sections to the left of the left-lower-to-right-
upper diagonal) and the slightly darker areas to the right of this same diagonal. Examining 
next Tape 08, the paler section is clearly highlighted by the procedure, and directly 
corresponds to the area where several layers of SC were removed by Tape 07 (Figure 6-6 
A and B). Tape 07 obviously removed many layers of SC as this pale area is still visible on 
the final tape (Tape 11) (Figure 6-9 A and B).  
 
It should be noted that the ‘particle analysis’ function of the software is designed to pick 
out distinct particles on, for example, plates of bacterial colonies. Homogeneous images 
thus provide a considerable challenge as it is looking for differences that are not there. 
The software thus finds patches which are relatively darker than the adjacent pixels, as 
seen for Tape 01 in Figure 6-6 A/B. For this homogeneous strip, a large artefactual 
particulate area is highlighted and measured. It is clearly not appropriate to perform this 
procedure on all tapes therefore; they must first be assessed visually for true areas of 
inhomogeneity. However, tapes with true areas affected by SC clumping can be assessed. 
 
6.4.2.3 Sectional profile plots 
 
Each image may be divided into segments, which are analysed for variability in greyscale 
values across the full width of the image. These are presented in Figure 6-6, Figure 6-7, 
Figure 6-8 and Figure 6-9, panels C. Note that these are the original greyscale values, 
thus low greyscale values correspond to dark pixels.  
 
Considering firstly Tape 01 (Figure 6-6 C), the greyscale plot rarely fluctuates by more 
than 5000 units. The greyscale value is generally between 40000 and 45000, 
corresponding to approximately 10% variability. This narrow fluctuation range indicates its 
homogeneity.  
 
The profile plots for Tape 07 (Figure 6-7 C) reflect well the inhomogeneity seen. Going 
from left to right along the profiles, troughs are seen when lumpy areas are seen on the 
tape. The variability of the greyscale value varies between 30000 and 50000, 
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Since Tape 07 removed a many layers of SC together in an inhomogeneous lump, tapes 
08 and 11 have a pale patch corresponding to this area (Figure 6-8 B and Figure 6-9 B). 
On the profile plots (Figure 6-8 C and Figure 6-9 C), peaks correspond to these pale areas. 
The variability of the greyscale value is again high: with greyscale values from 35000 to 
55000, representing 27-36% of the highest greyscale value.  
 
The profile plots shown are useful for quantifying the degree of inhomogeneity. The 
variability in the greyscale values across the plot increase markedly from ~10% for 
homogeneous strips to 20-40% for strips with lumps. This could be used to eliminate SC-
disrupting formulations from further clinical development studies. 
 
Full raw data and calculations for the tape set from Volunteer 1 Zovirax Site 1 are shown 
as an example in Appendices 6-A and 6-B. In Appendix 6-A, the calculations to derive H 
and G at an untreated site are given; in Appendix 6-B the data used to derive the drug 
concentration as a function of normalised depth within the SC profiles is provided. 
 
Thus, the stored images may be assessed for inhomogeneity by studying greyscale 
variability across sections of each tape (using sectional profile plots). These assessments 
could form the basis of an objective method to determine a formulation’s suitability for 
tape stripping studies. Although we consider here the ‘drug-in-SC profiling’ method for 
interpreting DPK data, the determination of a formulation’s suitability for tape stripping 
assessment would also be relevant to the ‘two-time’ metric described in Chapter 1. 




Distance across image (inches) 


































A B C 
Tape 01 
Figure 6-6: Image of Tape 01 from Volunteer 1 Pliva site 2 (B) along with the particle analysis plot and the fraction of area highlighted by this analysis 
(A); and the profile plots for the 5 segments (C). The segments in Panel C show the original greyscale values, such that high greyscale values 

















































































Figure 6-7: Images of Tape 07 from Volunteer 1 Pliva site 2 (B) along with the particle analysis plot and the fraction of area highlighted by this 
analysis (A); and the profile plots for the 5 segments (C). The segments in Panel C show the original greyscale values, such that high greyscale values 
correspond to pale pixels and vice versa. 
A B C 








































A B C 
Figure 6-8: Images of Tape 08 from Volunteer 1 Pliva site 2 (B) along with the particle analysis plot and the fraction of area highlighted by this analysis (A); and the profile 












































Figure 6-9: Images of Tape 11 from Volunteer 1 Pliva site 2 (B) along with the particle analysis plot and the fraction of area highlighted by this analysis (A); and the profile 
plots for the 5 segments (C). The segments in Panel C show the original greyscale values, such that high greyscale values correspond to pale pixels and vice versa. 
Distance (inches) 
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6.5 Conclusions 
 
We have discussed the use of a novel imaging method to quantify the amount of SC per 
tape strip, and the application to dermato-pharmacokinetic studies. This novel imaging 
method has previously been shown to be more sensitive, precise, reproducible, stable 
and rapid than weighing.  
 
Two commercial acyclovir creams were studied, with the amount of SC per tape measured 
using the weighing and novel imaging methods. When the drug-permeation curves thus 
produced were normalised, the results from the weighing and imaging methods were 
comparable. Dermato-pharmacokinetic parameters were estimated from the appropriate 
solutions to Fick’s second law, and no significant difference was found between the 
parameters obtained from either method. The diffusivity estimates are the same for both 
methods, and the partition coefficient from the drug-permeation profiles from the imaging 
method may easily be compared with those derived from mass measurements. This 
allows the results of future studies, performed using the imaging method, to be compared 
with previous work. 
 
We have shown that the mean greyscale values derived from the imaging method may be 
used to substitute mass measurements for all aspects of the tape stripping dermato-
pharmacokinetic analysis.  
 
The partition coefficients, Km, obtained here for acyclovir, are within the same order of 
magnitude (numerically close to 1) as other drugs studied previously, despite remarkably 
different physicochemical properties. In other words, the drug concentration in the SC at 
the surface of the barrier approximately equals its concentration in the vehicle. One 
interpretation for this (apparent) coincidence is that residual formulation remains on the 
skin surface, or in the skin furrows, after formulation removal. An alternative hypothesis is 
that the drug, and key excipients in which the drug is soluble, enter the SC as a “unit”, 
only separating from one another deeper within the SC layers. Some evidence that this 
may be the case has already been presented; it has been shown that the proportion of a 
cosolvent, such as propylene glycol, in formulations of equal thermodynamic activity, can 
affect partitioning in a manner not easily related to drug concentration [111]. Further, 
propylene glycol has been shown to permeate more rapidly through the SC than 
ibuprofen, helping to maintain a saturated drug concentration in the SC after formulation 
removal, and hence affecting the kinetics of clearance from the SC [113]. Therefore, 
bioequivalence assessments between formulations must consider differences between 
their excipients. This presents analytical challenges for future work as excipient 
proportions are generally not released for commercial reasons. 
 
Of the two acyclovir creams considered in this study, it is apparent that the generic Pliva 
formulation disrupts SC structure and cohesivity. This formulation is thus unsuitable for 
clinical use, as barrier function may be compromised and drug permeation will be altered.  
 
The stored images of each tape strip may be assessed for inhomogeneity by studying 
greyscale variability across sections of each tape (using sectional profile plots). 
Furthermore, the area of the tape affected by SC clumping may be measured. These 
assessments could form the basis of a rapid, objective method to determine a 
formulation’s suitability for clinical evaluation. Although we consider here the ‘drug-in-SC 
profiling’ method for interpreting DPK data, the determination of a formulation’s 
suitability for tape stripping assessment would also be relevant to the ‘two-time’ metric 
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The imaging method is thus recommended to replace the traditionally used weighing 
method to determine the amount of SC on each tape strip.  It is simple, rapid, sensitive, 
and reproducible. The greyscale values obtained are sensitive relative measures of the 
amount of SC per tape and may be used directly in dermato-pharmacokinetic studies to 
obtain useful parameters to describe the rate and extent of permeation. Drug-permeation 
profiles and dermato-pharmacokinetic parameters may be used to assess and compare 
formulations. In addition, the permanent records of each tape may be analysed further to 
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Thesis Conclusions 
The assessment of most topical formulations currently relies on expensive, subjective 
clinical trials. While new chemical entities must, of course, be assessed in this way, the 
development of generic formulations would benefit from objective, validated 
measurements of drug permeation, to assess bioequivalence.  
 
Tape stripping has been established as a promising method to assess the rate and extent 
of drug permeation through the SC. Since its inception, tape stripping progressed rapidly, 
resulting in the formalisation of the technique into FDA draft guidance in 1998 [86]. 
However, contradictory results from two different laboratories prompted the withdrawal of 
the guidance in 2002. Since then, methodological problems with the initial guidance have 
been identified and rectified. Furthermore, the metric originally described, whereby total 
drug amount after four uptake and four clearance times is measured, akin to the 
assessment of oral formulations, has been criticised as unnecessarily onerous in terms of 
time, skin sites and analysis. 
 
Two alternative metrics have been proposed. First, the total drug amount permeated after 
one uptake and one elimination time are compared (the ‘two-time’ metric). This metric 
seems very promising, and is particularly good where low levels of drug are found per 
tape, as tapes are combined for drug extraction. Additionally, it is quick to execute. The 
second metric is that considered in this thesis, whereby the concentration of drug as a 
function of depth reached within the SC is measured, and the resultant profiles fitted to 
an appropriate solution of Fick’s second law. Dermato-pharmacokinetic parameters are 
thus derived, to assess the rate and extent of drug permeation. Although more time 
consuming than the ‘two-time’ metric, drug penetration profiles can offer reasons to 
explain differences between formulations, and propose mechanisms for the influence of 
excipients on drug permeation [111, 113]  
 
To produce drug penetration profiles across the SC, data from each tape is required. To 
ease the comparison between different volunteers, it is important to normalise the depth 
reached within the SC relative to the total SC thickness, measured separately. The drug 
penetration profiles thus cover a range from 0 (at the skin surface) to 1 (at the SC- 
stratum granulosum interface). In this thesis, a novel non-linear model has been 
developed to measure the total SC thickness more accurately; objectively taking into the 
account any stratum corneum disjunctum layers as applicable.  
 
In order to calculate the SC thickness as above, determine the depth reached within the 
SC, and express masses of drug as a concentration relative to the ‘volume’ of SC per 
tape, the amount of SC per tape must be measured. Traditionally, weighing tapes before 
and after stripping has been used to estimate SC mass; protein extraction [103-108], UV- 
and IR-pseudoabsorption [102, 103], and have all been explored and have been further 
evaluated here.  
 
With regards protein extraction and analysis, the use of concentrated NaOH is not 
recommended, as it degrades SC keratins, and fails to extract all protein from the SC. A 
thiol/urea mixture described herein is suitable for protein extraction from keratin, and 
analysis may be performed with the universally compatible EZQ protein assay. The 
analysis is insufficiently sensitive however to distinguish between the very small masses 
of SC on 1.5 x 1.5 cm tape strips. Larger tape strips or combining tape strips could be 
considered for future use of this protein assay.  
 
Problems were noticed early on with the weighing method to assess SC amount per tape: 
variability with environmental conditions; low mass of SC relative to the mass of the tape; 
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Therefore, alternative methods were investigated. The UV-pseudoabsorption method has 
been already reported in the literature, but as large numbers of inhomogeneous tapes 
were discarded in these studies, due to light scattering, further evaluation was 
undertaken. The imaging method was developed after initially taking photographs of the 
tapes to illustrate clumping. Subsequently, analytical photography was investigated as a 
means to quantify the amount of SC per tape. 
 
Comparing the method features, the UV-pseudoabsorption and imaging methods have 
much better precision and signal:noise ratios than the weighing method, as well as being 
significantly quicker and less laborious. The imaging method, however, offers a some 
advantages over the UV pseudoabsorption method, in terms of signal:noise ratio, 
sensitivity range, proportion of strip analysed, and time costs. Moreover, it is not only able 
to measure the SC on inhomogeneous tapes, it can also assess the degree of 
inhomogeneity in order to exclude formulations from further study. 
 
To use the mean greyscale value, or integrated pixel density of a tape instead of the mass 
of SC, it was firstly attempted to correlate the two measurements for a collection of 600 
tapes to derive a conversion factor. This correlation, although significant, was not good 
enough to derive such a conversion factor. Looking at the data from these tapes, the 
weighing method appears less sensitive than the imaging method: global SC mass range 
was 0.05 to 0.15mg, whereas global greyscale values were between 5000 and 25000. 
This is no doubt a contributing factor to the poor correlation. Given the problems inherent 
with the weighing method, the value of such a correlation is questionable. It is a relative 
measure of SC amount per tape which is required to normalise drug permeation profiles, 
and this is most certainly provided by the precise and sensitive mean greyscale value or 
integrated pixel density. 
 
Thus, for 25 sites, the thickness was assessed using the previously developed non-linear 
model, but where the amount of SC per tape was measured by both the weighing and 
imaging methods. The cumulative integrated pixel densities replaced the cumulative 
thickness in the model. The measures of SC thickness by both methods were well-
correlated and when used to normalise the respective TEWL vs. cumulative depth 
profiles, the profiles overlapped. In addition, intra-subject variability was lower for the 
imaging method; the absolute greyscale values had fewer extreme values and better 
sensitivity than the corresponding absolute thickness values; and a better correlation was 
seen when normalised parameter estimates from the greyscale profiles were related to 
the initial TEWL, than when the parameters derived from the thickness profiles were 
used.  
 
Substituting the mass measurements for each tape with the corresponding integrated 
pixel density in dermato-pharmacokinetic comparisons of two acyclovir creams produced 
comparable drug permeation profiles. These were analysed using the appropriate solution 
to Fick’s second law and usable dermato-pharmacokinetic parameters were produced to 
compare formulations. 
 
Furthermore, the images produced may be examined to glean other interesting 
information. One acyclovir cream disrupted the SC structure and some SC was removed in 
clearly visible clumps. The area affected by these clumps can be highlighted and 
measured using greyscale threshold functions. The images may also be divided into 
sections to consider the variation in greyscale values across the image. Peaks and 
troughs can then be used to measure the inhomogeneous regions.  
 
When strips are always photographed in the same orientation, as was done in all these 
experiments, it is possible to stack all images from a particular site and construct a 3-


















































It is thus possible to visualise furrows in the skin, which may have importance for drug 
permeation. If the z-axis co-ordinate of these images was correlated with the resultant SC 
thickness estimated from the non-linear model, it may be possible to assign a scale to the 
thickness seen in the 3-dimensional images. It may then be possible estimate the depth 
reached by furrows in the SC.  
 
It is also possible, when full rather than cropped scans are taken, to accurately measure 
the area of a strip using the threshold function again. Taking both scans would not be 
unnecessarily arduous, and would allow a more accurate integrated pixel density to be 
measured if that was required for other applications. 
 
Thus far, dermato-pharmacokinetic studies using the ‘drug in SC permeation profiles’ 
have been conducted for terbinafine, ibuprofen, betamethasone valerate and acyclovir. 
The estimated partition coefficients, Km, for these physicochemically different drugs, 
formulated in different vehicles, have been estimated to be numerically close to 1. This 
implies that the drug concentration in the SC at the surface of the barrier is approximately 
equal to the concentration of drug in the vehicle. One possible explanation for this 
apparent coincidence is that residual formulation remains on the SC surface after the end 
of the application period. That is, the cleaning procedure to remove the formulation after 
the application period is inadequate. Comparisons have been made between cleaning the 
skin surface with dry tissues versus an alcohol wipe, after application of a gelled 
microemulsion formulation of betamethasone valerate [94]. Cleaning with an alcohol 
wipe reduced both the SC-vehicle partition coefficient, Km, and the deduced saturation 
levels of BMV in the SC, by approximately 50%. The total amount of drug in the SC, 
measured by the AUC, was also reduced. However, no effect was seen on the diffusivity of 
betamethasone valerate in the SC, suggesting that the brief exposure to alcohol during 
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have only been performed with betamethasone valerate, and with two simple gelled 
formulations, further work is needed to establish the effects of the cleaning procedure on 
formulations more similar to those used commercially.  
 
Traditional topical formulations warrant evaluation of a suitable cleaning procedure. To 
attempt to measure a drug’s SC-vehicle partition coefficient, uninfluenced by residual 
formulation, simple patch formulations of drugs may be applied and the dermato-
pharmacokinetics of drug permeation studied by tape stripping. Patch removal will 
remove all applied drug cleanly, with no formulation remaining on the surface or in 
putative skin furrows.  
 
To this end, preliminary in vitro and in vivo work has been performed with various patch 
formulations of betamethasone valerate, as presented in Appendix A – preliminary further 
work. Unfortunately, strong patch adhesion in vitro, and in limited (placebo) in vivo 
experiments, resulted in a significant fraction of the SC being removed by the patch, and 
subsequent tape strips of the deeper SC contained unquantifiable levels of drug. These 
studies need to be repeated using less aggressive patches. Incidentally, during this work, 
it was found that images of the patches, post removal from the skin, allowed them to be 
rapidly screened for excessive adhesivity.  
 
An alternative hypothesis to explain the apparent similarity between the SC-vehicle 
partition coefficients measured for terbinafine, ibuprofen, betamethasone valerate and 
acyclovir, is that the drug and key excipients, in which the drug is most soluble, enter the 
SC as a unit, and only separate from one another deeper within the barrier [111, 113]. 
This hypothesis could be tested further by concurrently measuring drug and key excipient 
concentrations on each tape strip, or remaining on the skin after each tape has been 
removed.  
 
Further work is also required to test drugs with different physicochemical properties and 
to examine multiple, clinically relevant, formulations of the same drug.  
 
Sufficient evidence has been presented in this work to replace the practice of weighing 
tapes before and after stripping to assess SC mass, with the imaging method, which 
provides a precise and sensitive relative measure of the amount of SC per tape. The 
majority of the strip is analysed, and the method boasts a high signal: noise ratio.  
 
The use of such an imaging method will simplify and quicken tape stripping experiments 
considerably, while still enabling drug concentration as a function of SC depth profiles to 
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Appendix A – Preliminary Further Work 
Deducing the stratum corneum – vehicle partition coefficient 





Tape stripping stratum corneum (SC) following application of a formulation allows drug 
concentration as a function of depth within the SC to be determined. Fitting these data to 
an appropriate solution of Fick’s second law of diffusion allows the drug’s diffusivity 
across the SC and its SC-vehicle partition coefficient to be assessed, and these derived 
dermato-pharmacokinetic (DPK) parameters can then be used to compare different 
formulations. It has been noted that the derived partition coefficients for three drugs of 
distinct physicochemical properties, derived from quite different vehicles, are all rather 
similar and numerically close to 1. This could be due to the influence of residual 
formulation, incompletely removed by the cleaning procedures used, on the skin surface, 
or that drug plus key excipients (in which the active is quite soluble) are taken up into the 
SC together and then only separate when they have travelled further into the barrier.   
 
In this preliminary study, betamethasone valerate was formulated into simple adhesive 
patches, the removal of which should unambiguously avoid any potential artefacts. 
However, patch adhesion in vitro; and in limited (placebo) in vivo experiments, was 
substantial such that (i) a significant fraction of SC was removed with the patch, and (ii) 
the level of drug in the remaining SC was too low to quantify. While the investigation 
needs to be repeated, therefore, using less aggressive patches, it was noted that the high 
resolution imaging procedure used was able to simply and rapidly assess the extent to 




Tape stripping involves removing sequential layers of the stratum corneum (SC). It can be 
performed with minimum discomfort and relative ease in vivo, usually on the volar 
forearm of healthy volunteers.  
 
If a formulation is applied to the skin prior to tape stripping, drug may be extracted from 
the tapes to quantify the mass of drug which has permeated into the SC. Since the SC is 
the principal barrier to drug absorption, the pharmacokinetics of drug passage through 
this layer have been related to topical bioavailability [84]. Topical formulations may be 
compared and bioequivalence assessed, therefore, from the derived data. 
 
The original United States Food and Drug Administration (FDA) guidance [86], on the 
determination of dermato-pharmacokinetic from tape stripping experiments (since 
withdrawn) is unnecessarily arduous (see Chapter 1). An alternative approach is to 
determine the profile of drug concentration (Cx) as a function of depth within the SC (h) 
after an application time (t). Data are fitted to the appropriate solution of Fick’s second 
law of diffusion (Eq. A-1) to derive the drug’s SC-vehicle partition coefficient (Km) and its 
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where Cv is the drug concentration in the vehicle. At the skin surface, h/H = 0, and the 
concentration of drug (Cx) equals KmCv. 
 
The literature reveals that the derived values of Km from this analysis for terbinafine [84, 
92], ibuprofen [51, 109, 110] and betamethasone valerate [77, 112], three drugs of 
different physicochemical properties, delivered from a number of quite different 
formulations, are (almost without exception), numerically very close to a value of 1. In 
other words, the drug concentration in the SC at the surface of the barrier approximately 
equals its concentration in the vehicle. One interpretation of this (apparent) coincidence 
is that residual formulation at the end of the application period has not been effectively 
removed by the cleaning procedure employed. An alternative hypothesis is that the drug 
and key excipients, in which the drug is most soluble, enter the SC as a “unit”, and only 
separate from one another deeper within the barrier [113].  
 
To explore this question further, betamethasone was formulated into some simple 
adhesive patches. It was anticipated that the systems would ensure that no residual 
vehicle would be left on the skin upon their removal and permit, as a result, an 
unambiguous estimation of Km. Experiments have been performed in vitro on porcine skin 
and, in a more limited fashion, using a placebo patch, in vivo in a human volunteer. The 
amount of SC removed with each tape has been assessed gravimetrically and also by 
high resolution imaging. The imaging technique was used in addition to quantify the 
amount of the barrier removed by the patch itself. 
 




Simple patches, were prepared by LTS Lohmann Therapie Systeme (Andernach, Germany) 
(Table A-1). In vitro studies were performed with either silicone or polyacrylate adhesive 
patches containing betamethasone valerate (BMV). The limited in vivo studies were 
carried out with a placebo polyacrylate patch. 
 
 Silicone1 Polyacrylate2 Polyacrylate2 (placebo) 
Adhesive (%) 98 95 100 
BMV concentration (%) 2 5 0 
Area (cm2) 4.9 4.9 4.8 
Shape Circle Circle Square 
Application time (hrs) 2 6 2 
Experiment In vitro In vitro In vivo 
Table A-1: Patch characteristics. 1 Bio-PSA 4301, 2 Durotak 387-2287. 
 
Skin penetration experiments 
 
Prior to any procedure (in vitro or in vivo) loose outer layers of stratum disjunctum at the 
skin sites to be examined were removed with two light “pre-tapes” and discarded.  
 
In the in vitro experiments, abdominal porcine skin was used. Tissue was obtained 
immediately post-slaughter of the animal, washed under cold, running water, dried and 
then dermatomed to approximately 750µm (ZimmerTM Electric Dermatome, Dover, OH). 
The skin was cut into pieces which were individually wrapped in parafilm before storing at 
-20°C until use. Before use, the skin was thoroughly defrosted and hairs were carefully 
trimmed before patch application.  
 
Patches were applied for 2 or 6 hours as indicated in Table A-1. After patch removal, a 
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weighed (Sartorius Microbalance SE-2F, precision 0.1µg; Sartorius AG, Goettingen, 
Germany) piece of Scotch Book tape 845 (3M, St Paul, MN) was placed over the template 
and adhesion to the skin was systematically assured by running a clean cotton bud over 
the tape. All tapes were reweighed post-stripping. To correct for any variation in 
environmental conditions, and for changes in the mass of a tape that may occur with 
time, 3-5 blank correction tapes were weighed at the same time as the experimental tape 
strips. The change in mass of these blank tapes was used to correct the calculated mass 
of SC on each tape. 
 
Subsequently, all tapes were mounted onto slides and photographed under controlled 
lighting conditions using a Coolscan V ED slide scanner (Nikon UK Limited, Kingston upon 
Thames, UK). Image resolution was 4000 pixels per inch (157.5 pixels/mm). Photographs 
fully illustrating this method are shown in General Appendix I. The scanner was set to 
positive scan in the greyscale colour space of 14 bit depth, with no transformations or 
camera adjustments. Further information on the detailed settings is presented in General 
Appendix II. Cropped images, 2213 x 2203 pixels (approximately 1.4cm x 1.4cm; 9822 
KB each) were recorded and then analysed with ImageJ (Rasband, W.S., ImageJ, U. S. 
National Institutes of Health, Bethesda, Maryland, USA; freeware from 
http://rsb.info.nih.gov/ij/). A scale of 159.07 pixels/mm was applied by measuring the 
full length of one side of the image. During image analysis, each of the 4875239 pixels in 
the image was assigned a greyscale value (16 bit) between 0 and 64608, representing 
black and white, respectively. The mean corrected greyscale value across all pixels was 
‘corrected’ by subtraction from the mean greyscale value for a blank tape (64355); in this 
way, large values corresponded to dark images, and more SC. The mean greyscale values 
were multiplied by the total strip area (195.1mm2 for all tapes in this study, measured 
from the scaled images) to produce an integrated pixel density of each tape. The 
cumulative integrated pixel density has been shown to be relative measure of amount of 
SC per tape (Chapters 5 and Chapter 6).  
 
Next, the tapes extracted overnight in 1ml of 60:40 acetonitrile:water, with vigorous 
shaking. Samples were then filtered (Chronus 0.45µm filters) before analysis for 
betamethasone valerate before HPLC analysis (PG80 pump, ASI-100 autosampler, TCC-
100 column oven, PDA-100 UV lamp from Dionex Corporation Sunnyvale, California, USA) 
using a 25cm column (HiQSil C18) at 25°C and 65:35 acetonitrile:water mobile phase 
running at 1ml/min. No interfering peaks were seen from the patch nor tape. Standards 
of betamethasone 17-valerate (Sigma-Aldrich Company Ltd, Gillingham, UK) were 
prepared in 60:40 acetonitrile:water over the range: 0.02-0.96 µg/ml. 
 
For the in vivo study, 3 placebo patches were applied to the volar forearm of one healthy 
female volunteer (26 years old, no history of dermatological disease) for 2 hours. Ethical 
approval was granted by the Salisbury Local Research Ethics Committee; the Declaration 
of Helsinki protocols were followed, and written informed consent was obtained. Tape 
stripping (with mass and greyscale measurements made for each tape) was performed as 
above, but with transepidermal water loss measurements made before and after each 
strip using a closed-chamber evaporimeter (Biox Aquaflux AF102, Biox Systems Ltd, 
London, UK; measurement range 0-100 g.m2h-1; resolution ±0.05 g.m2h-1; the TEWL was 
obtained as mean of 10 successive measurements having a CV<1%). This was to 
determine the thickness of the SC remaining after patch removal, and that of an 
untreated adjacent site, as described below.  
 
Determination of SC thickness 
 
In vivo, at the sites where a placebo patch had been applied, and at an adjacent 
untreated skin site, TEWL was measured before and after each strip. The sequence was 
repeated until the TEWL value was 3-4 times the initial value (usually 60-80g.m-2h-1). This 
allowed the SC thickness, H or G, to be estimated from the baseline-corrected non-linear 

































































































    
 
model, using both the mass and imaging measurements respectively, as described 



















 Eq. A-3 
 
In Eq. A-2, the thickness of the SC removed (h), is determined gravimetrically. The change 
in TEWL as a function of thickness of SC stripped is fitted to Eq. A-2 to obtain values of 
the SC thickness (H), the product of the SC-viable epidermal partition coefficient of water 
(K), its diffusivity in the barrier (D), and the concentration gradient of water (∆C) across 
the membrane, and the baseline correction factor, B. 
  
In Eq. A-3, the SC removed by each strip is assessed by the cumulative greyscale value 
(g), and the fitting yields the total SC greyscale value (G), and, once again, values for 
D·K·∆C and B. Values derived from this model are denoted with subscript ‘g’.  
 
Fitting was performed with WinNonLin® (software version 5.1, Pharsight Corporation, 
Mountain View, CA) using an ASCII user-defined model. All statistical tests and graphs 
utilised GraphPad Prism® (version 4.00 for Windows, GraphPad Software, San Diego, CA). 
 
Results and Discussion 
 
Silicone patches containing 2% BMV, applied for 2 hours, did not deliver a quantifiable 
amount of BMV into porcine SC, as assessed by tape stripping (n=4). It was thought that 
this could have been due to the very hydrophobic nature of the adhesive, for which BMV 
would have considerable affinity. The experiment was then repeated (n=4) with the less 
hydrophobic polyacrylate patch applied for 6 hours. However, once again, levels of drug 
on the tape strips were lower than the limit of quantification and were often less than the 
level of detection.  
 
A possible explanation for these results is that the patches themselves removed a 
significant fraction of the SC upon their removal at the end of the application period. As a 
consequence, the BMV, which had been released from the patch, would have been 
removed with the SC adhered to the patch. To determine whether the adhesive patches 
did, in fact, strip off an appreciable amount of SC, a limited number of in vivo 
measurements of SC thickness remaining after (placebo) polyacrylate patch removal were 
compared to the corresponding values at an adjacent, untreated site. In vivo experiments 
were preferred because (a) they are more relevant, and (b) they are simpler to perform 
and generally more reproducible. 
 
The results of these experiments are shown in Figure A-1 and Figure A-2 which show the 
evaluation of apparent SC thickness by the gravimetric and imaging methods (TEWL data 
fitted to Eq. A-2 and Eq. A-3 above), respectively. Irrespective of the measurement 
method, the conclusion is unambiguous: the adhesive patches stripped off ~45-60% of 
the SC when removed at the end of the 2hr application period. The measured TEWL at 
skin sites immediately post-patch removal is approximately double that of untreated, 
unstripped skin. Even allowing for any occlusive effects of the patch application, it is clear 















































































    
127 
Using the imaging method, it was possible to derive a mean greyscale value for each of 
the three placebo patches, after removal from the skin, by photographing them in the 
scanner. These values were corrected using the mean greyscale value of an unused 
patch. Figure A-3 (a) shows tape 1 from the untreated skin site. It is darker than the 
corresponding first tapes from the skin sites 1-3 to which the patches have been applied 
(Figure A-3 (c)), implying a greater quantity of SC removed. Indeed, normally, more SC is 
removed from the upper layers of SC. The darkness of the patches post-application, on 
the other hand, is striking in comparison (Figure A-3 (d)).  As the unused patch is very pale 
(Eq A-3 (b)), the intensity and mean greyscale values shown by the patches post-
application confirms the removal of a significant amount of SC. This suggests a simple 
means for rapidly evaluating other, less adhesive, patches when this work is continued.  
The aggressive nature of the patch can be further appreciated from the full scan shown in 
Figure A-3 (e), which shows that layers of SC at the edges of the application area were 
also removed. 
 

































































Figure A-1: TEWL versus cumulative thickness of SC removed at an untreated skin site (●) and at 
sites 1 (■), 2 (□) and 3 () to which placebo adhesive patches have been applied. The calculated 
SC thicknesses (H) deduced from fitting Eq. A-2 to the profiles (▬) are indicated. 
 

































































































    
 














































































Figure A-2: TEWL versus cumulative integrated pixel density of SC removed at an untreated skin 
site (●) and at sites 1 (■), 2 (□) and 3 () to which placebo adhesive patches have been applied. 























































































































Figure A-3: Images from the in vivo experiments, with their corresponding corrected mean 
greyscale values underneath.  
(a) Tape 1 from untreated skin.  
(b) Adhesive surface of patch before application to skin  
(c) Tape 1 from skin after patch removal from skin sites 1-3.  
(d) Adhesive surface of patch post-removal from skin sites 1-3.  









































































































While the initial objective of this study was not successful, the experiments have revealed 
a potentially valuable approach with which to rapidly screen patch formulations for their 
in vivo adhesivity. To pursue the goal of unambiguously determining an SC-formulation 
partition coefficient, the experimental protocol should be repeated with patches 
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General Appendix I  
Illustrated instructions for the novel imaging method 
 
1) Mount tape strip on slide 





















Stratum corneum strip  
(1.5cm x 1.5cm) 
Tape strip (3cm x 2 cm) 
Slide holder  
(total size 5cm x 5cm,  
internal window 2.3cm x 3.5cm) 
Slide feeder available to 



























































    
132 
 
3) Perform scan  
a) Settings set in Nikon Scan 4.0.2 software, as described in General Appendix 
III.  
b) Preview scan performed (~10 seconds) 
 
 
c) Crop centred over preview image (2213 pixels x 2203 pixels, approximately 






























































d) Full scan performed (~30 seconds) 



































Charged couple device (CCD) 
sensor 
• Converts photons to 
electrical charge 
• 4000 dpi 
Light source: LEDs 
• Cool 
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4) Analyse image using Image J 
a) Import image sequence (File → Import → Image sequence). This opens all 
tape strip images from one or more experiments. 
b) Set scale (select full width of scan with ‘line’ tool, then Analyse → Set scale, 
and note known width of scan). Scale set to 158.09 pixels/mm 




d) Save results as Excel spreadsheet 
 
Measurements 
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General Appendix II  
Settings for capturing images using Nikon Scan 4.0.2 
 
 
Tool Palette Settings 
 
• Crop: 2213 x 2203 pixels 
• Curves: Off 
• Colour Balance: Off 
• Un-sharp Mark: Off 
• LCH Editor: Off 
• Analogue gain: Off 
• Scan Image Enhancer: Off 




• Film Type: Positive 
• Scan Colour Space: Greyscale 
• Bit Depth: 14 
• Transformations: None 
• Settings: see under preferences 
below. 
Preferences (subsequently saved under method file name) 
 
• Gamma: Off 
• Colour Management: Use Nikon colour management system 
o Monitor: Use factory default 
o RGB Colour Space: sRGB 
o CMYK: use factory default CMYK profile 
• Single Scan: All Unselected 
• Batch Scan:  
o Prompt for information before scan 
o Create scan log 
o Save to disk 
o Stop on errors 
o All others unselected 
• File Saving: Default file format – TIFF 
• Automatic Actions: All unselected 
• Advanced Colour:  
o RGB 
o White point target: Master 255, Red 255, Green, 255, Blue 255 
o Grey point target: Red 128, Green 128, Blue 128 
o Black target point: Master 0, Red 0, Green 0, Blue 0 
• Greyscale: 
o White point target: Greyscale 255 
o Blank point target: Greyscale 0 
• Auto-contrast calculations (% excluded): 
o Black: 0.5 
o White: 0.5 
o Sample point size: 1x1 
• Preview settings: all unselected except “cache preview image for single image 
adapter” 
• Grid settings: 
o Colour: Black 
o Display grid lines every: 10 inches 
o Display 4 subdivisions per line 
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General Appendix III  
 
Mean greyscale values for blank tapes for correction of all 
mean greyscale values 
 
 
Six blank tapes were photographed (14 bit) using a Coolscan V ED slide scanner (Nikon 
UK Limited, Kingston upon Thames, UK) at a resolution of 4000 pixels per inch (157.5 
pixels/mm) with a crop of 2213 x 2203 pixels. Photographs fully illustrating this method 
are presented in General Appendix I. All settings were exactly the same as for tapes with 
SC from all experiments. Full scanner settings are detailed in General Appendix II. 
 
Cropped images (9822 KB each) were saved and analysed with ImageJ (Rasband, W.S., 
U. S. National Institutes of Health, Bethesda,  
Maryland, USA; freeware from http://rsb.info.nih.gov/ij/). A scale of 159.07 pixels/mm 
was applied to the full image width. During image analysis, each of the 4875239 pixels in 
the image is assigned a greyscale value (16 bit) in the range 0 - 64608, where 0 and 
64608 designate black and white respectively. 
 
The results are shown in the table below. The blank tapes, with a total of 6 × 4875239 
pixels, were very homogeneous with 98.5 ± 0.6% of all pixels having the highest (i.e. 
palest) greyscale value, namely 64424 ± 7. The overall average greyscale value over 6 × 
4875239 pixels, was 64355 ± 29. All mean greyscale values reported for tapes with SC 
have been corrected by subtracting from 64355. 
 
  Greyscale 
value (1) 
No. of pixels % of pixels at 
palest greyscale 
Average  




























Average 64424 (2)   98.5 64355 
SD 7 (2)   0.6 29.4 
 
 
(1)  These are original greyscale values such that high values correspond to pale pixels. 
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Appendix 2-A   











































1 50.1394 50.2577 0.1183 0.1014 0.68 0.68 0.34 15.41 0.065 14.17 14.35 
2 50.6286 50.7342 0.1056 0.0887 0.59 1.27 0.97 15.98 0.063 14.98 15.14 
3 49.8001 49.9034 0.1033 0.0864 0.58 1.84 1.55 16.28 0.061 15.85 15.99 
4 49.9540 50.0587 0.1047 0.0878 0.59 2.43 2.14 15.61 0.064 16.85 16.96 
5 49.6118 49.7325 0.1207 0.1038 0.69 3.12 2.77 18.33 0.055 18.15 18.23 
6 50.1635 50.2725 0.1090 0.0921 0.61 3.73 3.43 19.86 0.050 19.77 19.82 
7 49.6808 49.7778 0.0970 0.0801 0.53 4.27 4.00 19.70 0.051 21.52 21.53 
8 49.4506 49.544 0.0934 0.0765 0.51 4.78 4.52 22.64 0.044 23.47 23.44 
9 49.7122 49.8307 0.1185 0.1016 0.68 5.45 5.12 25.71 0.039 26.26 26.19 
10 50.6022 50.7276 0.1254 0.1085 0.72 6.18 5.82 28.76 0.035 30.76 30.62 
11 50.1265 50.2226 0.0961 0.0792 0.53 6.71 6.44 36.53 0.027 36.60 36.39 
12 49.5563 49.6404 0.0841 0.0672 0.45 7.15 6.93 44.18 0.023 43.21 42.97 
13 51.3989 51.4996 0.1007 0.0838 0.56 7.71 7.43 56.13 0.018 53.51 53.28 
14 49.9554 50.0644 0.1090 0.0921 0.61 8.33 8.02 74.01 0.014 75.11 75.19 
            
Correction tapes    H (µm) estimate 10.59 9.65 9.38 
1 50.1585 50.1757 0.0172     SER 0.41 0.08 0.11 
2 49.7582 49.7686 0.0104     CV (%) 3.83 0.78 1.21 
3 50.6124 50.6278 0.0154    D·K·∆C estimate 147.32 120.50 97.55 
4 49.6526 49.6811 0.0285     SER 8.42 4.04 8.75 
5 49.6156 49.6287 0.0131     CV (%) 5.71 3.35 8.97 
       B estimate   3.38 
        SER   1.29 
        CV (%)   38.19 
       WRSS   34.77 22.84 
       DF   13.00 12.00 
       AIC     18.61 14.31 
 
Abbreviations: 
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Appendix 3-A  
Statistical tests to compare linear regression outputs 
 
A pair of data sets is fitted to a linear regression. The null hypothesis (H0) is that the slope 
of line 1 = slope of line 2. This is tested by firstly calculating the following for each of the 
two data sets: 
 

















Residual degrees of freedom (RDF) = number of data points – 2 
 
     
















































21 DataSetDataSet RDFRDFv +=  
      
 
We reject H0 if  | t |   ≥   tα(2),v  where tα(2),v may be found in t tables. 
 
As the slopes were found to be different, comparisons of intercepts was not necessary, 





Appendix 3-B  
Incompatibilities 
 























A P / 23225 [138] BCA 560 5-25 mg 
(2) 
  1 250 0.20 3 1 1 100 100 




30   IC   IC         
C P / 23200 [138] Bradford = Bio-
Rad = Coomassie 
465-595 100-
1400 
60  1 2000 0.50 3 5 1000 100 100 




60   100 0.05 4   TIC 500 500 
G P / 23235 [138] Micro-BCA 562nm 2-40 10 1 50 0.20 3 1 1 50 10 
H P / 23240 [138] Modified Lowry 750nm 1-1500 10 1 10 0.20 3 1 1 100 1000 
I  I / N6666 [145] Nanoorange Fluo. 
470/570 
0.01-10 360 IC IC 10mM 1 0.02 100 10 10 




300   IC       0.1 (4)     





L I / Q33210 [148] Quant-IT  Fluo. 
470/570 
0.25-5 180         0.02 1     
Table for Appendix 3-B: Protein assay methods (suitable for 96-well high throughput assay) considered for assaying protein extracted from tape strips. Invitrogen EZQ 
method chosen as: washing stages result in universal compatibility; relatively high sensitivity.  
Fluo. : fluorescence.   IC: Incompatible, but concentration unspecified.  TIC: totally incompatible.  2-ME: 2-mercaptoethanol (a reducing agent). 
 PMSF: phenylmethanesulphonylfluoride  Tris: tris(hydroxymethyl)aminomethane 
Notes: (1) Reference given as: company (P: Pierce Biotechnology; S: Sigma-Aldrich, I: Invitrogen) / product number, with corresponding technical reference. 
(2) Limit of total protein per sample  
(3)  As checked by author during research  
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Appendix 3-C  

















  9 2 50 9 50         
[149]             0.2   0.1N or 1N acetic acid used to 
neutralise -> causes 
precipitation 
degrease with di-ethyl ether first. 
Fractions named after pH at which they 
precipitate 
[103] G           1 1     
[104, 
105] 
D           1 1   750nm 
[106] D, modified 
Bradford 
          1 1     
[107, 
108] 
C           1 1   595nm 
[140] skinMAP               0.2%SDS, 30min, 0.5%propylene 
glycol, PBS, temp 4-10oC 
Used SkinMAP and Luminex  
 
Table for Appendix 3-C: Summary of extraction solutions used to extract keratin from the skin.  
2-ME: 2-mercaptoethanol (a reducing agent).  PMSF: phenylmethanesulphonylfluoride  Tris: tris(hydroxymethyl)aminomethane 
 
Notes: (1) for code see Appendix 3-B. 
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Appendix 3-D   
Full raw data and calculations, from 4 different SC 
quantification methods, for one skin site.  
 


































1 50.3071 50.4371 0.1300 0.1410  195.1 44636 19719 8423 3847140  
2 51.9762 52.0280 0.0518 0.0628  195.1 51763 12591 10501 2456540  
3 50.9307 51.0233 0.0926 0.1036  195.1 47450 16904 10903 3297997  
4 51.2327 51.3040 0.0713 0.0823  195.1 48845 15510 11710 3026023  
5 50.5219 50.6281 0.1062 0.1172  195.1 45607 18748 13482 3657668  
6 51.9184 52.0378 0.1194 0.1304  195.1 44798 19557 13071 3815520  
7 51.5153 51.6669 0.1516 0.1626  195.1 45231 19123 11463 3730968  
8 51.8138 51.9621 0.1483 0.1593  195.1 40427 23928 11660 4668278  
9 51.1054 51.2086 0.1032 0.1142  195.1 47822 16532 14190 3225488  
10 49.6921 49.7850 0.0929 0.1039  195.1 47396 16959 11897 3308720  
11 50.6760 50.7796 0.1036 0.1146  195.1 45670 18685 10981 3645361  
12 52.4643 52.5597 0.0954 0.1064  195.1 44968 19386 13355 3782278  
13 50.7187 50.8268 0.1081 0.1191  195.1 46045 18310 12156 3572274  
14 51.8426 51.9085 0.0659 0.0769  195.1 52680 11674 13810 2277630  
15 48.9446 49.0594 0.1148 0.1258  195.1 44112 20243 13784 3949413  
16 50.6424 50.7072 0.0648 0.0758  195.1 52226 12128 14032 2366262  
17 50.3263 50.4643 0.1380 0.1490  195.1 43056 21299 13267 4155439  
18 51.4064 51.5068 0.1004 0.1114  195.1 47222 17132 14794 3342532  
            
Corrected tapes      
1 50.1658 50.1539 -0.0119      
2 48.6800 48.6672 -0.0128         
3 50.3839 50.3744 -0.0095         
4 51.2590 51.2491 -0.0099         
5 49.6129 49.6019 -0.0110         
            
  Average -0.011         
  SD 0.00137         
 
Notes: 
(1) Mean greyscale value of blank tape = 64355 
(2) Corrected SD calculated from Eq. 6-7 
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1 1721.3 55.4 1768.9 56.3 1909.9 58.8 56.8 1.7 
2 1383.3 49.4 1191.6 46.0 1605.3 53.3 49.6 3.7 
3 2110.3 62.3 2155.9 63.2 2024.6 60.8 62.1 1.2 
4 1088.7 23.3 1139.1 24.7 1560.1 36.6 28.2 7.3 
5 1113.7 24.0 1017.4 21.3 1154.1 25.1 23.5 2.0 
6 1173.4 25.7 1568.7 36.8 1888.7 45.8 36.1 10.1 
7 1604.4 37.8 1513.4 35.3 853.7 16.7 29.9 11.5 
8 1535.7 35.9 1334.7 30.2 1998.1 48.9 38.3 9.6 
9 1178.7 25.8 1785.7 42.9 1435.4 33.1 33.9 8.6 
10 377.1 ND 468.4 ND 857.7 16.8 ND   
11 709.7 ND 633.4 10.5 1062.1 22.6 ND   
12 1298.1 29.2 1371.1 31.2 1349.7 30.6 30.4 1.1 
13 1449.1 33.4 1092.4 23.4 910.7 18.3 25.0 7.7 
14 573.1 ND 703.4 ND 1094.7 23.5 ND   
15 1956.1 47.7 1825.4 44.0 2129.4 52.6 48.1 4.3 
16 100.4 ND 467.4 ND 875.7 ND ND   
17 3376.4 87.7 2470.1 62.2 2608.7 66.1 72.0 13.7 
18 1040.4 21.9 1491.1 34.6 842.7 16.4 24.3 9.3 
         
2 EZQ plates used to analyse tapes   
Tape 1-3 (plate A)   
Blank tape extracted. Fluorescence = 10140   
Calibration curve: y =56.1x - 1387.9, R2 = 0.99   
   
Tapes 4-18 (plate B)   
Blank tape extracted. Fluorescence = 11164   
Calibration curve: y =35.55x - 260.35, R2 = 0.98   
Abbreviations: fluo:   fluorescence conc:    concentration ND:    not detectable 
 
3-D Continued. 
Tape No. 4.    UV pseudoabsorption method 
 Average abs. (430nm) SD abs. (430nm) Mean abs. (278nm) SD abs. (278nm.) 
1 0.4902 0.0031 0.5692 0.0072 
2 0.2700 0.0010 0.2999 0.0028 
3 0.3754 0.0034 0.4311 0.0070 
4 0.3231 0.0028 0.3694 0.0026 
5 0.3865 0.0016 0.4422 0.0048 
6 0.4192 0.0023 0.4741 0.0040 
7 0.4141 0.0015 0.4649 0.0011 
8 0.5610 0.0043 0.6336 0.0062 
9 0.3446 0.0084 0.3970 0.0117 
10 0.3643 0.0035 0.4068 0.0032 
11 0.4160 0.0019 0.4624 0.0030 
12 0.4205 0.0019 0.4616 0.0042 
13 0.3910 0.0009 0.4307 0.0029 
14 0.2809 0.0050 0.3215 0.0107 
15 0.4664 0.0029 0.5294 0.0051 
16 0.2775 0.0053 0.3140 0.0071 
17 0.5160 0.0076 0.5975 0.0134 
18 0.3571 0.0019 0.3902 0.0026 
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Appendix 5-A   
Full raw data and calculations, for gravimetric and imaging 






















1 48.4974 48.5745 0.0771 0.0842 0.56 
2 49.6639 49.7861 0.1222 0.1293 0.86 
3 50.3989 50.4985 0.0996 0.1067 0.71 
4 48.0222 48.1480 0.1258 0.1329 0.89 
5 49.1347 49.2219 0.0872 0.0943 0.63 
6 50.0676 50.1861 0.1185 0.1256 0.84 
7 48.7472 48.8335 0.0863 0.0934 0.62 
8 49.1190 49.2063 0.0873 0.0944 0.63 
9 48.0312 48.1378 0.1066 0.1137 0.76 
10 48.9488 49.0714 0.1226 0.1297 0.86 
11 48.8877 49.0532 0.1655 0.1726 1.15 
12 50.5865 50.8058 0.2193 0.2264 1.51 
13 50.3418 50.4579 0.1161 0.1232 0.82 
14 50.2114 50.3392 0.1278 0.1349 0.90 
15 49.9968 50.0976 0.1008 0.1079 0.72 
      
Correction tapes    
1 49.0345 49.0282 -0.0063   
2 50.7700 50.7598 -0.0102   
3 49.3648 49.3574 -0.0074   
4 48.7818 48.7782 -0.0036   
5 50.5135 50.5057 -0.0078   
      
  Average -0.0071   
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Gravimetric method (continued) 












1 0.56 11.6 11.3 0.04 0.04 
2 1.42 11.7 11.7 0.10 0.06 
3 2.13 12.2 12.1 0.15 0.05 
4 3.02 12.6 12.7 0.21 0.06 
5 3.65 12.7 13.2 0.26 0.04 
6 4.49 13.6 14.0 0.32 0.06 
7 5.11 15.1 14.6 0.36 0.04 
8 5.74 14.9 15.4 0.41 0.04 
9 6.49 16.7 16.5 0.46 0.05 
10 7.36 18.1 18.0 0.52 0.06 
11 8.51 22.3 20.8 0.60 0.08 
12 10.02 25.8 26.8 0.71 0.11 
13 10.84 31.5 32.3 0.77 0.06 
14 11.74 43.6 42.8 0.83 0.06 
15 12.46 59.3 59.4 0.88 0.05 
      
H (µm) estimate 14.12 H/H (µm) estimate 1.00 
SER 0.08 SER 0.01 
CV (%) 0.60 CV (%) 0.60 
D·K·∆C estimate 91.03 D·K·∆C/H estimate 6.46 
SER 4.87 SER 0.35 
CV (%) 5.35 CV (%) 5.35 
B estimate 4.54 B estimate 4.51 
SER 0.51 SER 0.51 
CV (%) 11.30 CV (%) 11.38 
 
Abbreviation Cum:  cumulative 
 
Notes: 
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1 55290 9064 1.77 1.77 11.0 0.06 0.06 
2 53377 10978 2.14 3.91 11.5 0.12 0.07 
3 55444 8911 1.74 5.65 11.9 0.18 0.06 
4 52710 11644 2.27 7.92 12.6 0.25 0.07 
5 55621 8733 1.70 9.63 13.1 0.31 0.05 
6 53904 10450 2.04 11.66 14.0 0.37 0.07 
7 56091 8264 1.61 13.28 14.8 0.42 0.05 
8 55793 8562 1.67 14.95 15.7 0.48 0.05 
9 57216 7138 1.39 16.34 16.7 0.52 0.04 
10 54509 9846 1.92 18.26 18.4 0.58 0.06 
11 50716 13639 2.66 20.92 21.8 0.67 0.08 
12 52569 11786 2.30 23.22 26.6 0.74 0.07 
13 56341 8014 1.56 24.79 31.7 0.79 0.05 
14 54665 9689 1.89 26.68 42.4 0.85 0.06 
15 56772 7582 1.48 28.16 59.7 0.90 0.05 
        
10-6 x G estimate 
(mm2) 31.36 G/G estimate 1.00 
  
10-6 x SER 0.13 SER 0.00   
CV (%) 0.41 CV (%) 0.43   
10-6 x (D·K·∆C)g 
estimate 174.68 D·K·∆C/G estimate 5.60 
  
10-6 x SER 7.20 SER 0.24   
CV (%) 4.12 CV (%) 4.28   
Bg estimate 5 Bg estimate 5.05   
SER 0 SER 0.40   
CV (%) 7.51 CV (%) 7.90   
 
Abbreviations:  Corr: corrected  
   Cum: cumulative 
   Pred:  predicted 
 
Notes: 
(1) Mean corrected greyscale value of blank tape = 64355 
(2) Integrated pixel density = area of strip x Mean corrected greyscale value.  




































-- -- AA AA
    
146 
Appendix 6-A   
Calculation of SC thickness, H and G: Full raw data and 






































1 53.9051 54.0944 0.1893 0.1837 0.8 0.8 0.4 13.0 12.4 
2 50.2336 50.4174 0.1838 0.1782 0.8 1.6 1.2 13.6 13.8 
3 50.8033 50.9486 0.1453 0.1397 0.6 2.2 1.9 14.2 13.8 
4 54.3478 54.4768 0.1290 0.1234 0.5 2.8 2.5 14.8 15.0 
5 51.4377 51.5983 0.1606 0.1550 0.7 3.5 3.1 15.6 15.5 
6 51.5380 51.6628 0.1248 0.1192 0.5 4.0 3.7 16.3 17.1 
7 52.2722 52.4271 0.1549 0.1493 0.7 4.7 4.3 17.5 18.8 
8 54.8702 54.9969 0.1267 0.1211 0.5 5.2 4.9 18.6 19.1 
9 49.4688 49.5988 0.1300 0.1244 0.6 5.8 5.5 20.0 19.6 
10 49.3366 49.4512 0.1146 0.1090 0.5 6.2 6.0 21.6 20.5 
11 50.7056 50.8491 0.1435 0.1379 0.6 6.8 6.5 24.1 25.3 
12 52.0782 52.2049 0.1267 0.1211 0.5 7.4 7.1 27.2 26.3 
13 50.9585 51.0660 0.1075 0.1019 0.5 7.8 7.6 30.7 30.0 
14 50.0080 50.1310 0.1230 0.1174 0.5 8.4 8.1 36.6 36.2 
15 49.8609 50.0010 0.1401 0.1345 0.6 9.0 8.7 48.2 49.4 
16 50.3391 50.4548 0.1157 0.1101 0.5 9.4 9.2 67.4 67.1 
          
Correction tapes       
1 51.4273 51.4366 0.0093   H (µm) estimate 10.5  
2 50.5463 50.5463 0.0000   SER 0.06  
3 51.5717 51.5813 0.0096   CV (%) 0.52  
4 52.8375 52.8358 -0.0017   D·K·∆C estimate 65.6  
5 52.1444 52.1551 0.0107   SER 3.48  
      CV (%) 5.31  
  Average 0.0056   B estimate 6.3  
  SD 0.0059   SER 0.57  
 
Abbreviations:  Corr: corrected  
   Cum: cumulative 
   Pred:  predicted 
Notes: 
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1 42297 22058 4.30 4.30 13.2 12.4 
2 40999 23355 4.56 8.86 13.7 13.8 
3 44127 20228 3.95 12.81 14.2 13.8 
4 43462 20892 4.08 16.88 14.7 15.0 
5 40789 23566 4.60 21.48 15.5 15.5 
6 42384 21971 4.29 25.77 16.3 17.1 
7 41185 23170 4.52 30.29 17.3 18.8 
8 42890 21465 4.19 34.48 18.5 19.1 
9 43199 21155 4.13 38.61 19.9 19.6 
10 44921 19434 3.79 42.40 21.5 20.5 
11 42226 22128 4.32 46.71 24.0 25.3 
12 43752 20602 4.02 50.73 27.1 26.3 
13 45518 18836 3.68 54.41 31.0 30.0 
14 44736 19619 3.83 58.24 37.2 36.2 
15 44607 19747 3.85 62.09 47.7 49.4 
16 45582 18772 3.66 65.75 67.4 67.1 
       
  10-6  G estimate (mm2) 73.42 
  10-6  SER 0.46 
  CV (%) 0.63 
  10-6  (D·K·∆C)g estimate 467.20 
  10-6  SER 29.07 
  CV (%) 6.22 
  Bg estimate 6.47 
  SER 0.67 
  CV (%) 10.31 
 
Notes: 
(1) Mean corrected greyscale value of blank tape = 64355 
(2) Integrated pixel density = area of strip x Mean corrected greyscale value.  
Area of all strips = 195.1mm2 
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Appendix 6-B   
Deriving data for normalised drug concentration as a 
function of SC depth profiles: full raw data and calculations 





























1 52.5413 52.6842 0.1429 0.1443 0.64 0.64 0.06 0.03 
2 52.0141 52.17 0.1559 0.1573 0.70 1.34 0.13 0.09 
3 52.1938 52.3265 0.1327 0.1341 0.60 1.94 0.18 0.16 
4 51.4062 51.5756 0.1694 0.1708 0.76 2.70 0.26 0.22 
5 53.4335 53.5644 0.1309 0.1323 0.59 3.28 0.31 0.28 
6 50.8222 50.9478 0.1256 0.1270 0.56 3.85 0.37 0.34 
7 51.5398 51.6388 0.099 0.1004 0.45 4.30 0.41 0.39 
8 52.1515 52.2575 0.106 0.1074 0.48 4.77 0.45 0.43 
9 51.6394 51.7334 0.094 0.0954 0.42 5.20 0.49 0.47 
10 52.6538 52.7579 0.1041 0.1055 0.47 5.67 0.54 0.52 
11 49.6137 49.7135 0.0998 0.1012 0.45 6.12 0.58 0.56 
12 52.9664 53.1071 0.1407 0.1421 0.63 6.75 0.64 0.61 
13 50.4293 50.5173 0.088 0.0894 0.40 7.15 0.68 0.66 
14 51.1609 51.2806 0.1197 0.1211 0.54 7.68 0.73 0.70 
15 51.7623 51.847 0.0847 0.0861 0.38 8.07 0.77 0.75 
16 50.1586 50.2668 0.1082 0.1096 0.49 8.55 0.81 0.79 
17 50.2949 50.4057 0.1108 0.1122 0.50 9.05 0.86 0.84 
18 50.1672 50.3007 0.1335 0.1349 0.60 9.65 0.92 0.89 
19 50.7595 50.8464 0.0869 0.0883 0.39 10.05 0.95 0.94 
  Total (mg) = 2.26     
         
Correction tapes      
1 50.5838 50.5863 0.0025     
2 53.4481 53.4549 0.0068     
3 50.2542 50.2476 -0.0066     
4 49.8504 49.8452 -0.0052     
5 52.0591 52.0544 -0.0047     
        
  Average -0.0014     
  SD 0.0058     
 
Notes: 
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g/G (3) Half 
way 
g/G 
1 49805 14550 2.84 2.84 0.04 0.02 
2 47081 17273 3.37 6.21 0.08 0.06 
3 46739 17615 3.44 9.65 0.13 0.11 
4 42248 22106 4.31 13.96 0.19 0.16 
5 43129 21226 4.14 18.10 0.25 0.22 
6 41970 22385 4.37 22.47 0.31 0.28 
7 45045 19309 3.77 26.24 0.36 0.33 
8 42872 21483 4.19 30.43 0.41 0.39 
9 45496 18858 3.68 34.11 0.46 0.44 
10 43339 21015 4.10 38.21 0.52 0.49 
11 45542 18812 3.67 41.88 0.57 0.55 
12 42256 22099 4.31 46.19 0.63 0.60 
13 47749 16606 3.24 49.43 0.67 0.65 
14 42593 21762 4.25 53.68 0.73 0.70 
15 47405 16950 3.31 56.98 0.78 0.75 
16 44617 19737 3.85 60.83 0.83 0.80 
17 44795 19560 3.82 64.65 0.88 0.85 
18 42868 21487 4.19 68.84 0.94 0.91 
19 49616 14738 2.88 71.72 0.98 0.96 
 Total = 367574     
 
Abbreviations  Corr: corrected 
   Cum: cumulative 
 
Notes: 
(1) Mean corrected greyscale value of blank tape = 64355 
(2) Integrated pixel density = area of strip x Mean corrected greyscale value.  
Area of all strips = 195.1mm2 
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   Gravimetric method  Imaging method 





Cx (µg/mg) (2) Cx/Rm (3) 
 
 106  Cg (µg) (4) 
 
Cg/Rg (5) 
1 2.05 0.68 4.73 3.04  46.94 4.91 
2 1.73 0.58 3.67 2.36  33.42 3.49 
3 0.66 0.22 1.64 1.06  12.51 1.31 
4 1.15 0.38 2.25 1.45  17.39 1.82 
5 0.62 0.21 1.57 1.01  9.78 1.02 
6 0.52 0.17 1.36 0.88  7.74 0.81 
7 0.27 0.09 0.88 0.57  4.58 0.48 
8 0.23 0.08 0.72 0.46  3.58 0.37 
9 0.18 0.06 0.64 0.41  3.25 0.34 
10 0.27 0.09 0.86 0.56  4.34 0.45 
11 0.76 0.25 2.51 1.61  13.50 1.41 
12 0.94 0.31 2.21 1.42  14.20 1.48 
13 0.33 0.11 1.23 0.79  6.63 0.69 
14 0.22 0.07 0.61 0.39  3.39 0.35 
15 0.21 0.07 0.80 0.51  4.06 0.42 
16 0.10 0.03 0.30 0.19  1.67 0.17 
17 0.12 0.04 0.34 0.22  1.96 0.21 
18 0.14 0.05 0.34 0.22  2.11 0.22 
19 0.05 0.02 0.17 0.11  1.04 0.11 
Total (µg) = 3.52      
       






(1) As tapes extracted in 1ml water, this is equal to the concentration of ACV measured by 
HPLC. 
(2) Cx: concentration of drug at position x within the SC (as measured by cumulative 
thickness measurements). 
(3) 
See Eq. 6-5 for definition. 
 Rm = 1.56 µg/mg. 
(4) 
Cg: concentration of drug at position x within the SC (as measured by cumulative 
integrated pixel densities). 
(5) 
See Eq. 6-6 for definition.  
Rg = 9.57 x 10
-6
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Appendix 6-C   











































RSD varies from 0.03 – 14 % 
y= 3.012 x -0.016 
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Appendix 6-D  
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Appendix 6-E   














1 18665 16374 20597 20735 
2 11636 13317 12543 13364 
3 62.3 81.3 60.9 64.5 
4 0.089 0.083 0.125 0.132 











1 20604 18728 23300 20098 
2 14025 14610 14294 14606 
3 68.1 78.0 61.3 72.7 
4 0.117 0.123 0.115 0.097 












1 22857 20107 16846 20151 
2 14078 13903 13704 14552 
3 61.6 69.1 81.3 72.2 
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1 17357 19582 15886 15628 
2 14532 14405 14728 13881 
3 83.7 73.6 92.7 88.8 
4 0.094 0.117 0.085 0.098 












1 19808 22207 13802 17306 
2 14368 14166 13833 14343 
3 72.5 63.8 100.2 82.9 
4 0.148 0.138 0.104 0.102 
 
 
1. Mean corrected greyscale value;   
2. Corrected standard deviation;  
3. Relative standard deviation;  
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Appendix 6-F   
Images and SC measurements for Volunteer 1, Zovirax, Site1 
 
 










1 14550 17273 17616 22107 
2 12816 13000 13913 14290 
3 88.1 75.3 79.0 64.6 
4 0.144 0.157 0.134 0.171 











1 21226 22385 19309 21483 
2 14802 14821 15111 15145 
3 69.7 66.2 78.3 70.5 
4 0.132 0.127 0.100 0.107 












1 18858 21015 22099 16606 
2 15203 15220 15465 14561 
3 80.6 72.4 70.0 87.7 
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1 21762 16950 19738 19738 
2 14343 14504 14813 14813 
3 65.9 85.6 75.0 75.0 
4 0.089 0.121 0.086 0.110 










1 19560 21487 14738  
2 14258 13985 13727  
3 72.9 65.1 93.1  




1. Mean corrected greyscale value;   
2. Corrected standard deviation;  
3. Relative standard deviation;  
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Appendix 6-G   
Images and SC measurements for Volunteer 1, Zovirax, Site2 
 










1 17892 16895 20405 21541 
2 11842 11889 13159 13539 
3 66.2 70.4 64.5 62.9 
4 0.131 0.129 0.183 0.169 











1 24969 26269 27113 23492 
2 13579 13767 13498 14599 
3 54.4 52.4 49.8 62.1 
4 0.177 0.171 0.152 0.107 












1 26373 20357 18053 19714 
2 14323 15044 14742 14215 
3 54.3 73.9 81.7 72.1 
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1 22066 20169 17931 
2 14675 14510 14871 
3 66.5 71.9 82.9 




1. Mean corrected greyscale value;   
2. Corrected standard deviation;  
3. Relative standard deviation;  
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Appendix 6-H   
Images and SC measurements for Volunteer 2, Pliva, Site1 
 










1 9040 16567 6797 14944 
2 12382 12582 10648 11818 
3 137.0 75.9 156.7 79.1 
4 0.118 0.161 0.058 0.150 











1 11826 5704 4669 13123 
2 12190 8933 8837 12573 
3 103.1 156.6 189.3 95.8 
4 0.069 0.070 0.064 0.129 












1 13172 9811 8873 10515 
2 12569 11426 11591 12209 
3 95.4 116.5 130.6 116.1 
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1 13721 10462 13950 10016 
2 12793 12227 13035 12294 
3 93.2 116.9 93.4 122.7 
4 0.148 0.103 0.136 0.067 










1 11763 10545 16561  
2 11945 12351 13869  
3 101.5 117.1 83.7  




1. Mean corrected greyscale value;   
2. Corrected standard deviation;  
3. Relative standard deviation;  
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Appendix 6-I   
Images and SC measurements for Volunteer 2, Pliva, Site 2 
 










1 12543 13877 14207 16685 
2 11841 11284 11409 12332 
3 94.4 81.3 80.3 73.9 
4 0.016 0.124 0.151 0.156 











1 15085 18970 15468 19332 
2 12199 12850 12816 12449 
3 80.9 67.7 82.9 64.4 
4 0.121 0.158 0.122 0.170 












1 16008 16779 14160 18238 
2 12981 12835 12868 13086 
3 81.1 76.5 90.9 71.7 
4 0.132 0.156 0.127 0.178 

































-- -- II II
    
 









1 15837 12614 14000 
2 13558 12422 12788 
3 85.6 98.5 91.3 




1. Mean corrected greyscale value;   
2. Corrected standard deviation;  
3. Relative standard deviation;  
4. Mass of SC (mg)  
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Appendix 6-J   
Images and SC measurements for Volunteer 2, Zovirax, Site1 
 










1 12109 12644 15381 18591 
2 9807 10669 10828 11659 
3 81.0 84.4 70.4 62.7 
4 0.161 0.157 0.158 0.169 











1 19180 18950 19011 18500 
2 12107 12922 12933 12915 
3 63.1 68.2 68.0 69.8 
4 0.154 0.134 0.117 0.124 












1 19795 3795 12744 14273 
2 12139 7721 11960 12603 
3 61.3 203.5 93.8 88.3 
4 0.136 0.025 0.107 0.108 
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1. Mean corrected greyscale value;   
2. Corrected standard deviation;  
3. Relative standard deviation;  
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Appendix 6-K  
Images and SC measurements for Volunteer 2, Zovirax, Site2 
 










1 14349 14506 13860 16199 
2 11560 12042 12399 13019 
3 80.6 83.0 89.5 80.4 
4 0.137 0.119 0.131 0.159 











1 16521 15696 15332 17160 
2 13808 14235 14159 14100 
3 83.6 90.7 92.4 82.2 
4 0.145 0.105 0.095 0.127 












1 15802 14074 13508 16786 
2 14153 13458 13280 13908 
3 89.6 95.6 98.3 82.9 
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1 13821 10615 7276 
2 12889 11820 10718 
3 93.3 111.3 147.3 




1. Mean corrected greyscale value;   
2. Corrected standard deviation;  
3. Relative standard deviation;  






































1. Y.N. Kalia, F. Pirot, and R.H. Guy. Homogeneous transport in a heterogeneous 
membrane: water diffusion across human stratum corneum in vivo. Biophys J. 
71:2692-2700 (1996). 
2. N. Sekkat, Y.N. Kalia, and R.H. Guy. Porcine ear skin as a model for the 
assessment of transdermal drug delivery to premature neonates. Pharm Res. 
21:1390-1397 (2004). 
3. J. Hadgraftand R.H. Guy. Feasibility assessment in topical and transdermal 
delivery: Mathematical models and in vitro studies. In R.H. Guyand J. Hadgraft 
(eds.), Drugs and the pharmaceutical sciences 123 -Transdermal drug delivery, M. 
Dekker, New York, 2003, pp. viii, 383 p. 
4. J. Crank. Chapter 4: Diffusion in plane sheet. The mathematics of diffusion, 
Clarendon Press, Oxford, 1975, pp. viii, 414p. 
5. G.L. Flynn. Physicochemical determinants of skin absorption. In T.R. Gerrityand 
C.J. Henry (eds.), Principles of route-to-route extrapolation for risk assessment 
Elsevier, New York, 1990, p. 322p. 
6. B.E. Vecchiaand A.L. Bunge. Evaluating the transdermal permeability of 
chemicals. In R.H. Guyand J. Hadgraft (eds.), Drugs and the pharmaceutical 
sciences 123 - Transdermal drug delivery, M. Dekker, New York, 2003, pp. viii, 
383 p. 
7. F.M. Williams. Evaluations and predictions of dermal absorption of toxic chemicals 
(EDETOX) - Final Report, European Commission, 2004. 
8. J. Kruse, D. Golden, S. Wilkinson, F. Williams, S. Kezic, and J. Corish. Analysis, 
interpretation, and extrapolation of dermal permeation data using diffusion-based 
mathematical models. J Pharm Sci. 96:682-703 (2007). 
9. R.O. Pottsand R.H. Guy. Predicting skin permeability. Pharm Res. 9:663-669 
(1992). 
10. R.L. Cleekand A.L. Bunge. A New Method for Estimating Dermal Absorption from 
Chemical-Exposure .1. General-Approach. Pharm Res. 10:497-506 (1993). 
11. D. Fitzpatrick, J. Corish, and B. Hayes. Modelling skin permeability in risk 
assessment - the future. Chemosphere. 55:1309-1314 (2004). 
12. G.P. Lian, L.J. Chen, and L.J. Han. An evaluation of mathematical models for 
predicting skin permeability. J Pharm Sci. 97:584-598 (2008). 
13. B.E. Vecchiaand A.L. Bunge. Skin absorption databases and predictive equations. 
In R.H. Guyand J. Hadgraft (eds.), Drugs and the pharmaceutical sciences 123 - 
Transdermal drug delivery, M. Dekker, New York, 2003, pp. viii, 383 p. 
14. J. Hadgraftand C. Valenta. pH, pK(a) and dermal delivery. Int J Pharm. 200:243-
247 (2000). 
15. W.J. Pughand J. Hadgraft. Ab-Initio Prediction of Human Skin Permeability 
Coefficients. Int J Pharm. 103:163-178 (1994). 
16. M.S. Roberts, W.J. Pugh, J. Hadgraft, and A.C. Watkinson. Epidermal permeability 
penetrant structure relationships .1. An analysis of methods of predicting 
penetration of monofunctional solutes from aqueous solutions. Int J Pharm. 
126:219-233 (1995). 
17. M.S. Roberts, W.J. Pugh, and J. Hadgraft. Epidermal permeability: Penetrant 
structure relationships .2. The effect of H-bonding groups in penetrants on their 
diffusion through the stratum corneum. Int J Pharm. 132:23-32 (1996). 
18. W.J. Pugh, M.S. Roberts, and J. Hadgraft. Epidermal permeability - Penetrant 
structure relationships .3. The effect of hydrogen bonding interactions and 






























s     
168 
19. W.J. Pugh, I.T. Degim, and J. Hadgraft. Epidermal permeability-penetrant structure 
relationships: 4, QSAR of permeant diffusion across human stratum corneum in 
terms of molecular weight, H-bonding and electronic charge. Int J Pharm. 
197:203-211 (2000). 
20. M. Turowskiand R. Kaliszan. Keratin immobilized on silica as a new stationary 
phase for chromatographic modelling of skin permeation. J Pharm Biomed Anal. 
15:1325-1333 (1997). 
21. A. Nasal, M. Sznitowska, A. Bucinski, and R. Kaliszan. Hydrophobicity parameter 
from high-performance liquid chromatography on an immobilized artificial 
membrane column and its relationship to bioactivity. J Chromatogr A. 692:83-89 
(1995). 
22. J.J. Martínez-Pla, Y. Martín-Biosca, S. Sagrado, R.M. Villanueva-Camañas, and M.J. 
Medina-Hernández. Biopartitioning micellar chromatography to predict skin 
permeability. Biomed Chromatogr. 17:530-537 (2003). 
23. J.J. Martínez-Pla, Y. Martín-Biosca, S. Sagrado, R.M. Villanueva-Camañas, and M.J. 
Medina-Hernández. Evaluation of the pH effect of formulations on the skin 
permeability of drugs by biopartitioning micellar chromatography. J Chromatogr A. 
1047:255-262 (2004). 
24. I.T. Degim. New tools and approaches for predicting skin permeability. Drug 
Discov Today. 11:517-523 (2006). 
25. T. Degim, J. Hadgraft, S. Ilbasmis, and Y. Ozkan. Prediction of skin penetration 
using artificial neural network (ANN) modeling. J Pharm Sci. 92:656-664 (2003). 
26. L.J. Chen, G.P. Lian, and L.J. Han. Prediction of human skin permeability using 
artificial neural network (ANN) modeling. Acta Pharmacologica Sinica. 28:591-
600 (2007). 
27. C.W. Lim, S. Fujiwara, F. Yamashita, and M. Hashida. Prediction of human skin 
permeability using a combination of molecular orbital calculations and artificial 
neural network. Biol Pharm Bull. 25:361-366 (2002). 
28. A.K. Pannier, R.M. Brand, and D.D. Jones. Fuzzy modeling of skin permeability 
coefficients. Pharm Res. 20:143-148 (2003). 
29. R.O. Pottsand R.H. Guy. A predictive algorithm for skin permeability: the effects of 
molecular size and hydrogen bond activity. Pharm Res. 12:1628-1633 (1995). 
30. M.H. Abraham, F. Martins, and R.C. Mitchell. Algorithms for skin permeability 
using hydrogen bond descriptors: the problem of steroids. J Pharm Pharmacol. 
49:858-865 (1997). 
31. A.L. Bungeand R.L. Cleek. A New Method for Estimating Dermal Absorption from 
Chemical-Exposure .2. Effect of Molecular-Weight and Octanol Water Partitioning. 
Pharm Res. 12:88-95 (1995). 
32. A.L. Bunge, R.L. Cleek, and B.E. Vecchia. A New Method for Estimating Dermal 
Absorption from Chemical-Exposure .3. Compared with Steady-State Methods for 
Prediction and Data-Analysis. Pharm Res. 12:972-982 (1995). 
33. S. Mitragotri. A theoretical analysis of permeation of small hydrophobic solutes 
across the stratum corneum based on scaled particle theory. J Pharm Sci. 
91:744-752 (2002). 
34. M.E. Johnson, D. Blankschtein, and R. Langer. Evaluation of solute permeation 
through the stratum corneum: Lateral bilayer diffusion as the primary transport 
mechanism. J Pharm Sci. 86:1162-1172 (1997). 
35. S. Mitragotri, M.E. Johnson, D. Blankschtein, and R. Langer. An analysis of the size 
selectivity of solute partitioning, diffusion, and permeation across lipid bilayers. 
Biophys J. 77:1268-1283 (1999). 
36. S. Mitragotri. Modeling skin permeability to hydrophilic and hydrophobic solutes 
based on four permeation pathways. J Controlled Release. 86:69-92 (2003). 
37. EC. Council Directive 76/768/EEC, of 27 Jul 1976, on the approximation of the 
laws of the Member States relating to cosmetic products (as amended), 1976. 
38. EC. Council Directive 2004/23/EC, of the 31 Mar 2004, on setting standards of 





























s     
169 
preservation, storage and distribution of human tissues and cells, 2004. 
39. N.A. Monteiro-Riviere, A.O. Inman, T.H. Snider, J.A. Blank, and D.W. Hobson. 
Comparison of an in vitro skin model to normal human skin for dermatological 
research. Microsc Res Tech. 37:172-179 (1997). 
40. F. Netzlaff, M. Kaca, U. Bock, E. Haltner-Ukomadu, P. Meiers, C.-M. Lehr, and U.F. 
Schaefer. Permeability of the reconstructed human epidermis model Episkin® in 
comparison to various human skin preparations. Eur J Pharm Biopharm. 66:127-
134 (2007). 
41. F. Netzlaff, C.M. Lehr, P.W. Wertz, and U.F. Schaefer. The human epidermis 
models EpiSkin®, SkinEthic® and EpiDerm®: An evaluation of morphology and 
their suitability for testing phototoxicity, irritancy, corrosivity, and substance 
transport. Eur J Pharm Biopharm. 60:167-178 (2005). 
42. T. Welss, D.A. Basketter, and K.R. Schröder. In vitro skin irritation: facts and 
future. State of the art review of mechanisms and models. Toxicol In Vitro. 
18:231-243 (2004). 
43. B. Godinand E. Touitou. Transdermal skin delivery: Predictions for humans from in 
vivo, ex vivo and animal models. Adv Drug Deliv Rev. 59:1152-1161 (2007). 
44. F.P. Schmook, J.G. Meingassner, and A. Billich. Comparison of human skin or 
epidermis models with human and animal skin in in-vitro percutaneous 
absorption. Int J Pharm. 215:51-56 (2001). 
45. S. Lombardi Borgia, P. Schlupp, W. Mehnert, and M. Schäfer-Korting. In vitro skin 
absorption and drug release - A comparison of six commercial prednicarbate 
preparations for topical use. Eur J Pharm Biopharm. 68:380-389 (2008). 
46. S.D. Roy, J. Fujiki, and J.S. Fleitman. Permeabilities of Alkyl P-Aminobenzoates 
through Living Skin Equivalent and Cadaver Skin. J Pharm Sci. 82:1266-1268 
(1993). 
47. B. van Ravenzwaayand E. Leibold. A comparison between in vitro rat and human 
and in vivo rat skin absorption studies. Hum Exp Toxicol. 23:421-430 (2004). 
48. M.E. Robertsand K.R. Mueller. Comparisons of Invitro Nitroglycerin (Tng) Flux 
across Yucatan Pig, Hairless Mouse, and Human Skins. Pharm Res. 7:673-676 
(1990). 
49. U. Jacobi, M. Kaiser, R. Toll, S. Mangelsdorf, H. Audring, N. Otberg, W. Sterry, and 
J. Lademann. Porcine ear skin: an in vitro model for human skin. Skin Res 
Technol. 13:19-24 (2007). 
50. S. Singh, K. Zhao, and J. Singh. In vitro permeability and binding of hydrocarbons 
in pig ear and human abdominal skin. Drug Chem Toxicol. 25:83 - 92 (2002). 
51. C. Herkenne, A. Naik, Y.N. Kalia, J. Hadgraft, and R.H. Guy. Pig ear skin ex vivo as 
a model for in vivo dermatopharmacokinetic studies in man. Pharm Res. 
23:1850-1856 (2006). 
52. EMEA. Modified Release Oral and Transdermal Dosage Forms. Section II: 
Pharmacokinetic and Clinical Evaluation. In C.f.P.M. Products (ed.), 1999. 
53. V.P. Shah. Transdermal drug delivery system regulatory issues. In R.H. Guyand J. 
Hadgraft (eds.), Drugs and the pharmaceutical sciences 123 -Transdermal drug 
delivery, M. Dekker, New York, 2003, pp. viii, 383 p. 
54. A. de la Pena, P. Liu, and H. Derendorf. Microdialysis in peripheral tissues. Adv 
Drug Del Rev. 45:189-216 (2000). 
55. E.C.M. de Lange, A.G. de Boer, and D.D. Breimer. Methodological issues in 
microdialysis sampling for pharmacokinetic studies. Adv Drug Del Rev. 45:125-
148 (2000). 
56. I. Tegeder, U. Muth-Selbach, J. Lotsch, G. Rusing, R. Oelkers, K. Brune, S. Meller, 
G.R. Kelm, F. Sorgel, and G. Geisslinger. Application of microdialysis for the 
determination of muscle and subcutaneous tissue concentrations after oral and 
topical ibuprofen administration. Clin Pharmacol Ther. 65:357-368 (1999). 
57. M. Kreilgaard, M.J.B. Kemme, J. Burggraaf, R.C. Schoemaker, and A.F. Cohen. 
Influence of a microemulsion vehicle on cutaneous bioequivalence of a lipophilic 





























s     
170 
18:593-599 (2001). 
58. E. Benfeldt, J. Serup, and T. Menne. Effect of barrier perturbation on cutaneous 
salicylic acid penetration in human skin: in vivo pharmacokinetics using 
microdialysis and non-invasive quantification of barrier function. Br J Dermatol. 
140:739-748 (1999). 
59. I. Tegeder, L. Brautigam, M. Podda, S. Meier, R. Kaufmann, G. Geisslinger, and M. 
Grundmann-Kollmann. Time course of 8-methoxypsoralen concentrations in skin 
and plasma after topical (bath and cream) and oral administration of 8-
methoxypsoralen. Clin Pharmacol Ther. 71:153-161 (2002). 
60. M. Kreilgaard. Assessment of cutaneous drug delivery using microdialysis. Adv 
Drug Deliv Rev. 54:S99-S121 (2002). 
61. S. Schmidt, R. Banks, V. Kumar, K.H. Rand, and H. Derendorf. Clinical 
microdialysis in skin and soft tissues: An update. J Clin Pharmacol. 48:351-364 
(2008). 
62. M.I. Davies, J.D. Cooper, S.S. Desmond, C.E. Lunte, and S.M. Lunte. Analytical 
considerations for microdialysis sampling. Adv Drug Deliv Rev. 45:169-188 
(2000). 
63. E. Benfeldtand L. Groth. Feasibility of measuring lipophilic or protein-bound drugs 
in the dermis by in vivo microdialysis after topical or systemic drug administration. 
Acta Derm Venereol. 78:274-278 (1998). 
64. L. Stahle. On mathematical models of microdialysis: geometry, steady-state 
models, recovery and probe radius. Adv Drug Del Rev. 45:149-167 (2000). 
65. FDA. Guidance for Industry - Topical Dermatologic Corticosteroids: in vivo 
bioequivalence. In F.a.D.A. U.S. Department of Health and Human Services, 
Centre for Drug Evaluation and Research (CDER) (ed.), 1995. 
66. H.Y. Gaoand A.L.W. Po. Topical Formulations of Fluocinolone Acetonide - Are 
Creams, Gels and Ointments Bioequivalent and Does Dilution Affect Activity. Eur J 
Clin Pharmacol. 46:71-75 (1994). 
67. S.Y. Chanand A.L.W. Po. Quantitative Skin Blanching Assay of Corticosteroid 
Creams Using Tristimulus Color Analysis. J Pharm Pharmacol. 44:371-378 (1992). 
68. E.W. Smith, J.M. Haigh, and R.B. Walker. Analysis of chromameter results 
obtained from corticosteroid-induced skin blanching. I: Manipulation of data. 
Pharm Res. 15:280-285 (1998). 
69. J.M. Haighand I. Kanfer. Assessment of topical corticosteroid preparations: the 
human skin blanching assay. Int J Pharm. 19:245-262 (1984). 
70. L.K. Pershing, B.S. Silver, G.G. Krueger, V.P. Shah, and J.P. Skelley. Feasibility of 
Measuring the Bioavailability of Topical Betamethasone Dipropionate in 
Commercial Formulations Using Drug Content in Skin and a Skin Blanching 
Bioassay. Pharm Res. 9:45-51 (1992). 
71. L.K. Pershing, S. Bakhtian, C.E. Poncelet, J.L. Corlett, and V.P. Shah. Comparison 
of skin stripping, in vitro release, and skin blanching response methods to 
measure dose response and similarity of triamcinolone acetonide cream 
strengths from two manufactured sources. J Pharm Sci. 91:1312-1323 (2002). 
72. R. Woodfordand B.W. Barry. Bioavailability and Activity of Betamethasone 17-
Benzoate in Gel and Cream Formulations - Comparison with Proprietary Topical 
Corticosteroid Preparations in Vasoconstrictor Assay. Current Therapeutic 
Research-Clinical and Experimental. 16:338-345 (1974). 
73. L.K. Pershing, L.D. Lambert, V.P. Shah, and S.Y. Lam. Variability and Correlation of 
Chromameter and Tape-Stripping Methods with the Visual Skin Blanching Assay in 
the Quantitative Assessment of Topical 0.05-Percent Betamethasone 
Dipropionate Bioavailability in Humans. Int J Pharm. 86:201-210 (1992). 
74. J.R. Gibson, J.M. Kirsch, C.R. Darley, S.G. Harvey, C.A. Burke, and M.E. Hanson. An 
Assessment of the Relationship between Vasoconstrictor Assay Findings, Clinical 
Efficacy and Skin Thinning Effects of a Variety of Undiluted and Diluted 
Corticosteroid Preparations. Br J Dermatol. 111:204-212 (1984). 





























s     
171 
skin vasoconstriction: visual ranking, chromameter measurement or digital 
imaging analysis. Dermatology. 205:3-10 (2002). 
76. S. Wiedersberg, C.S. Leopold, and R.H. Guy. Bioavailability and bioequivalence of 
topical glucocorticoids. Eur J Pharm Biopharm. 68:453-466 (2008). 
77. S. Wiedersberg, C.S. Leopold, and R.H. Guy. Topical application of betamethasone 
17-valerate formulations: tape stripping versus pharmacodynamic response. In 
PhD thesis: Dermatopharmacokinetics and Pharmacodynamics of topical 
glucorcoritcoids. To be published. , Department of Pharmacy and Pharmacology, 
University of Bath, Bath, 2006. 
78. B. Müller, M. Kasper, C. Surber, and G. Imanidis. Permeation, metabolism and site 
of action concentration of nicotinic acid derivatives in human skin: Correlation 
with topical pharmacological effect. Eur J Pharm Sci. 20:181-195 (2003). 
79. M.C. Poelman, B. Piot, F. Guyon, M. Deroni, and J.L. Leveque. Assessment of 
Topical Non-Steroidal Anti-Inflammatory Drugs. J Pharm Pharmacol. 41:720-722 
(1989). 
80. R. Parker, P. Lehman, and T. Franz. Human In vivo bioequivalence assay for 
topical retinoic acid formulations (PIII-10. Only abstracts of papers from the "95th 
annual meeting of the American Society for Clinical Pharmacology and 
Therapeutics" published). Clin Pharmacol Ther. 55:184 (1994). 
81. T. Franzand P. Lehman. Bioequivalence methodology for tretinoin products (PDD 
7222. Only conference abstract published). Pharm Res. 12:S-248 (1995). 
82. T. Franz, P. Lehman, N. Agrawal, and S. Franz. Tretinoin Bioavailability / 
Bioequivalence: use of transepidermal water loss (TEWL) technique (PDD 7302. 
Only conference abstract published). Pharm Res. 13:S-308 (1996). 
83. J.W. Fluhr, M.P. Vienne, C. Lauze, P. Dupuy, W. Gehring, and M. Gloor. Tolerance 
profile of retinol, retinaldehyde and retinoic acid under maximized and long-term 
clinical conditions. Dermatology. 199:57-60 (1999). 
84. I. Alberti, Y.N. Kalia, A. Naik, and R.H. Guy. Assessment and prediction of the 
cutaneous bioavailability of topical terbinafine, in vivo, in man. Pharm Res. 
18:1472-1475 (2001). 
85. A. Rougier, D. Dupuis, C. Lotte, R. Roguet, and H. Schaefer. In vivo correlation 
between stratum corneum reservoir function and percutaneous absorption. J 
Invest Dermatol. 81:275-278 (1983). 
86. FDA. Guidance for Industry: Topical Dermatological Drug Product NDAs and 
ANDAs — In Vivo Bioavailability, Bioequivalence, In Vitro Release, and Associated 
Studies (Draft guidance). In F.a.D.A. U.S. Department of Health and Human 
Services, Centre for Drug Evaluation and Research (CDER) (ed.), 1998. 
87. D.o.H.a.H.S. US FDA. Draft Guidance for Industry on Topical Dermatological Drug 
Product NDAs and ANDAs—In Vivo Bioavailability, Bioequivalence, In Vitro Release 
and Associated Studies; Withdrawal. [Docket Number 98D-0388]. Fed Regist. 
67:35122 (2002). 
88. T. Franz. Study No.1, Avita Gel 0.025% vs Retin-A Gel 0.025%, Advisory 
Committee for Pharmaceutical Sciences Meeting, Centre for Drug Evaluation and 
Research (CDER), Food and Drug Administration (FDA), Rockville, MD, November 
29, 2001.  (2001). 
89. L.K. Pershing, J.L. Nelson, J.L. Corlett, S.P. Shrivastava, D.B. Hare, and V.P. Shah. 
Assessment of dermatopharmacokinetic approach in the bioequivalence 
determination of topical tretinoin gel products. J Am Acad Dermatol. 48:740-751 
(2003). 
90. L. Pershing. Bioequivalence Assessment of three 0.025% tretinoin gel products: 
Dermatopharmacokinetic vs. Clinical Trials Methods, Advisory Committee for 
Pharmaceutical Sciences Meeting, Centre for Drug Evaluation and Research 
(CDER), Food and Drug Administration (FDA), Rockville, MD. November 29, 2001. 
 (2001). 
91. L.K. Pershing, J.L. Corlett, and J.L. Nelson. Comparison of 





























s     
172 
assessment of miconazole nitrate vaginal cream, 2% in humans. Pharm Res. 
19:270-277 (2002). 
92. I. Alberti, Y.N. Kalia, A. Naik, J.D. Bonny, and R.H. Guy. In vivo assessment of 
enhanced topical delivery of terbinafine to human stratum corneum. J Control 
Release. 71:319-327 (2001). 
93. A.L. Bunge, B. N’Dri-Stempfer, W. Navidi, and R.H. Guy. Therapeutic equivalence 
of topical products: Revised final report. Submitted to Department of Health and 
Human Services, Food and Drug Administration, Colorado School of Mines,, 
Golden, Colorado, 2008. 
94. S. Wiedersberg, C.S. Leopold, and R.H. Guy. Dermatopharmacokinetics of 
betamethasone 17-valerate: Influence of formulation viscosity and skin surface 
cleaning procedure. Eur J Pharm Biopharm. 71:362-366 (2009). 
95. W. Navidi, A. Hutchinson, B. N'Dri-Stempfer, and A. Bunge. Determining 
bioequivalence of topical dermatological drug products by tape-stripping. Journal 
of Pharmacokinetics and Pharmacodynamics. 35:337-348 (2008). 
96. B. N'Dri-Stempfer, W.C. Navidi, R.H. Guy, and A.L. Bunge. Optimizing metrics for 
the assessment of bioequivalence between topical drug products. Pharm Res. 
25:1621-1630 (2008). 
97. L.K. Pershing. Dermatopharmacokinetic bioequivalence study on three tretinoin, 
0.025%, products. Final Report to the Food and Drug Administration (FDA). In 
S.L.C. University of Utah (ed.), 2000. 
98. B. N’Dri-Stempfer, W. Navidi, R. Guy, and A. Bunge. Improved bioequivalence 
assessment of topical dermatological drug products using 
dermatopharmacokinetics, In preparation. 
99. R.L. Andersonand J.M. Cassidy. Variations in physical dimensions and chemical 
composition of human stratum corneum. J Investig Dermatol. 61:30-32 (1973). 
100. L.M. Russell, S. Wiedersberg, and M.B. Delgado-Charro. The determination of 
stratum corneum thickness - An alternative approach. Eur J Pharm Biopharm. 
69:861-870 (2008). 
101. Y.N. Kalia, I. Alberti, N. Sekkat, C. Curdy, A. Naik, and R.H. Guy. Normalization of 
stratum corneum barrier function and transepidermal water loss in vivo. Pharm 
Res. 17:1148-1150 (2000). 
102. H.J. Weigmann, U. Lindemann, C. Antoniou, G.N. Tsikrikas, A.I. Stratigos, A. 
Katsambas, W. Sterry, and J. Lademann. UV/VIS absorbance allows rapid, 
accurate, and reproducible mass determination of corneocytes removed by tape 
stripping. Skin Pharmacol Appl Skin Physiol. 16:217-227 (2003). 
103. R. Voegeli, J. Heiland, S. Doppler, A.V. Rawlings, and T. Schreier. Efficient and 
simple quantification of stratum corneum proteins on tape strippings by infrared 
densitometry. Skin Res Technol. 13:242-251 (2007). 
104. F. Dreher, A. Arens, J.J. Hostynek, S. Mudumba, J. Ademola, and H.I. Maibach. 
Colorimetric method for quantifying human Stratum corneum removed by 
adhesive-tape stripping. Acta Derm Venereol. 78:186-189 (1998). 
105. F. Dreher, B.S. Modjtahedi, S.P. Modjtahedi, and H.I. Maibach. Quantification of 
stratum corneum removal by adhesive tape stripping by total protein assay in 96-
well microplates. Skin Res Technol. 11:97-101 (2005). 
106. Y.C. Chaoand L.A. Nylander-French. Determination of keratin protein in a tape-
stripped skin sample from jet fuel exposed skin. Ann Occup Hyg. 48:65-73 
(2004). 
107. A. Bornkessel, M. Flach, M. Arens-Corell, P. Elsner, and J.W. Fluhr. Functional 
assessment of a washing emulsion for sensitive skin: mild impairment of stratum 
corneum hydration, pH, barrier function, lipid content, integrity and cohesion in a 
controlled washing test. Skin Res Technol. 11:53-60 (2005). 
108. J.W. Fluhr, J. Kao, M. Jain, S.K. Ahn, K.R. Feingold, and P.M. Elias. Generation of 
free fatty acids from phospholipids regulates stratum corneum acidification and 
integrity. J Invest Dermatol. 117:44-51 (2001). 





























s     
173 
Dermatopharmacokinetic prediction of topical drug bioavailability in vivo. J Invest 
Dermatol. 127:887-894 (2007). 
110. C. Herkenne, A. Naik, Y.N. Kalia, J. Hadgraft, and R.H. Guy. Ibuprofen transport 
into and through skin from topical formulations: in vitro-in vivo comparison. J 
Invest Dermatol. 127:135-142 (2007). 
111. C. Herkenne, A. Naik, Y.N. Kalia, J. Hadgraft, and R.H. Guy. Effect of propylene 
glycol on ibuprofen absorption into human skin in vivo. J Pharm Sci. 97:185-197 
(2008). 
112. S. Wiedersberg, A. Naik, C.S. Leopold, and R.H. Guy. Pharmacodynamics and 
dermatopharmacokinetics of betamethasone 17-valerate: assessment of topical 
bioavailability. Br J Dermatol. 160:676-686 (2009). 
113. S. Nicoli, A.L. Bunge, M.B. Delgado-Charro, and R.H. Guy. 
Dermatopharmacokinetics: factors influencing drug clearance from the stratum 
corneum. Pharm Res. 26:865-871 (2009). 
114. M.B. Reddy, A.L. Stinchcomb, R.H. Guy, and A.L. Bunge. Determining dermal 
absorption parameters in vivo from tape strip data. Pharm Res. 19:292-298 
(2002). 
115. V.P. Shah, G.L. Flynn, A. Yacobi, H.I. Maibach, C. Bon, N.M. Fleischer, T.J. Franz, 
S.A. Kaplan, J. Kawamoto, L.J. Lesko, J.P. Marty, L.K. Pershing, H. Schaefer, J.A. 
Sequeira, S.P. Shrivastava, J. Wilkin, and R.L. Williams. Bioequivalence of topical 
dermatological dosage forms--methods of evaluation of bioequivalence. Pharm 
Res. 15:167-171 (1998). 
116. K.A. Holbrookand G.F. Odland. Regional differences in the thickness (cell layers) 
of the human stratum corneum: an ultrastructural analysis. J Invest Dermatol. 
62:415-422 (1974). 
117. M. Denda, L.C. Wood, S. Emami, C. Calhoun, B.E. Brown, P.M. Elias, and K.R. 
Feingold. The epidermal hyperplasia associated with repeated barrier disruption 
by acetone treatment or tape stripping cannot be attributed to increased water 
loss. Arch Dermatol Res. 288:230-238 (1996). 
118. G. Erikssonand L.O. Lamke. Regeneration of human epidermal surface and water 
barrier function after stripping. A combined study with electron microscopy and 
measurement of evaporative loss. Acta Derm Venereol. 51:169-178 (1971). 
119. T. Frodinand M. Skogh. Measurement of transepidermal water loss using an 
evaporimeter to follow the restitution of the barrier layer of human epidermis after 
stripping the stratum corneum. Acta Derm Venereol. 64:537-540 (1984). 
120. I. Alberti, Y.N. Kalia, A. Naik, J. Bonny, and R.H. Guy. Effect of ethanol and 
isopropyl myristate on the availability of topical terbinafine in human stratum 
corneum, in vivo. Int J Pharm. 219:11-19 (2001). 
121. F. Pirot, Yogeshvar N. Kalia, Audra L. Stinchcomb, G. Keating, A. Bunge, and 
Richard H. Guy. Characterization of the permeability barrier of human skin in vivo, 
Proc Natl Acad Sci USA, Vol. 94, 1997, pp. 1562-1567. 
122. F. Pirot, E. Berardesca, Y.N. Kalia, M. Singh, H.I. Maibach, and R.H. Guy. Stratum 
corneum thickness and apparent water diffusivity: facile and noninvasive 
quantitation in vivo. Pharm Res. 15:492-494 (1998). 
123. E.H. Choi, M.-Q. Man, F. Wang, X. Zhang, B.E. Brown, K.R. Feingold, and P.M. Elias. 
Is Endogenous Glycerol a Determinant of Stratum Corneum Hydration in Humans? 
J Investig Dermatol. 125:288-293 (2005). 
124. P. Corcuff, F. Fiat, and A.M. Minondo. Ultrastructure of the human stratum 
corneum. Skin Pharmacol Appl Skin Physiol. 14 Suppl 1:4-9 (2001). 
125. M. Haftek, M. Simon, and G. Serre. Corneodesmosomes: pivotal actors in the 
stratum corneum cohesion and desquamation. In P.M. Eliasand K.R. Feingold 
(eds.), Skin barrier, Taylor & Francis, New York, N.Y. ; London, 2006, pp. 171-190. 
126. R.I. Spearman. Some light microscopical observations on the stratum corneum of 
the guinea-pig, man and common seal. Br J Dermatol. 83:582-590 (1970). 
127. J. Gabrielssonand D. Weiner. Modeling strategies. In J. Gabrielssonand D. Weiner 





























s     
174 
applications, Apotekarsocieteten, Stockholm, 2006, pp. 389-463. 
128. H. Motulskyand A. Christopoulos. Comparing models using Akaike's Information 
Criterion (AIC). In H. Motulskyand A. Christopoulos (eds.), Fitting models to 
biological data using linear and nonlinear regression: a practical guide to curve 
fitting, Oxford University Press, Oxford, 2004. 
129. H. Motulskyand A. Christopoulos. Comparing models using the extra sum-of-
squares F test. In H. Motulskyand A. Christopoulos (eds.), Fitting models to 
biological data using linear and nonlinear regression: a practical guide to curve 
fitting, Oxford University Press, Oxford, 2004. 
130. J.H. Zar. Appendix B: Statistical Tables and Graphs. In J.H. Zar (ed.), Biostatistical 
analysis, Prentice-Hall, Englewood Cliffs, N.J., 1984. 
131. J.S. Lo, H.A. Oriba, H.I. Maibach, and P.L. Bailin. Transepidermal potassium ion, 
chloride ion, and water flux across delipidized and cellophane tape-stripped skin. 
Dermatologica. 180:66-68 (1990). 
132. M. Haftek, M. Simon, and G. Serre. Corneodesmosomes: pivotal actors in the 
Stratum Corneum Cohesion and Desquamation. In P.M. Eliasand K.R. Feingold 
(eds.), Skin barrier, Taylor & Francis, New York, N.Y. ; London, 2006. 
133. A.G. Matoltsyand C.A. Balsamo. A study of the components of the cornified 
epithelium of human skin. J Biophys Biochem Cytol. 1:339-360 (1955). 
134. T. Kitaharaand H. Ogawa. The extraction and characterization of human nail 
keratin. J Dermatol Sci. 2:402-406 (1991). 
135. T. Kitaharaand H. Ogawa. Variation of differentiation in nail and bovine hoof cells. 
J Invest Dermatol. 102:725-729 (1994). 
136. O.H. Lowry, N.J. Rosebrough, A.L. Farr, and R.J. Randall. Protein measurement 
with the Folin phenol reagent. J Biol Chem. 193:265-275 (1951). 
137. Sigma-Aldrich. Technical Bulletin for Product B6916 (2004). Accessed Nov 2008 
from http://www.sigmaaldrich.com/sigma/bulletin/b6916bul.pdf. 
138. PierceBiotechnology. Protein Assay Technical Handbook (2005). Accessed Nov 
2008 from http://www.piercenet.com/files/1601325ProteinAssay.pdf. 
139. PierceBiotechnology. Modified Lowry Protein Assay kit (Instructions) (2005). 
Accessed Nov 2008 from http://www.piercenet.com/files/0389dh4.pdf. 
140. S.W. Hendrix, K.H. Miller, T.E. Youket, R. Adam, R.J. O'Connor, J.G. Morel, and B.E. 
Tepper. Optimization of the skin multiple analyte profile bioanalytical method for 
determination of skin biomarkers from D-Squame tape samples. Skin Res 
Technol. 13:330-342 (2007). 
141. J.H. Zar. Chapter 17, section 17.1. Biostatistical analysis, Prentice Hall ; London : 
Prentice-Hall International, Upper Saddle River, N.J., 1996, p. 1 v. (various 
pagings). 
142. H.J. Weigmann, J. Lademann, H. Meffert, H. Schaefer, and W. Sterry. 
Determination of the horny layer profile by tape stripping in combination with 
optical spectroscopy in the visible range as a prerequisite to quantify 
percutaneous absorption. Skin Pharmacol Appl Skin Physiol. 12:34-45 (1999). 
143. E. Marttin, M.T.A. NeelissenSubnel, F.H.N. DeHaan, and H.E. Bodde. A critical 
comparison of methods to quantify stratum corneum removed by tape stripping. 
Skin Pharmacol. 9:69-77 (1996). 
144. Sigma-Aldrich. Micro Lowry, Onishi & Barr Modification - Technical Bulletin (2004). 
Accessed Nov 2008 from 
http://www.sigmaaldrich.com/sigma/bulletin/tp0200bul.pdf. 
145. Invitrogen-MolecularProbes. NanoOrange® Protein Quantitation Kit (N6666) 
(2008). Accessed Nov 2008 from 
http://probes.invitrogen.com/media/pis/mp06666.pdf. 
146. Invitrogen-MolecularProbes. CBQCA Protein Quantitation Kit (C-6667) (2001). 
Accessed Nov 2008 from http://probes.invitrogen.com/media/pis/mp06667.pdf. 
147. Invitrogen-MolecularProbes. EZQ ® Protein Quantitation Kit (R33200) (2005). 
Accessed Nov 2008 from http://probes.invitrogen.com/media/pis/mp33200.pdf. 





























s     
175 
Accessed Nov 2008 from http://probes.invitrogen.com/media/pis/mp33210.pdf. 
149. F.W. Bauer. Studies on isolated keratin fractions from mammalian epidermis. I. 
Physicochemical properties of the fractions. Dermatologica. 144:217-228 (1972). 
 
 
